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SUMMARY 
 
mTOR signaling influence a wide range of cellular process including protein synthesis 
(Iadevaia et al., 2012; Ma and Blenis, 2009; Thoreen et al., 2012), lipids synthesis (Lamming 
and Sabatini, 2013), transcription (Dibble and Manning, 2013; Vazquez-Martin et al., 2011), 
nucleotides biosynthesis (Ben-Sahra et al., 2013; Robitaille et al., 2013) and cellular 
energetics (Albert and Hall, 2015; Duvel et al., 2010; Inoki et al., 2012). In muscle, 
suppression of mTORC1 signaling results in several phenotypic changes including decreased 
life expectancy, increased glycogen deposits and alterations of the twitch kinetics of slow 
fibres (Bentzinger et al., 2008), however it is unclear what is its specific role in the excitation 
contraction (EC) coupling. Likewise, the ryanodine receptor (RyR), the calcium release 
channel of the sarcoplasmic reticulum, plays a fundamental role in calcium homeostasis in a 
variety of cells and particularly in muscle (Lanner et al., 2010). Mutations in the gene 
encoding this channel have been associated with a number of debilitating or life-threatening 
neuromuscular pathologies including malignant hyperthermia (Kolb et al., 1982; Rosenberg 
et al., 2015; Treves et al., 2005), but little or no knowledge is known about their 
pathophysiological influence in mild bleeding disorders. In this thesis we investigated in 
greater detail 1) the effect of the mTORC1 signalling pathway on the integrity of the protein 
participants in skeletal muscle EC coupling and calcium homeostasis by using a muscle 
specific Raptor KO mouse model. 2) The calcium homeostasis of vascular smooth muscle 
cells of an MH mouse model and its association to mild bleeding disorders as also observed 
in MH patients.  
As far as the mTOR is concerned, we found that in raptor knockout (RamKO) mice, the bulk 
of glycogen phosphorylase (GP) is mainly associated in its cAMP-non-stimulated form with 
sarcoplasmic reticulum (SR) membranes. In addition, radio ligand binding assay showed a 
ryanodine to dihydropyridine receptors (DHPRs) ratio of 0.79 and 1.35 for wild-type (WT) 
and raptor KO skeletal muscle membranes respectively, which was confirmed by Western 
Blot analysis. Peak amplitude and time to peak of the global calcium transients evoked by 
supramaximal field stimulation were not different between WT and raptor KO. However, the 
increase in the voltage sensor-uncoupled RyRs leads to an increase of both frequency and 
mass of elementary calcium release events (ECRE) induced by hyper-osmotic shock in flexor 
digitorum brevis (FDB) fibres from raptor KO. These findings together with previous reports 
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should be taken into consideration in the clinical practice when rapamycin or its analogs 
(rapalogs) is administrated to patients. 
As far as RYR1–mutations in human patients and its relationship to bleeding abnormlities is 
concerned, 8/20 mutation carriers revealed abnormal bleeding scores compared with their 
healthy relatives (0/11). Similarly, MHS RYR1Y522S knock in mice exhibited 3 times longer 
bleeding times compared to their wild type littermates. The bleeding defect of MHS mice 
could be reversed by pre-treatment with the ryanodine receptor 1 antagonist dantrolene. 
Primary vascular SMCs from RYR1Y522S knock-in mice exhibited a higher frequency of 
subplasmalemmal Ca2+ sparks leading to a more negative resting membrane potential. 
Furthermore, Ca2+ sparks were blocked by pre-treatment with ryanodine or dantrolene. These 
results stimulated us to generate a model that could explain how impaired calcium 
homeostasis addressed by RyR1 mutation could affect bleeding without influencing platelet 
or coagulation factor function. Our results on impaired calcium homeostasis caused by RyR1 
mutations could extend to other tissues that functionally express this channel. 
 In conclusion, the present study shows that the protein composition and function of the 
molecular machinery involved in skeletal muscle excitation–contraction (EC) coupling is 
affected by mTORC1 signaling and that RYR1 mutations cause prolonged bleeding by 
altering vascular SMC function and emphasize the potential therapeutic value of dantrolene 
in the treatment of such bleeding abnormalities. 
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 1 
INTRODUCTION  
 
Muscle is a soft tissue, whose main purpose is to produce motion and force in animals. The 
generation of limb and trunk movements, the control of breathing as well as involuntary 
visceral movement, heart beating and vascular tone are controlled by muscles. 
Morphological, structural and functional features allow to classify them grossly in three main 
types: skeletal, cardiac and smooth muscles. The first two share a common feature: a regular 
striation pattern easily observable under the microscope, while smooth muscles lack such a 
remarkable characteristic. 
All muscles cause motion by cycles of contraction and relaxation that are tightly controlled 
by complex protein machineries, however, different muscle types differ in the ways these 
cycles are triggered and terminated and interference of its delicate homeostasis may lead to 
severe diseases (Lanner, 2012; Le Rumeur, 2015; Timchenko, 2013).  
In the past decades a number of experimental evidence has uncovered the important role of 
mTOR signaling in a wide range of cellular anabolic process including protein synthesis 
(Iadevaia et al., 2012; Ma and Blenis, 2009; Thoreen et al., 2012), lipid synthesis (Lamming 
and Sabatini, 2013), transcription (Dibble and Manning, 2013; Vazquez-Martin et al., 2011), 
nucleotides biosynthesis (Ben-Sahra et al., 2013; Robitaille et al., 2013) and cellular 
energetics (Albert and Hall, 2015; Duvel et al., 2010; Inoki et al., 2012). It is also no surprise 
that skeletal muscle, representing approximately 40 percent of our body weight, is also 
influenced by the mTOR signalling pathway. This is also supported by the growing number 
of publications relating to mTOR signaling in muscle pathophysiology in recent years 
(Bentzinger et al., 2013; Bentzinger et al., 2008; Bodine et al., 2001a; Khurana and Davies, 
2003; Lawrence, 2001; Leger et al., 2006; Ribeiro et al., 2015). 
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mTOR signaling in skeletal muscle 
 
mTOR: a brief overview  
 
mTOR is a protein kinase that belongs to the family of Phosphoinositide 3-kinase (PI3K)-
related kinases (PIKKs) (Baretic and Williams, 2014). This group of proteins shares a 
common structure consisting of a conserved kinase core domain; a short conserved segment 
referred to as FATC domain, which is located just at the C-terminal of the kinase domain, 
and a long series of variable helical repeats forming the α-solenoid domain. mTOR, as the 
other family member of PIKKs, is characterized by the fact that it preferentially 
phosphorylates its substrate on a serine or threonine residue (Kang et al., 2013).  
In order to function and exert its enzymatic activity mTOR requires a set of accompanying 
proteins. Thus, mTOR forms two multicomponent distinct catalytic complexes: mTOR 
complex 1 (mTORC1) composed by the mTOR kinase active core, and additional regulatory 
proteins including the regulatory associated protein of mTOR (RAPTOR), the mammalian 
lethal with SEC13 protein 8 (mLST8), the Proline-Rich Akt Substrate of 40 KDa (PRAS40) 
and the DEP-domain-containing mTOR interacting protein (DEPTOR). This complex is best 
known for being the target of rapamycin (Heitman et al., 1991), a suppressor of eukaryotic 
cell proliferation produced by the bacterium Streptomyces hygroscopicus (Vezina et al., 
1975) and clinically used as an  immunosupresant  (Brattstrom et al., 2000; Kahan et al., 
1998). 
The other functional complex referred to as mTOR complex 2 (mTORC2) is equipped with 
the catalytic unit mTOR and the associated proteins rapamycin-insensitive companion of 
mTOR (RICTOR), mLST8, the protein observed with RICTOR 1/2 (PROTOR 1/2) and 
DEPTOR. This complex was initially believed to be independent of rapamycin (Jacinto et al., 
2004), however new evidence shows that it can be affected by this drug depending on the cell 
types, dose and in a time-dependent fashion. (Sarbassov et al., 2006). 
Thus, mTORC1 and mTORC2 contain both distinct and shared proteins. However, they 
differ markedly as to their upstream stimulants, as well as their regulatory and functional 
output (see Figure 1).  
mTORC1 responds to a set of upstream signals including growth factors, stress, oxygen, 
energy status and amino acids, to promote cell growth by regulating positively anabolic 
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processes including protein and lipid synthesis, energy metabolism and negatively catabolic 
process such as autophagy and lysosome biogenesis (for extended and detailed reviews on 
mTOR signaling see (Cornu et al., 2013; Hall, 2008; Laplante and Sabatini, 2012). Once 
mTORC1 is activated, it phosphorylates several substrate including the translational 
regulators eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and 
ribosomal protein S6 kinase 1 (S6K1) to coordinate the initiation of protein synthesis (Ma 
and Blenis, 2009). Moreover, mTORC1 also operates on sterol regulatory element-binding 
protein 1/2 (SREBP1/2), which are transcription factors that control the synthesis of genes 
involved in fatty acid and cholesterol anabolism (Laplante and Sabatini, 2009). 
 
 
Figure 1. Overview of the mTOR signalling pathway in cellular function with the main upstream 
input and downstream effectors. For details see the text explanation. 
 
On the other hand, knowledge of mTORC2 function is less clear and reports relating to its 
functional role are more sparse. Nonetheless, it is known that mTORC2 is more sensitive to 
growth factors than nutrients and plays an important role in the dynamics of actin 
cytoskeleton by associating with ribosomes (Jacinto et al., 2004; Sarbassov et al., 2004; 
Zinzalla et al., 2011) possibly involving Protein Kinase C alpha (PKCα) and the small 
GTPases Rho and Rac. Figure 1 shows a summary of the main cellular processes controlled 
by the mTOR signaling complexes as well as some of its input stimulus. 
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mTORC1 signaling in different pathological conditions  
 
Since mTORC1 activation includes a long list of regulatory metabolic pathways that roughly 
determine cell proliferation, its pharmacological control represents a key tool in 
understanding not only its functional mechanism but also its significance in the development 
and prevention of several diseases. The mechanism of action of rapamycin involves the 
proline isomerase FKBP12 to form the Rapamicine-FKBP12 complex (Heitman et al., 1991; 
Koltin et al., 1991; Sabatini et al., 1994). This Rapamicin-FKBP12 complex binds to the 
mTOR N-terminal of the kinase domain (Chen et al., 1995) and acts as an allosteric inhibitor, 
therefor preventing mTORC1function.  
Rapamycin, (commercially known as Sirolimus or Rapamune) which is used worldwide was 
FDA approved in the U.S. in 1999 and in Europe is given to patients since 2001 (European 
Medices Agency, 2015) and by (U. S. Food and Drug Administration, 2015), it is used to 
treat a range of impaired mTOR functions including Cancer (Baselga et al., 2012), organ 
transplantation immunosuppressant (Calne et al., 1989; Lorber et al., 2005; Schuler et al., 
1997) and neurological disorders (Cardamone et al., 2014). More recently, it has been 
discovered to prolong the life span of animals (Ehninger et al., 2014; Fok et al., 2014; 
Harrison et al., 2009) though there its effect on prolonging human lifespan is controversial 
(Johnson et al., 2013). 
Nevertheless, uses of rapamycin in a clinical context continue growing. The extensive use of 
rapamycin or its analogs (rapalogs) demands more knowledge to understand better its 
function in a more systemic approach. To achieve this aim we explored the role of the 
mTORC1 pathway on skeletal muscle physiology, particularly in controlling calcium 
homeostasis and the protein complexes involved in this process. In the next section I will 
describe the finding of the role of mTORC1 in muscle biology. 
 
 
 
The mTORC1 pathway influences skeletal muscle 
 
Skeletal muscle is an organ that has incredible adaptive capabilities in response to several 
physiological (e.g., exercise) and pathological (systemic diseases, myopathy, and aging) 
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conditions. Some of these adaptive processes include hypertrophy, atrophy, regeneration, 
fiber type conversion and mitochondrial biogenesis that ultimately result in a change of the 
muscle performance. Thus for instance, formation of muscle mass, is a complex process 
determined by the balance between new protein synthesis and degradation; both of then 
tightly regulated and interrelated (Sandri, 2008). Both systems require energy, a checkpoint 
where the body decides either to promote growth and hypertrophy or activate protein 
breakdown and atrophy. mTORC1 plays an important role in muscle growth closely related  
to the metabolic response. In fact it seems to be involved in the maintenance of mitochondrial 
oxidative function by directly regulating mitochondrial gene expression through the control 
of transcription complexes such as like Yin Yang 1  (YY1) and Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) (Cunningham et al., 2007) both 
master regulators of mitochondrial gene biogenesis.  
Additionally, Insulin Factor-like Growth Type 1 (IGF-1) was shown to be able to increase 
muscle protein synthesis mediated by the PI3K/Akt/mTOR signaling pathway in a 
rapamycin-sensitive manner (Ohanna et al., 2005; Rommel et al., 2001), linking in this way 
metabolic input with muscle growth. 
Recent evidence has revealed that mTORC1 represents a crucial signaling pathway 
determining protein synthesis in skeletal muscle. In mechanical-load induced growth Bodine 
et al. demonstrated that the adaptive hypertrophy of adult skeletal muscles seems to be 
crucially regulated by the activation of the Akt/mTOR pathway and its downstream targets 
S6K1 and 4E-BP1 (Bodine et al., 2001b). 
In the same line, dramatic changes in muscle phenotype are observed when mTOR or some 
of its associated proteins are knocked out in animal models. For example at the level of whole 
body, Knocking Out (KO) mTOR (Gangloff et al., 2004; Murakami et al., 2004) or its 
companions RAPTOR and mLST8 (Guertin et al., 2006) is embryonically lethal. 
Furthermore, conditional muscle specific KO of mTORC1 mouse models display a wide 
range of muscle pathologies. In particular such mice display features of muscular dystrophy 
(MD) and metabolic changes including increased glucose uptake and glycogen synthesis, 
associated with reduced glycogen breakdown, increased glycogen accumulation and 
premature death (Risson et al., 2009). 
Consistent with these findings, mice with muscle specific KO of RAPTOR (RAmKO) 
previously generated by Bentzinger and colleagues, exhibited a reduced life-span as well as 
some features of dystrophy with elevated numbers of muscle fibers with centralized nuclei 
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and the presence of central core-like structures, changes in mitochondrial function, increased 
glycogen content, a higher proportion of fast muscle fibers accompanied by a switch from 
oxidative to glucolityc metabolism and decreased muscle mass (Bentzinger et al., 2008).  
In a more functional approach made in the same study by Bentzinger and colleagues ablation 
of RAPTOR in muscle not only significantly compromised the voluntary running wheel 
exercise in these mice but also in vitro dissected muscle extensor digitorum brevis (EDL) and 
soleus exhibited a diminished performance when submitted to strenuous fatigue protocols. 
These changes were correlated with an important reduction of mechanical properties of the 
muscle such as twitch force and maximal tetanic absolute force, which were accompanied by 
a featured phenotype with slow kinetics (longer time to peak, half time to peak and relaxation 
time). 
Nevertheless, calcium, a secondary messenger that intervenes in a number of physiological 
processes, and in particular in muscle it underlies excitation contraction coupling and 
therefore force generation had not been investigated in relation to mTOR complexes and 
muscle function and in this context it should be mentioned that mishandling of calcium 
homeostasis is an important factor that compromises muscle performance and leads to several 
neuromuscular diseases (MacLennan, 2000; Treves et al., 2005). 
Many of the degenerated muscle phenotype features caused by suppressing the mTORC1 
signaling pathway and its downstream targets, might alter not only metabolism, protein 
synthesis and muscle performance but also affect directly the calcium dynamics through the 
molecular machinery that operates the excitation contraction (EC) process. This aspect was 
investigated during my PhD and we provide evidence (results section manuscript 1) that 
mTORC1 inactivation by ablation of its regulatory protein RAPTOR, affects the 
macromolecular EC coupling integrity and therefore the calcium homeostasis in skeletal 
muscle. 
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An overview to skeletal muscle physiology 
 
Structural organization of skeletal muscle 
 
Muscle, the tissue responsible for all the movement in organisms, is composed of elongated 
thin fused multinucleated cells called fibers. A muscle unit is composed of several elongated 
fibers lying parallel to each other and held together in bundles by connective tissue. They 
have a finely organized architecture that enables them to rapidly undergo significant changes 
in shape and size, which is then translated into motion. Motion is a highly dynamic process 
due to the shortening and elongation of the fiber size, a process referred to as contraction and 
relaxation respectively.  
A remarkable feature of muscle fibers is the presence of multiple nuclei formed by the fusion 
of myoblasts (premature muscle cells) at the embryonic stage and the presence of many 
mitochondria, the power generating organelle that supplies the energy required by muscle 
cells (Hill, 2012).  
Fibers are equipped with numerous myofibrils, a cylindrical structure of about 1-2 μm in 
diameter, extending along the fiber. They constitute the contractile elements made up of 
cytoskeletal microfilaments that, when observed under the microscope, display 
distinguishable repeated dark and light bands called A band and I band,a  respectively.  
An A band is composed of set of thick filaments that overlap on both ends with thin 
filaments. The central region of the band A, where thin filaments are not present, is called the 
H zone and at its center it is divided by the M line. The I band is composed by thin filaments 
that do not project to the A band and are connected by the Z line at the center. Thick 
filaments are made up myosin chains that extend perpendicularly from the M line towards the 
Z line, whereas thin filaments are made up primarily of the protein actin, that on the contrary, 
extend from the Z line towards the band M. The smallest functional contractile unit in 
muscle, the sarcomere, is defined as the section between two consecutive Z line. A detailed 
scheme of the structural organization of a myofibril is shown on Figure 2. 
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Figure 2. Structural organization of a skeletal muscle sarcomere. A An electron microscope (EM) 
micrograph of the organization of myofibrils from rabbit psoas muscle (magnification 60000x) taken 
from pioneer structural work of Hugh Huxley on the determination of the myofilaments array 
(Huxley, 1957). B schematic representation of myofilaments organized in a sarcomere. The blue and 
grey threads represent the thin filaments and the red threads represent the thick filaments. 
 
This arrangement of the contractile proteins is specific and necessary in order to allow force 
generation in the muscle by the shortening of the sarcomere, a mechanism known as “cross-
bridge” or sliding-filaments (Podolsky, 1961). This mechanism consists in shortening the 
distance between two adjacent Z lines through the sliding of the thick filaments (myosin) and 
thin filaments (actin) passed one another by mechanical interaction (Huxley, 1969). This is an 
energy dependent process that involves the regulatory proteins troponin and tropomyosin 
forming a molecular complex together with the actin filaments that are in motion (active) 
only in the presence of calcium (Ebashi, 1972; Hayashi, 1952; Weber and Winicur, 1961). 
 
Muscle fiber type 
 
Skeletal muscles can be divided in different subgroups that have adapted to perform special 
functions  e.g. from long lasting, continuous and low-intensity activities to fast, explosive and 
high- intensity activities. 
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Although the contractile properties, calcium kinetics, molecular composition, histochemical 
and biochemical features have helped to identify at least four different muscle fiber types 
known as slow type I and fast types IIA, IIX/D and IIB (Bottinelli and Reggiani, 2000; 
Calderon et al., 2010; Schiaffino and Reggiani, 2011), for reasons of simplicity we will use 
an old conventional classification of two muscle types: the fast-twitch muscles, characterized 
by glycolytic metabolism and specialized for phasic activity, generally identified as white 
muscles, and the slow-twitch muscles, rich in myoglobin and oxidative enzymes and 
specialized for more continuous activity, also called red muscles (Cassens and Cooper, 1971). 
 
EC coupling  
 
The generation of force requires a sophisticated mechanism of signal communication that 
initiates contractile proteins activity and consecutively terminates it. This signal starts in the 
neurons innervating the muscle fiber and is transmitted through chemical and physical 
communication in a space denominated the neuromuscular junction: the edge between a 
terminal axon from a motor neuron and the sarcolemma of a muscle fiber (Del Castillo and 
Katz, 1954). When a motor neuron generates an action potential, a fast and sudden transient 
change in the membrane potential triggers the exocytosis of neurotransmitters including 
acetylcholine (Augustine and Kasai, 2007; Fatt and Katz, 1951). The surface of the muscle 
fiber membrane is equipped with acetylcholine receptors able to sense this signal and 
translate it into an action potential within the whole sarcolemma, the cellular membrane of 
the muscle fiber. Similar to what occurs in neurons, in muscle fibers the action potential is an 
electrical signal that is detected by antenna proteins able to translate this information into a 
chemical signal. The L-type voltage-dependent calcium channel referred to as 
dihydropyridine receptor or Cav1.1 is a voltage sensor that acts as a physical-chemical 
translator of this signal. It is located at the T-tubules (Fosset et al., 1983): invaginations of the 
sarcolemma that extend radially in an intricate network into the center of the fibers and is 
tightly connected with the muscle sarcoplasmic reticulum (SR) cisternae (Catterall, 1991; 
Nelson and Benson, 1963; Porter and Palade, 1957). The SR constitutes an extended calcium 
store organelle formed by a longitudinal section and another section disposed in close contact 
with the T-tubule called terminal cisternae (Costello et al., 1986; Meissner, 1975). The 
structure formed by a T-tubule with two adjacent terminal cisternae is referred to as triad and 
contains the functional unit of electrical and mechanical coupling (Franzini-Armstrong, 
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1980). In this membrane junction formed by the T-tubule and the SR several proteins have 
been identified aside the Cav1.1 channel, including the calcium release channel of the SR or 
ryanodine receptor (RyR) (Kawamoto et al., 1986), a large homotetrameric protein of about 
560 KDa (Zucchi and Ronca-Testoni, 1997). 
 
This protein assembles in clusters of four units (tetrads) forming what is considered to be the 
“feet” that bridge the SR and the T-tubule. Each tetrad in the SR is associated with four 
aligned Cav.1.1 of the sarcolemma in alternate positions so that they form a coupled 
checkerboard structure (Block et al., 1988). In other words, the Cav1.1 is associated with the 
tetrads forming a coupled unit every 2 tetrads. This can be better visualized as shown in 
Figure 3. 
 
 
 
Figure 3. Tetrad organization in the SR-T-tubule junction. The empty circles forming a tetrad 
represent the uncoupled RyR, whereas the filled circles are the Cav1.1. aligned with the RyR forming 
a coupled tetras in an alternated pattern. From the model of Block and colleagues 1988. 
 
Such an arrangement seems to be important for the controlled opening of the RyR by the 
voltage sensor Cav1.1, since experimental evidence have shown that artificially uncoupling 
the RyR-Cav1.1 communication leads to elementary calcium release events called sparks 
(Apostol et al., 2009), and the presence of sparks can indicate  a deleterious signal of 
impaired calcium homeostasis in some myopathies (Franzini-Armstrong et al., 1991; Wang et 
al., 2005). 
Thus, when an action potential reaches the sarcolemma, it produces structural conformational 
changes of the Cav1.1 that are physically connected with RyR, which once activated leads to 
a massive and transient calcium release from the SR to the cytosol. Free cytosolic calcium is 
RyR/DHPR=	0.79	
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the trigger signal that allows the cross-bridge formation of the contractile proteins myosin 
and actin to generate contraction. 
The sequence of events in the muscle initiated by an electrical signal transformed in a 
contractile response is referred to as excitation-contraction coupling (EC coupling). This 
concept was first introduced by Alexander Sandow more than sixty years ago (Sandow, 
1952) and much has been discovered since concerning the molecular mechanism involved in 
EC coupling. The termination of this event is conducted by a decrease of the cytosolic 
calcium concentration of the fiber to resting levels leading to muscle relaxation.  
 
 
 
Figure 4. Sequence of events that take place during the EC coupling in a muscle fiber. Contraction is 
initiated by an electrical signal that propagated along the sarcolemma (1). The signal is received by 
the voltage sensor Cav1.1 and transmitted to a coupled RyR channel to trigger calcium release (2). 
The cytosolic calcium content increases dramatically and activates the contractile proteins (3). The 
cytosolic calcium level is restored to resting level and therefore the relaxation by reuptaking calcium 
to the SR of through the SERCA calcium pump activity or ejected out of the cell by the NCX (4). 
 
To allow this to occur, the cell uses an energy-dependent mechanism to diminish the 
cytosolic calcium content to its resting level by the active extrusion of the cytosolic calcium 
through the sarcoplasmic/endoplasmic calcium ATPase (SERCA) that reuptakes the calcium 
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from the cytosol and translocates it back into the SR (Inesi, 1985). The sodium-calcium 
exchanger (NCX) located at the sarcolemmal membrane also contributes though to a lesser 
extent in skeletal muscle, to restoring the calcium concentration back to resting levels by 
transporting calcium into the extracellular space (Gonzalez-Serratos et al., 1996).  
A representation of the sequence of events that occurs in a muscle fiber from the reception of 
an action potential till the generation of contraction is shown in Figure 4. Although, the 
process that comprise the initiation of the contraction triggered by an action potential until 
the restoration of the calcium levels is broadly understood, the role of many additional 
molecular components that are present in T-tubules and in the SR junctional face as well as in 
the SR lumen are still under investigation and their role in regulating and fine tuning the EC 
coupling machinery not completely understood.  
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Major proteins involved in skeletal muscle EC coupling 
 
The SR contains a set of proteins that are directly or indirectly involved in the EC coupling 
process. Many of these proteins relay important information and are involved in the calcium 
handling, whereas other proteins are still being discovered and their roles are under 
investigation (Barone et al., 2015; Treves et al., 2009). 
Some of the major molecular components of the EC coupling machinery are displayed in 
Figure 4. Some of these proteins and others not shown in the cartoon will be described in 
more detail below. 
 
   
 
Figure 5. Some proteins in the EC coupling located in the SR and T-Tubule membrane system. Major 
proteins participating in the EC coupling are represented here (RyR, Cav1.1 and SERCA), as well as 
others minor proteins with buffer or structural organization properties. Cav1.1, Skeletal isoform of 
Type L voltage calcium channel; CSQ, Calsequestrin, JNT, Junctin; JP-45, Junctional Protein of 45 
KDa; SERCA, Sarco/Endoplasmic reticulum Ca2+ ATPase; SRLM, Sarcalumenin; TRD, Triadin; 
RyR, Ryanodine receptor. 
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RyR 
 
The RyR is a calcium channel located on the SR or endoplasmic reticulum in many excitable 
and nonexcitable cells (Giannini et al., 1995; Ledbetter et al., 1994). Three isoforms have 
been identified in mammals referred to as RyR1 RyR2 and RyR3. RyR1 is expressed mainly 
in skeletal muscle and RyR2 is present in cardiac muscle while RyR3 is associated with the 
nervous system particularly the brain (Mackrill et al., 1997). Smooth muscle cells are 
heterogeneous and express all three isoforms (Fritz et al., 2007; Neylon et al., 1995). RyR1 
and RyR2 have been more extensively investigated because of their crucial role in EC 
coupling in skeletal and cardiac muscle, respectively. In humans the gene that encodes for 
RyR1 is located on chromosome 19q13.2 and spans 106 exons, which translates into a 
polypeptide chain of 5038 residues (Gillies et al., 2015). A number of mutations have an 
important impact on RyR1 function and have been associated with several musculoskeletal 
diseases including Malignant Hyperthermia (MH), central core disease (CCD) and 
multiminicore diseases (MmD) (Treves et al., 2005; Treves et al., 2009).  
In skeletal muscle RyR1 assembles into a homotetrameric structure of about 2 MDa where 
each subunit has a molecular weight of approximately 560 kDa, with the shape of a square 
around the central pore. Recent structural data predict that each RyR1 contains 6 
transmembrane domains arranged with the amino and carboxy terminal tails located at the 
cytosolic face of the SR membrane (Zalk et al., 2015). The C-terminus region forms the 
channel, whereas the large N-terminal domain serves as a scaffold, which interacts with other 
regulatory proteins modulating the pore opening. A detailed representation of the architecture 
of the Ryanodine receptor can be visualized in the Figure 6. 
Although RyR1 activity is largely controlled by the calcium channel, voltage sensing Cav1.1 
(Rios and Brum, 1987) by allosteric interaction (Kugler et al., 2004; Proenza et al., 2002; 
Sheridan et al., 2006), other protein such as calmodulin, FKBP12, triadin, junctin, 
calsequestrin also interact with RyR1 (Lanner et al., 2010; Zalk et al., 2007). Additionally, 
and not less importantly small molecules such as ATP, calcium and magnesium serve as 
positive or negative regulators of RyR1 activity (Laver et al., 2001; Meissner et al., 1986; 
Meissner et al., 1997). 
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Figure 6. Architecture of the Ryanodine receptor. A, color-code schematic representation of the RyR. 
B, Predicted structure of the RyR tetramer displayed at different perspectives. B-sol, bridge solenoid; 
C-sol, core solenoid; N-sol, N-terminus solenoid. Coloured as follows: blue, N-terminal domain; 
cyan, SPRY1, SPRY2 and SPRY3; salmon, clamp region (RY12 repeats), and phosphorylation 
domain (RY34 repeats); yellow, FKBP12; green, the bridge solenoid scaffold; red, the core solenoid; 
and orange, transmembrane and C-terminal domains; purple, putative Ca2+-binding domain (EF).  
 
RyR1 function and Malignant Hyperthermia 
 
Unbalance of calcium dynamics caused by dysfunctional RyR1 has been associated with 
several human neuromuscular diseases (see for example reviews by (Hwang et al., 2012; 
Treves et al., 2008). Dominant and recessive mutations identified in the RyR1, the gene 
encoding RyR1 have been linked to disorders including central core disease (CCD) (Wu et 
al., 2006), centronuclear myopathy (CNM) (Wilmshurst et al., 2010), multiminicore disease 
(MmD) (Ferreiro et al., 2002), congenital fiber type disproportion (Clarke et al., 2010), 
heat/exercise induced rhabdomyolysis (Capacchione et al., 2010) and malignant hyperthermia 
(MH) (MacLennan et al., 1990; McCarthy et al., 1990). MH is an autosomal dominant 
disease, in which genetically predisposed individuals react to inhalation anesthetics (e.g., 
A 
B 
View from the Lumen View in the plane of the 
SR membrane  
View from the Cytosol  
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halothane) and depolarizing muscle relaxants (e.g., succinylcholine) or exercise/heat, by 
undergoing a hypermetabolic reaction which is potentially fatal if not treated promptly 
(Denborough, 1998; Rosenberg et al., 2015). The mechanism underlying this pathology 
implicates an uncontrolled rise in the cytosolic calcium concentration due to release from the 
SR mediated by RyR1 after the predisposed individual comes into contact with a trigger 
agent. The elevated cytosolic calcium induces generalized muscle contractures, activates 
glycogenolysis and metabolism resulting in the generation of heat and excess lactate 
production (Jurkat-Rott et al., 2000). The most notable clinical symptoms include metabolic 
acidosis, hypercapnia, rhabdomyoloysis, generalized muscle rigidity, hyperthermia and 
tachycardia. 
When recognized early, treatments of the MH crisis can be implemented by methods for 
lowering the body temperature such as immersion in an as ice bath and rapid administration 
of the antidote dantrolene. This drug normalizes the cellular resting calcium level by blocking 
calcium release driven by RyR1 hyperactivation (Krause et al., 2004; Paul-Pletzer et al., 
2002; Zhao et al., 2001). 
Although the incidence of this disorder ranges from 1:10,000 and 1:250,000 general 
anesthesias, it is estimated that the prevalence of RYR1 causative mutations of MH 
predisposition in the population might be much higher (1:3000 to 1:8500) (Rosenberg et al., 
2007). However, the true number of individuals with MHS is difficult to estimate, principally 
due the fact that in the majority of MH susceptible individuals do not present any physical 
symptoms of muscle dysfunction until they come into contact with a trigger agent in surgery 
or when exposed to high temperatures or stress (Hopkins et al., 1991). Investigations into the 
genetic background and family history of individuals can lead to the identification of this 
disorder that can then be properly investigated either by molecular tools (genetic diagnosis) 
or functionally (in vitro contracture test). In this way, when a potential MH susceptible 
individual is found, and the diagnosis ascertained (including identification of mutations in 
RYR1 or other genes (Gillies et al., 2015; Gonsalves et al., 2013; Hwang et al., 2012) 
alternative anesthetics can be safety administered. In the absence of a genetic diagnosis 
individuals undergo the in vitro contracture test (IVCT) in which the force generated by a 
fresh muscle biopsy is challenged with increasing concentrations of the trigger agent 
halothane or caffeine and the force generated and thresholds values to the stimulants are 
determined and compared to those of normal, non susceptible individuals (Hopkins et al., 
2015).  
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Although, the European Malignant Hyperthermia Group (EMHG) haves reported 35 
causative mutations in the RyR1 for the diagnosis of MHs, 240 mutations seem to be linked to 
the clinical or molecular MH phenotype among the more than 600 variants reported in the 
databank (European Malignant Hyperthermia, 2016; Rosenberg et al., 2003). Additionally, 
two mutations in the gene that encode the α1S subunit of the Cav1.1 (CACNA1S) have also 
been identified as a MHs causative.  
Interestingly, channelopathies associated with RyR1 mutations do not cause the same 
phenotype at functional level (Treves et al., 2008). Depending on the effect on RyR1 
function, mutations are classified as causing 1) Hypersensitive channels: higher probability of 
electrical or chemical activation, 2) Leaky channels: Ca2+ dysregulation leading to depletion 
of SR stores, 3) Voltage sensor uncoupled channels: inability of the Cav1.1 to correctly 
mediate activation of RyR1 and finally 4) Low RyR1 expression level. Most of the RyR1 
mutations associated with MH principally belong to the first and second categories.  
Experimental data have revealed that MH-related mutations in RyR1 knocked-in in mause 
cause an enhanced muscle contractility in response to pharmacological agents (halothane, 
caffeine) and heat (Chelu et al., 2006; Gallant and Lentz, 1992); enhanced voltage-dependent 
stimulation (Dietze et al., 2000), decreased sensitivity to inactivation by Mg2+ and Ca2+ 
(Owen et al., 1997). 
 
DHPR 
 
The Cav1.1 also called dihydropiridine (DHPR) receptor is a voltage-gated calcium channel 
belonging to the family of transmembrane channel proteins that includes voltage-gate sodium 
and potassium channels (Catterall, 1995). Based on its homology, biophysical and 
pharmacological properties, the voltage gate calcium channel comprises a family of at least 
ten members (Cav1.1-1.4; Cav2.1-2.3; Cav3.1-3.3, where Cav1.1 and Cav1.2 are referred to 
as the skeletal and the cardiac form respectively because of their initial identification and 
distribution in such tissues (Curtis and Catterall, 1984; Glossmann et al., 1984).  
The DHPR is a ~430 kDa heteropentamer composed of different subunits:  α1, α2, β, δ and γ. 
The α1 subunit  (Cav1.1) (190 KDa) encompasses both the voltage sensor and the pore, thus 
conferring the major biophysical and functional properties to the channel; whereas the α2δ, β 
and γ subunits control channel expression, membrane incorporation, drug binding and gating 
characteristics of the pore subunit (Buraei and Yang, 2013; Dolphin, 2012; Triggle, 2006). 
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The α1 subunit is a protein of about 2000 amino acid residues organized in 4 repeated 
domains (I-IV), each one containing six transmembrane segments (S1-S6) and both amino- 
and carboxi terminus ends are oriented towards the cytosolic space. The loop between 
domains II-III of the of the α1 subunit are critical for the mechanical communication with the 
RyR1 (Grabner et al., 1999; Lu et al., 1994; Tanabe et al., 1990), however other domains of 
the α1 subunit appear to interact with the RyR1 as well (Slavik et al., 1997).  
The β subunit has a molecular weight of about 55 KDa and its distribution is confined to the 
cytoplasmic face of the channel. It has two important functions: 1) it regulates the 
transport/insertion of the α1 subunit into the sarcolemma (Beurg et al., 1999a; Beurg et al., 
1999b; Gregg et al., 1996) and 2) it acts as a scaffolding protein that stabilizes the 
communication between the α1 subunit of the DHPR.1 and the RyR1 (Neuhuber et al., 1998; 
Schredelseker et al., 2005). 
Regarding the other subunits (α2, δ and γ), not much is known about their contribution to the 
DHPR channel function/regulation (Obermair et al., 2008). 
SERCA 
 
SERCAs are 110 KDa transmembrane proteins located in the terminal cisternae and the 
longitudinal SR, where there are particularly abundant representing approximately 80 percent 
of the total protein content (Costello et al., 1986; Meissner, 1975; Zorzato et al., 1986). They 
play two important functions in muscule calcium homeostasis: 1) removal of the cytosolic 
free calcium thus contributing to the relaxation process and 2) refilling the calcium store after 
contraction by taking up the cytosolic calcium and pumping it back the SR in a ATP- 
dependent way. 
SERCAs are monomeric integral membrane proteins composed of a large cytosolic segment 
“headpiece” connected to a transmembrane domain (M) by a short stalk segment. The 
cytosolic segment consists of 3 separated domains: A, N and P. The A domain may work as 
an actuator or anchor for Domain N, which binds nucleotide. The phosphorylation site is 
contained whitin domain P which is connected to the transmembrane domain (M) the last 
domain (A) that acts as a actuator or anchor for the domain N, connecting the transmembrane 
domain (M); the latter is made up of ten transmembrane helices (M1-M10) anchoring the 
protein to the SR. (Toyoshima et al., 2000). Mammalian cells express three different genes 
(ATP2A1-3) encoding for five different SERCA isoforms: SERCAla,b, SERCA2a–c, 
SERCA3a–f. In skeletal muscle SERCA1a is principally expressed in adult fast-twitch fibers, 
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while SERCA2a is present in slow-twitch fibers and cardiac muscle (Damiani et al., 1981; 
DeFoor et al., 1980; Jorgensen et al., 1988; Jorgensen and Jones, 1986; Zubrzycka-Gaarn et 
al., 1984). SERCA2b and SERCA3 are ubiquitously expressed in different tissues (Burk et 
al., 1989; Gunteski-Hamblin et al., 1988; Lytton et al., 1989) 
As other ATPase pumps, SERCA utilizes the energy obtained from the hydrolysis of ATP to 
maintain a calcium concentration gradient of about 4 orders of magnitude between the lumen 
of the SR (millimolar) and the cytosol (sub-micromolar). The kinetic mechanism is such that 
two calcium ions are transported into the SR lumen for each molecule of ATP hydrolyzed in 
exchange of two or three protons (H+) (Hasselbach, 1980; Olesen et al., 2007; Yu et al., 
1993). 
SERCA pump activity is regulated by the proteins phospholamban and sarcolipin in a tissue 
specific fashion (Periasamy and Kalyanasundaram, 2007). In cardiac SR, phospholamban 
binds to and regulates the activity of SERCA2a depending on its phosphorylation state 
(MacLennan and Kranias, 2003). In its dephosphorylated form, phospholamban is an 
inhibitor of SERCA2a, but, when phosphorylated by PKA (or Ca2+/CaM kinase), 
phospholamban dissociates from SERCA2a, activating this Ca2+ pump. 
On the other hand sarcolipin, a smaller homologue of phospholamban lacking the 
phosphorylation site (Mascioni et al., 2002), is almost exclusively expressed in fast-twitch 
muscles associated with SERCA1. Sarcolipin modulates SERCA1 activity by decreasing its 
calcium affinity at low calcium concentrations, whereas at high calcium concentrations it 
enhance SERCA1a activity by increasing the Vmax (Odermatt et al., 1998). 
A number of others factors including calcium ion concentration, ATP levels, pH, and ADP 
and inorganic phosphate levels also influence SERCA pump activity. 
 
Calsequestrin 
 
The calcium binding protein calsequestrin is the main protein component of the lumen of the 
terminal cisternae in striated muscles (Costello et al., 1986; Saito et al., 1984).  Although it is 
a soluble protein, it is almost entirely located in the terminal cisternae of the SR (Franzini-
Armstrong et al., 1987; Wagenknecht et al., 2002), where it is anchored to the junctional face 
through its interaction with the SR membrane proteins triadin (95 KDA), junctin (20 KDa) 
and JP45 (Beard et al., 2004; Beard et al., 2009; Zhang et al., 1997). This quaternary complex 
serves to buffer calcium near the site of calcium release and additionally it communicates the 
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calcium store level to the RyR, thereby regulating internally the activity of the RyR channel 
(Beard et al., 2005; Beard et al., 2009; Ikemoto et al., 1989; Qin et al., 2009). Calsequestrin 
has a high capacity (40-50 mol of Ca2+ × mol-1 of protein) and low affinity (dissociation 
constant KD = 1 mM) Ca
2+ binding properties (MacLennan and Wong, 1971), thus it acts as a 
calcium buffer and a calcium storage reservoir in the SR. When the luminal calcium 
concentration is high (~1mM) calsequestrin aggregates to form a linear polymer thereby 
increasing its calcium binding capacity (He et al., 1993). The monomeric structure of 
calsequestrin is composed of three similarly folded domains (DI-III) where each domain 
exposes acidic amino acid residues to the exterior increasing cation binding (Wang et al., 
1998). 
Calsequestrin is present in mammalian cells in two isoforms: the “skeletal” form 
Calsequestrin 1 (migrating with an apparent mol mass of 63 KDa) and the “cardiac” form 
calsequestrin 2 (migrating with an apparent molecular mass of 55 KDa), encoded by two 
different genes CASQ1 and CASQ2, respectively (Fliegel et al., 1990; Scott et al., 1988). 
Calsequestrin 1 is expressed in fast- and slow-twitch skeletal muscles, whereas the cardiac 
isoform is expressed in both cardiac muscle and slow-twitch skeletal muscles (Biral et al., 
1992; Damiani and Margreth, 1994; Damiani et al., 1990; Scott et al., 1988). Calsequestrin 
has also been reported to be present in other tissues including smooth muscle cells and 
cerebellum (Damiani et al., 1988; Novak and Soukup, 2011; Volpe et al., 1990; Volpe et al., 
1994). 
 
Calreticulin 
 
Calreticulin is a 46 KDa calcium binding protein present in the luminal space of the 
endoplasmic reticulum (ER) or SR and is expressed in a wide range of tissues (Michalak et 
al., 1999). Similar to calsequestrin, calreticulin can bind calcium with high capacity and 
relatively low affinity (25 mol of Ca2+ × mol-1 of calreticulin). The protein consists of three 
functional domains: N-, P- and C-. The N- and the P domains are implicated in its chaperone 
function, whereas the C-domain highly rich in negatively charged amino acids is responsible 
for its calcium binding properties (Michalak et al., 1999; Nakamura et al., 2001; Prins and 
Michalak, 2011; Treves et al., 1990).  
Calreticulin also plays an important role as a chaperone and together with calnexin (an ER 
integral membrane chaperone) and ERp57 (Protein disulfide-isomerase A3, resident in the 
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ER) contributes to the quality control and folding of newly-synthesized (glyco)proteins 
(Trombetta, 2003). Recent studies suggest that calreticulin influence SERCA expression and 
activity in heart, thus acting possibly not only as calcium buffer but also as a calcium 
reuptake regulator (Jiao et al., 2012; Shimura et al., 2008) 
 
Sarcalumenin 
 
Sarcalumenin is another calcium binding protein of the SR lumen present in striated muscle 
(Rossi and Dirksen, 2006; Treves et al., 2009). It is predominantly found in the longitudinal 
SR localized together with SERCA (Leberer et al., 1990).  
Two isoforms of sarcalumenin exist, a 160 kDa and a 35 kDa glycoprotein that are formed as 
alternative spliced products of a primary transcript encoded by the SAR gene. This protein 
exhibits a high capacity and moderated affinity for calcium (35 mol of Ca2+ × mol−1 of 
sarcalumenin; KD =0.6 mM) (Leberer et al., 1990).. Although sarcalumenin is not crucial for 
muscle function, its absence in mouse leads to poor calcium re-uptake into the SR, thus 
revealing its important role in calcium handling (Manring et al., 2014; Yoshida et al., 2005).  
 
 
Albumin 
 
Albumin is a globular 66.5 KDa protein present in serum involved in the transport of 
proteins, cations (Na+, Ca2+ and K+), fatty acids, hormones, bilirubin and drugs, but whose 
main function is to regulate the colloidal osmotic pressure of blood (Merlot et al., 2014). 
Although albumin is widely distributed in the extracellular environment, some is also present 
within the cell. Studies have demonstrated that albumin can interact with different proteins 
including calreticulin (Fritzsche et al., 2004). Interesting, albumin seems to have additional 
functions in skeletal muscle particularly in the t-tubular membrane, where it constitutes 
around 7 % of the total proteins content (Knudson and Campbell, 1989). Thus, this protein 
has been used as an important marker of tubule integrity and composition in skeletal muscle. 
(Knudson and Campbell, 1989; Muller and Heizmann, 1982), 
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SR protein of 35 KDa (SRP-35) 
 
SRP-35 is a recently identified protein of the SR membrane complex of skeletal muscle. This 
protein has a molecular weight of 35 KDa (hence its name) and is a transmembranal protein 
of the SR with its N- terminus embedded in the SR membrane and a C- terminal catalytic 
domain orientated towards the myoplasm (Treves et al., 2012). SRP-35 belongs to the trans-
all retinol dehydrogenase family of proteins, which catalytic function is the conversion of all-
trans-retinol to retinaldehyde by reducing the cofactor NAD+ to NADH (Liden and Eriksson, 
2006). 
The retinoic acid signaling pathway is involved in the transcription of several genes, 
including some involved in growth, development, differentiation, cytokine production and 
metabolism (Napoli, 1996; Theodosiou et al., 2010). SRP35 is expressed in different tissues 
which are actively involved in metabolism including adipocyte, liver and skeletal muscle 
(Treves et al., 2012). In muscle the retionic acid pathway promotes the activation of 
transcription factors involved in myogenesis and muscle differentiation (Halevy and Lerman, 
1993; Muscat et al., 1994), however its specific role in skeletal muscle as a potential 
regulator of metabolism is currently being investigated. 
 
JP-45 
 
This protein of 45 KDa (JP-45) is located on the junctional face membrane of skeletal muscle 
SR. It was discovered as a minor constituent of the membrane proteins associated with the 
SR (Treves et al., 2009; Zorzato et al., 2000). Initial characterization of JP-45 showed that it 
consists of a single pass transmembrane domain with the C- terminus orientated towards the 
lumen of the SR and the N- terminus facing the cytosolic space (Zorzato et al., 2000). Its 
expression is exclusively confined to skeletal muscle where it is highly enriched in the SR of 
both fast and slow twitch fibers. JP-45 acts as a signaling switch between calsequestrin and 
Cav1.1 (Anderson et al., 2003). This interaction seems to be important for the appropriate 
control of Cav1.1 activity (Mosca et al., 2013). In summary, the role of JP-45 in EC coupling 
can be described as an important maintainer of the functional integrity of Cav1.1 since 
ablation of JP-45 in mouse decreases the functional expression of Cav1.1 in t-tubules, which 
is translated as a loss of muscle strength (Delbono et al., 2007). Additionally, genetic variants 
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of JP-45 can influence the functional characteristics of Cav1.1 in MH susceptible individuals 
(Yasuda et al., 2013). 
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Calcium Homeostasis 
 
Calcium is a universal second messenger that functions in a variety of signaling systems 
ranging from secretion, to transcriptional regulation, proliferation, fertilization and 
metabolism (Berridge et al., 2003). Because of its important function, cells have evolved a 
sophisticated mechanism to regulate its intracellular levels. As mentioned in a previous 
section, in muscle, calcium plays a decisive role as a trigger signal for the activation of the 
contractile proteins.  
 
Quantal calcium release unit: The Elementary Calcium Release Event (ECRE) as a 
fundamental calcium signal 
 
In muscle, a calcium transient is a transient and massive calcium release event that occurs in 
the cytoplasmic space as a response to a trigger signal. From a physiological point of view, 
the rapid and large calcium transient observed in EDL fibers, or the repetitive and slow 
cytosolic calcium changes observed in some smooth muscle cells, are both due to the 
activation of multiple microdomains of calcium release units. Such microdomains were 
initially identified in cardiac myocites and called calcium sparks (Cheng et al., 1993), sparks 
were shown to play an important role in the activation of neighboring clusters of RyR to 
activate more calcium release propagating the calcium signal, a process called calcium 
induced calcium release (CICR) (Fabiato, 1983).  
Localized calcium release events of similar nature have also been observed in other cells and 
were given different names, depending on their kinetics, subcellular localization or channels 
involved (Berridge, 2006; Cheng and Lederer, 2008; Niggli and Shirokova, 2007). Thus, 
microdomains of calcium release can be defined in general as “elementary calcium release 
events” (ECREs), and represent the minimum quantity of calcium released from one or a few  
release units (calcium channel) that combined give rise to the global calcium transient 
(Collier et al., 1999; Inoue and Bridge, 2003). 
Although discrete calcium release events have been identified in the ER due to the opening of 
inositol triphosphate receptors (InsP3R) (Yao et al., 1995; Yao and Parker, 1994), the RyR in 
its different isoforms, is the main calcium channel involved in the generation of calcium 
sparks. 
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Applying advanced microscopy techniques together with computational tools, the RyR-
dependent calcium ECREs have been the subject of extensive investigations and our 
understanding of their biophysical properties and regulation have greatly advanced 
(Bankhead et al., 2011; Csernoch et al., 2004; Demuro and Parker, 2008; Jiang et al., 1999; 
Picht et al., 2007). 
 
Initiation and termination of ECREs in muscle 
 
The activation and termination of ECREs activity might be due to several factors including 
intrinsic activity of the RyR channel, depolarization of the membrane, the presence of 
physiological or non- physiological ligands, cytosolic and SR calcium levels and 
phosphorylation of RyR among others (Lukyanenko and Gyorke, 1999; Satoh et al., 1997; 
Zhou et al., 2004). Studies in cardiac muscle cells suggest that spontaneous ECREs activity 
might be due to the intrinsic stochastic activity of RyR in the resting state (Cheng et al., 
1993). In skeletal muscle, this is markedly different, since spontaneous ECREs activity has 
not been observed in adult skeletal fibers under normal physiological conditions (Shirokova 
et al., 1998). This is due to the fact that the organization of the calcium release- coupling 
units (RyR-Cav1.1) in skeletal and cardiac muscle are fundamentally different. In particular, 
in skeletal muscle the Cav1.1 controls RyR activity by physical contact and specific spatial 
arrangement, while in cardiac muscle this control is only partial or lacking (Block et al., 
1988; Franzini-Armstrong, 1980). Nevertheless, ECREs can be induced in skeletal muscle 
fibers by artificially disrupting the RyR-Cav1.1 communication by osmotic shock, chemical 
permeabilization or mechanical removal of the sarcolemma (Apostol et al., 2009; Kirsch et 
al., 2001; Weisleder et al., 2012). 
Though the mechanisms governing calcium release are quite clear, this is not so for those 
controlling its termination and many mechanisms have been proposed to explain this process. 
At least five different models have been put forward to explain what terminates the ECRE. 
These mechanisms can be listed as follow:  
1) Local calcium depletion: this hypothesizes that a local reduction of calcium content in the 
SR reduces RyR activity (Launikonis et al., 2006); 
2) Coupled gating: involves two or more physically associated RyRs that influence each 
others gating behavior through mechanical contact (Marx et al., 1998);  
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3) Voltage sensor deactivation: consist in the deactivation of the voltage sensor in skeletal 
muscle cells (Cav1.1) that enforces early termination of an ongoing spark (Lacampagne et al., 
2000);  
4) Stochastic attrition: requires the random closure of independently gated channels that 
confers a finite probability for all channels in a cluster to close at once (Stern, 1992); 
5) Channel inactivation: this is a state in which the RyR calcium channel closes and no 
longer responds to stimuli that usually open it (Cheng and Lederer, 2008).  
 
ECRE as a physiological signal for normal EC coupling integrity 
 
Interestingly, ECREs behavior has been used as an important tool to study normal and 
pathological conditions in muscle. In fact in skeletal muscle spontaneous ECREs are not 
normally observed, and the occurrence of such events has been found to correlate with 
special or pathological conditions including stress, aging, mouse models knocked out for 
certain SR proteins or certain neuromuscular disorders (Ward and Lederer, 2005; Weisleder 
and Ma, 2006). For instance, in the mouse model of Duchenne muscular dystrophy (mdx), 
which lacks the structural protein dystrophin, osmotic stress or strenuous exercise conditions 
have been associated with impaired membrane organization that disrupts the interaction 
between the RyR-Cav1.1 proteins leading to the appearance of ECREs activity (Wang et al., 
2005). 
Additionally, during aging substantial changes of ECREs activity have been identified in 
skeletal muscle in response to hypertonic shock. As opposed to the dystrophic mdx mouse 
model however, aged skeletal muscles exhibit diminished osmotic-induced ECREs activity 
(Weisleder et al., 2006). This change was also accompanied by a full set of other changes 
including fragmentation of the SR membrane system, loss of EC coupling proteins 
components such as Cav1.1 (Delbono et al., 1995), calsequestrin (Margreth et al., 1999) 
SERCA (Schoneich et al., 1999) and a change in the RyR/Cav1.1 ratio (Renganathan et al., 
1997) that altogether maintain the appropriate organization, function and performance of the 
EC coupling machinery. 
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Overview of vascular smooth muscle cell physiology 
 
Vascular smooth muscle cell function and organization 
 
Smooth muscle cells are present in the tissues of several hollow organ including 
gastrointestinal and urinary tracts, respiratory airways, reproductive organs. Additionally, 
smooth muscle cells are the principal constituents responsible for maintaining the arterial 
tone in the circulatory system within vertebrates. Due to their diverse distribution within 
many systems, they are largely different in function and structure. However, smooth muscles 
can be roughly classified according to their contractile properties or their electrical coupling 
(Hill et al., 2012). As far as their contractile properties are concerned, they can be divided 
into tonic and phasic. Tonic smooth muscle cells can maintain force for long periods of time, 
while phasic smooth muscle cells can produce rhythmic or intermittent force activity. On the 
other hand, when smooth muscle cells are electrically coupled to each other by gap junctions, 
they function as a single entity called single-unit smooth muscle; on the other hand multi-unit 
smooth muscle lacks this feature working as independent units and individual cells are under 
more direct neural control than single-unit smooth muscles. Nevertheless many smooth 
muscle types do not fit in this classification and present a more mixed and heterogeneous 
contractile features (Hill, 2012). Not surprisingly, variability is also present within the 
smooth muscle cell populations present in the vascular system in small and large arteries. 
Smooth muscle cells present in large arteries are characterize by their tonic phenotype, while 
smooth muscle cells of the small resistance arteries typically exhibit phasic contractions 
(Reho et al., 2014).  
The dilation and contractile properties of blood vessels allows an adequate blood flow to the 
different organs throughout the body. The majority of blood vessels (except capillaries) are 
formed by three different layers: intima, media and adventitia and are shown in Figure 7.  
The inner layer, the intima, is a single layer of endothelial cells facing the lumen of the blood 
vessels in direct contact with the blood. It is separated from the next layer, the media by the 
basal lamina. The media is principally made up by smooth muscle cells disposed so that their 
contraction reduces the vessel diameters. An extracellular matrix of collagen, elastin and 
other glycoproteins not only surround and embed the smooth muscle cells but also provide 
elasticity to the blood vessel. Finally the adventitia is the outer layer and is composed of 
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collagen and fibroblasts and larger vessels may contain small blood vessels (vasa vasarum, 
which supply blood to the wall of large blood vessels), lymphatic vessels and autonomic 
nervous from the sympathetic system principally. 
 
 
 
Figure 7. Blood vessel layers composition. Except capillaries, blood vessels are composed of three 
distinguished layers named adventitia, media and intima as indicated by the arrows. The intima 
contains a single layer of endothelial cells. The media is equipped with a multilayer of smooth muscle 
cells that confers contractile properties to the vessels. The adventitia provides support and elasticity to 
the blood vessels and receives external signals from the autonomous nervous system and other cells 
(not shown). 
 
Vascular smooth muscle cell structure 
 
Smooth muscle cells are elongated and spindle shaped, typically from 5 to 10 µm in width 
and from 40 to 300 µm in length that are arranged in sheets. In addition to their small size 
and mononuclear structure, they do not contain T-tubules, are not striated and their SR is 
considerably less organized compared to skeletal or cardiac muscle cells. In smooth muscle 
tropomyosin is present but the regulatory protein troponin is lacking. However, the protein 
caldesmon that has an analogous regulatory function as the troponin-tropomyosin system is 
expressed (Gusev, 2001). 
Similar to skeletal and cardiac muscle, smooth muscles use actin and myosin to generate 
force, however they are not organized in the repeated band pattern found in striated muscles 
Adventitia 
Media 
Intima 
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since they do not form myofibrils and do not have a sarcomeric structure. Instead, smooth 
muscle contains structures called dense bodies within the cell and dense bands located closed 
to the sarcolemma that have a similar protein composition as the Z-lines, which function as 
anchoring centers for the contractile proteins. The actin filaments are attached to the dense 
bodies, and instead of being disposed in parallel along the cell as in skeletal and cardiac 
muscle, they are oriented slightly diagonally within the cell. On the other hand, each myosin 
filament is surrounded by several actin filaments and arranged so that the cross bridges are 
present along the whole filament length. Thus, the thick and thin contractile filament units 
form a dynamic cross-bridge lattice shape within the cell (Figure 8). Additionally, smooth 
muscle cells also contain intermediate filaments that are also anchored to the dense bodies, 
which do not participate directly in the contraction process but contribute to maintain the 
organization of the cytoskeleton and cell shape.  
 
 
 
 
 
Figure 8. Organization of a vascular smooth muscle cell. Major cellular structures (contractile 
filaments, dense bodies an bands, caveolae, SR and nucleus) are indicated by arrows. The actin and 
myosin contractile proteins form a lattice shape structure within the whole cell interconnected through 
the dense bodies and dense bands. 
 
Excitation contraction coupling in smooth muscle cells 
 
In resting conditions, vascular smooth muscle cells maintain low cytosolic calcium levels but 
a rise of the cytosolic calcium level will lead to the activation of the contractile apparatus  
(the actin and myosin system). As opposed to skeletal muscles however, the mechanisms 
underlying the activation and regulation of contraction are considerably different. Stimuli 
from different sources including sympathetic adrenergic nerves, circulating hormones, 
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substances released by endothelial cells or substances released by the tissue surrounding the 
vessels, can influence the vascular tone. At the same time, vascular smooth muscle cell 
contraction can be initiated by electrical, chemical or mechanical stimuli (Bolton, 1979; 
Gollasch and Nelson, 1997; Nakayama and Tanaka, 1994; Rembold, 1992). The summation 
of all inputs will determine the cytosolic calcium levels and therefor the contractile or relaxed 
state of the cell. Electrical depolarization of the sarcolemma elicits contraction primarily by 
opening the voltage activated calcium channel Cav1.2 (Clapp et al., 1987; Gollasch and 
Nelson, 1997; Vivaudou et al., 1988). Calcium influx via Cav1.2 can also occur by 
membrane depolarization activated by receptor operated channels (Large, 2002). Many 
different chemical stimuli (norepinephrine, epinephrine, angiotensin II, vasopressin, 
endothelin-1, and thromboxane A2) activate signal transduction pathways that ultimately lead 
to an increase of cytoplasmic calcium, producing contraction. High levels of cytosolic free 
calcium triggered by any of the mechanism mentioned above will bind to the calcium binding 
protein calmodulin, a protein structurally similar to troponin (Ikura, 1996). The calcium-
calmodulin complex binds to and activates the myosin light chain kinase that successively 
phosphorylates the myosin light chain in the presence of ATP. Myosin light chain 
phosphorylation permits the cross-bridge formation between the head of the myosin heavy 
chain and actin, leading to contraction. Since smooth muscles lack the troponin complex, the 
above mentioned proteins are the main regulators of contraction. Dephosphorylation of 
myosin light chains by the enzyme myosin light chain phosphatase provide the signals 
leading to termination of muscle contraction (Hirano et al., 2004).  
The SR/ER serves as a calcium store that can release calcium into the cytosol by activation of 
the inositol triphosphate receptors (InsP3 receptor) (Sasaguri et al., 1985; Somlyo et al., 
1985; Suematsu et al., 1984). RyR calcium channels are also present in the smooth muscle 
SR, however they participate to the excitation contraction coupling mechanism in a different 
way. As opposed to InsP3 receptors, localized calcium release via RyR channel activate 
calcium dependent potassium channels located at the sarcolemma, which, once activated, 
leads to spontaneous transient outward currents (STOCs) (Benham and Bolton, 1986; 
Ganitkevich and Isenberg, 1990). Activation of STOCs shifts the membrane potential to more 
negative values (hyperpolarized) and prevent calcium entrance via Cav1.2 (Jaggar et al., 
1998; Nelson et al., 1995; Perez et al., 1999), therefore inducing smooth muscle cell 
relaxation. In this context, since calcium has a dual role in smooth muscle cells, the spatial 
and temporal characteristics of the calcium transients are a critical determinant in whether the 
cells contract or relax. 
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Figure 9. EC coupling mechanism in vascular smooth muscle cells. Depolarization of the plasma 
membrane by an action potential or by activation of receptor operated channel (ROC) cause a calcium 
influx via the voltage sensor calcium channel (Cav1.2) (1). Chemical stimuli can also increase 
cytosolic calcium via signal transduction of Gq protein-coupled receptors that ultimately activate 
InsP3 receptors and mobilize calcium from the SR (2). Increased free cytosolic calcium binds to 
calmodulin and activates the myosin light chain kinase to initiate contraction (3). Decreased cytosolic 
calcium initiates the relaxation. Calcium is removed from the cytosol by re-uptaking into the SR 
through SERCA activity (4) or by extrusion to the extracellular space via the PMCA or the NCX (5). 
On the other hand relaxation can also be promotes by elementary calcium release (ECRE) activity 
through activation of RyR, which trigger STOCs from the calcium dependent potassium channels 
(BK) and hyperpolarize the sarcolemma preventing calcium influx from Cav1.2 (6). 
Dephosphorylation of myosin light chain via MLCP (7) or inhibition of MLCK (8) via cAMP 
production through activation of Gs protein-coupled receptors inhibit contraction. Ca-CAM: calcium–
calmodulin complex; PLC: phospholipace C; AC: adenylyl cyclase; MLCK: myosin light chain 
kinase; MLCP: myosin light chain kinase; STOCs: Spontaneous transient Outward Current(s). 
 
Similar to skeletal muscle, relaxation in smooth muscle cells is also accompanied by 
mechanisms that decrease the free cytosolic calcium concentration to resting levels. The main 
mechanisms involved in lowering the calcium concentration include 1) reuptake of calcium 
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to the SR via SERCA2 activity, 2) calcium extrusion to the extracellular space via PMCA 
(Cartwright et al., 2011; Floyd and Wray, 2007; Wray and Burdyga, 2010) or via the sodium 
calcium exchanger (NCX) (Nazer and van Breemen, 1998; Zhu et al., 1994) and to a lesser 
extent by the mitochondrial calcium uniporter (MCU) (McCarron et al., 2013).  
It should be mentioned that modulation of calcium homeostasis and therefor the vascular tone 
is greatly dependent on several signal transduction mechanisms. These mechanisms can be 
summarized as follows: 1) the inositol three phosphate (IP3) pathway via activation of Gq-
protein-coupled receptors (Wu et al., 1992) leading to SR calcium release (contraction); 2) 
inhibition of the myosin light chain kinase (relaxation) by cyclic adenosine monophosphate 
(cAMP) via activation of Gs-protein-coupled receptors (Takuwa, 1996) and 3) inhibition of 
the Cav1.2 calcium channel and the InsP3 receptor (relaxation) by protein kinase G (PKG) 
via endothelial nitric oxide (NO) production and formation of cyclic guanosine 
monophosphate (cGMP) (Zhao et al., 2015). 
Figure 9 summarizes the main mechanisms leading to calcium mobilization in vascular 
smooth muscle during EC coupling.  
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Hemostasis and bleeding disorders associated to impaired vascular response 
 
 
Hemostasis comprises the physiological response activated to arrest blood loss from an 
injured vessel (Colman, 2006). This complex process depends on the activation of different 
pathways within the vasculature, platelets and coagulation factors. The cascade of events 
taking place to stop the bleeding can be summarized as indicated below:  
1) Primary hemostasis: in this step two important events occur to prevent further blood loss: a 
local vascular contraction and platelet plug formation. The first event is a local vascular 
contraction also referred to as vascular spasm, which is caused by contraction of the smooth 
muscle cells lining the blood vessels and limits blood flow to the injured site. This vascular 
response is triggered by endothelins, small peptides released by cells lining the vessel and 
pain receptor in response to vessel injury (Loscalzo, 1995). Immediately following the 
vascular response, platelets that normally flow freely in the blood, encounter and adhere to 
the area of vessel injury due to the exposure of connective tissue and collagen fibers on the 
luminal face of the vessel (Broos et al., 2011). At this point platelets release their cytoplasmic 
granules containing chemicals that promote the recruitment and adhesion of more platelets to 
the site of injury and also maintain vasoconstriction. Thus a temporary plug is formed in the 
vessel wall that seals the injured vessel and serves as an initial defense against blood loss. 
2) Secondary hemostasis: in this step a more sophisticated and durable repair sequence of 
events occurs leading to the formation of the blood clot (or coagulation). Damage of the 
endothelium results in exposure of membrane-bound pro-coagulant factors (Tissue Factor) 
that act in conjunction with secreted platelet factors to activated the coagulation cascade: a 
series of enzymatic reactions that culminate in thrombin activation (Versteeg et al., 2013). 
The result is the formation of a gelatinous but robust clot made up of mesh of fibrin, an 
insoluble fibrous protein derived from fibrinogen in which platelets and blood cells are 
trapped.  
3) Fibrinolysis. As the vessel heals the normal blood flow is restored and the clot is removed. 
Fibrinolysis is the process by which the fibrin clot is broken down (Chapin and Hajjar, 2015). 
During this process a series of enzymatic reactions take place whereby plasminogen is 
converted into the active form plasmin, which gradually degrades the fibrin mesh within the 
clot. Additionally, vasodilatory substances are released allowing relaxation of the smooth 
muscle cells thereby helping to restore the normal circulation (de Maat et al., 2014). 
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Alterations on any of the components of this delicate balance will result in thrombosis or 
hemorrhagic disorders. A number of pathological conditions leading to hemorrhage have 
been well characterized and the most severe forms generally affect platelets function or 
coagulation factors (Czarnecki, 2008). However, bleeding disorders associated with impaired 
vessel contraction have been described. As far as the vascular system is concerned, bleeding 
may result from different deficiencies in different factors including deficiency of connective 
tissue function (e.g Ehlers-Danlos syndrome (Malfait and De Paepe, 2014)), arteriovenous 
malformation (e.g. hereditary hemorrhagic telangiectasia (Dittus et al., 2015)) vessel 
infiltration with amyloid (Mumford et al., 2000) or inflammatory processes caused by some 
infections (Chetty et al., 2000; Pulido-Perez et al., 2012). 
Nevertheless, the mechanism underlying many bleeding disorders are still uncertain, and such 
disorders are difficult to diagnosis (Quiroga and Mezzano, 2012; Tosetto et al., 2013). We 
hypothesized that impaired calcium homeostasis in smooth cells may be responsible for 
alterations of the primary vasoconstriction response and thus may be at the basis of mild 
bleeding disorders of undefined causes. Indeed though arterial smooth muscle cells play an 
important role in primary hemostasis, few studies have connected smooth muscle calcium 
homeostasis with bleeding abnormalities. In the next section (results, manuscript two) we 
present evidence that these two processes: namely smooth muscle Ca2+ homeostasis and 
bleeding physiology are importantly associated in order to maintain the appropriate balance 
of primary hemostasis. 
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RESULTS 
 
Manuscript I: mTORC1 signaling on EC coupling and Ca2+ homeostasis of skeletal 
muscle 
 
Summary of publication 1 
 
 
This study was undertaken following the observations of Bentzinger and colleagues (2008) in 
their RAPTOR KO muscle specific mouse model and the similar findings by Risson and 
coworkers (2009) in their muscle specific mTOR KO mouse model. These studies showed 
that mTOR plays an important role in skeletal muscle. Indeed, lack of this complex causes a 
dystrophic phenotype, fibers with centralized nuclei, presence or core-like structures, 
decreased muscle mass, reduced twitch force and maximal tetanic absolute force 
accompanied by a slow kinetics as well as changes in metabolism intracellular signaling. We 
decided to study in detail whether the molecular machinery of EC coupling is directly 
responsible for the deleterious changes observed on muscle performance and Ca2+ 
homeostasis. By immunoblotting we investigate the protein content of total SR preparations 
from skeletal muscles of RAPTOR KO (RamKO) and their WT littermates with commercial 
antibodies reacting against some of the main proteins participating in EC coupling (SERCA1, 
SERCA 2, calsequestrin, calreticulin, sarcalumenin, RyR1, DHPRα1, DHPR β1, albumin, 
SRP-35 or anti-JP-45). We also investigate by ligand binding the content of RyR1 and 
Cav1.1 proteins. Additionally, we investigated glycogen phosphorylase content and activity 
of total SR preparations. Finally we studied the Ca2+ homeostasis of enzymatically isolated 
single skeletal muscle fibers (EDL and soleus) by measuring the resting Ca2+ level, 
electrically elicited Ca2+ transient and Elementary calcium Release Events (ECREs) after 
osmotic shock. The results coming from this biochemical and functional characterization 
extend the role of mTORC1 signaling and implicate its function in maintaining the integrity 
of the molecular components of the EC coupling of skeletal muscles. 
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Raptor ablation in skeletal muscle decreases Cav1.1 expression and affects the 
function of the excitation–contraction coupling supramolecular complex¶ 
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Abstract 
The protein mammalian target of rapamycin (mTOR) is a serine/threonine kinase regulating a 
number of biochemical pathways controlling cell growth. mTOR exists in two complexes 
termed mTORC1 and mTORC2. Regulatory associated protein of mTOR (raptor) is 
associated with mTORC1 and is essential for its function. Ablation of raptor in skeletal 
muscle results in several phenotypic changes including decreased life expectancy, increased 
glycogen deposits and alterations of the twitch kinetics of slow fibres. In the present  paper, 
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we show that in muscle-specific raptor knockout (RamKO), the bulk of glycogen 
phosphorylase (GP) is mainly associated in its cAMP-non-stimulated form with sarcoplasmic 
reticulum (SR) membranes. In addition, 3[H]–ryanodine and 3[H]–PN200-110 equilibrium 
binding show a ryanodine to dihydropyridine receptors (DHPRs) ratio of 0.79 and 1.35 for 
wild-type (WT) and raptor KO skeletal muscle membranes respectively. Peak amplitude and 
time to peak of the global calcium transients evoked by supramaximal field stimulation were 
not different between WT and raptor KO. However, the increase in the voltage sensor-
uncoupled RyRs leads to an increase of both frequency and mass of elementary calcium 
release events (ECRE) induced by hyper-osmotic shock in flexor digitorum brevis (FDB) 
fibres from raptor KO. The present study shows that the protein composition and function of 
the molecular machinery involved in skeletal muscle excitation–contraction (E–C) coupling 
is affected by mTORC1 signalling. 
 
Key words  
Dihydropyridine receptor (DHPR), excitation–contraction (E–C) coupling, mammalian target 
of rapamycin (mTOR), ryanodine receptor (RyR), skeletal muscle sarcoplasmic reticulum 
(SR). 
 
Abbreviations: Ab, antibody; AM, acetoxymethylesther; BTS, N-benzyl-p-
toluensulfonamide; CR, calreticulin; CSA, cross-sectional area; DHPR, dihydropyridine 
receptor; DMEM, Dulbecco’s Modified Eagle’s medium; E–C, excitation–contraction; 
ECRE, elementary calcium release events; EDL, extensor digitorum longus; FDB, flexor 
digitorum brevis; FDHM, full duration at half-maximum amplitude; FKBP12, FK506-
binding protein; FWHM, full width at half-maximum amplitude; GP, glycogen 
phosphorylase; HEK, human embryonic kidney; KO, knockout; mLST8, mammalian lethal 
with SEC13 protein 8; mTOR, mammalian target of rapamycin; NR, normal Ringer; 
RamKO, muscle-specific raptor knockout; raptor, regulatory associated protein of mTOR; 
RyR, ryanodine receptor; SERCA, sarcoplasmic reticulum calcium pump; SR, sarcoplasmic 
reticulum; SRP-35, SR protein of 35 kDa; WT, wild-type. 
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Introduction 
 
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase controlling 
different biochemical pathways activated in response to growth factors and nutrient 
availability, including protein synthesis, ribosome biogenesis, nutrient transport, lipid 
synthesis and autophagy, thus playing a central role in metabolism, growth and aging [1–5]. 
Two different mTOR complexes possessing different roles within the cell have been 
identified: mTORC1 and mTORC2. The immunosuppressant drug rapamycin is an allosteric 
inhibitor of mTORC1, a complex playing a role in nutrient sensing and controlling protein 
synthesis, lipid synthesis and glycolysis [6]. After forming a complex with its cytoplasmic 
receptor FKBP12 (FK506-binding protein), rapamycin binds mTORC1 and induces its 
destabilization, resulting in the inability of mTOR to phosphorylate target proteins [6]. 
mTORC1 complex is made up of mTOR, regulatory associated protein of mTOR (raptor), 
mammalian lethal with SEC13 protein 8/G-protein β-subunit like protein (mLST8/GβL) and 
proline-rich Akt substrate of 40 kDa (PRAS40) [7,8]. Its kinase activity is regulated through 
a dynamic interaction between mTOR and raptor, the latter being a conserved 150 kDa 
protein, which besides mTOR, also interacts with S6K1 (ribosomal protein S6 kinase 1) and 
4E–BP1 (eukaryotic translation initiator factor 4E-binding protein 1). mTORC2 on the other 
hand, is largely insensitive to rapamycin, is active in growing cells and regulates the actin 
cytoskeleton, cell survival and apoptosis. It forms a complex with rictor, mSIN1 (target of 
rapamicin complex 2 subunit Mitogen-activated protein kinase 2-associated protein 1), 
mLST8 and mTOR [9]. 
During the past decade, research on the role of mTOR has revealed that this kinase is 
implicated in a variety of diseases, including cancer, neurodegeneration and metabolic 
disorders [9]. Furthermore mTOR activity has been shown to be involved in the control of 
muscle mass and indeed rapamycin treatment delays recovery of skeletal muscle from 
atrophy whereas activation of the mTOR’s upstream components induces muscle 
hypertorphy [10]. It has been shown that skeletal muscle-specific mTOR inactivation 
increases the glycogen content of muscle fibres, an effect linked to the down-regulation of 
glycogen phosphorylase (GP) and of other enzymes involved in the glycogenolytic pathway 
[11]. Similar results were also obtained by Bentzinger et al. [12] who investigated the role of 
the mTORC1 signalling pathway in skeletal muscle, by generating muscle-specific raptor 
knockout mice (RamKO). Skeletal muscles of RamKO mice became progressively atrophic, 
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had increased glycogen content and showed a transition of the metabolic signature from 
oxidative to glycolitic, despite slow twitch fibre-type predominance [12]. Although RamKO 
mice have poor in vivo oxidative muscle performance on the running wheel, in vitro tetanic 
stimulation shows that isolated extensor digitorum longus (EDL) and soleus from RamKO 
mice are more resistant to fatigue. The reduction in absolute force development is accounted 
for by the decrease in muscle mass, since after normalization for cross-sectional area (CSA) 
there is no significant difference in maximal tetanic force between control and RamKO mice. 
Nevertheless the twitch kinetics of the soleus from RamKO mice is dramatically affected: 
there is an increased time to peak and almost doubling of the half relaxation time. Because of 
these changes and because mTORC1 inhibition is a common therapeutic strategy in humans, 
we investigated in more detail the functional changes of ablation of mTORC1 in skeletal 
muscle by examining excitation–contraction (E–C) coupling in RamKO mice. E–C coupling 
involves the conversion of an electrical signal into a transient increase in the intracellular 
[Ca2+ ] and is initiated by conformational changes at the level of the L-type voltage-
dependent calcium channel [dihydropyridine receptor (DHPR), Cav1.1] localized in the 
membrane of the transverse tubules [13,14]. Activation of Ca2+ release from terminal 
cisternae is due to the transmission of a conformational change occurring on the DHPR to the 
ryanodine receptor (RyR) 1 via direct protein–protein interaction [15–17]. The resulting 
increase in the intracellular [Ca2+ ] is due to the opening of the RyR1 and this is followed by 
Ca2+ removal, which depends mostly on the activity of sarcoplasmic reticulum (SR) calcium 
pumps (SERCA) localized in the longitudinal SR and, to a lesser extent, on the sarcolemmal 
Na+ /Ca2+ exchanger and plas-malemma Ca2+ pump [18]. Mutations in the two Ca2+ channels 
(RyR1 and DHPR α1 subunit) directly involved in E–C coupling are the underlying feature of 
a group of several disorders including core myopathies in which the underlying histological 
feature is the presence of cores and fibre type I pre-dominance (for review see [19]). 
Interestingly, the muscles of RamKO mice also exhibit core-like structures and slow fibre-
type predominance [12]. 
In the present study, we investigated the functional and biochemical properties of the SR 
membranes from RamKO mice. We found that the inactivation of mTORC1 is associated 
with the compartmentalization of GP to SR membranes. In addition, we found an increase in 
the: (i) half-time of the decay of the calcium transient in soleus fibres; (ii) ryanodine to 
DHPRs ratio; (iii) frequency and mass of elementary calcium release events (ECRE) induced 
by hyperosmotic shock in FDB fibres. Altogether our data suggest that protein composition 
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and function of the membrane compartments involved in E–C coupling is affected by 
mTORC1 signalling. 
 
 
Materials and Methods 
 
RamKO mice 
 
Details of the targeting strategy and initial characterization of RamKO mice are previously 
described [12]. KO mice were identified by PCR amplification of genomic DNA. All 
experiments were conducted on male mice in accordance with local Kantonal guidelines and 
regulations (Kantonales Veterinäramt Basel Stadt). 
 
RNA extraction, reverse transcription and PCR reactions 
 
Total RNA was extracted from mouse leg muscles using Tri-reagent following the 
manufacturer’s recommendations (Molecular Research Centre). Total RNA was converted 
into cDNA using SuperScriptTM II Reverse Transcriptase (Invitrogen) as previously described 
[20]. PCR reactions were carried out using the following primer sets: mouse β-actin forward: 
5’-GGACCTGACAGACTACCTCA-3’ and reverse 5’-GCAGTAATCTCCTTCTGCAT-3’; 
DHPRα1 (Cav1.1) forward 5’-CATTAGGTAGAGCCGTGCACCTG-3’ and reverse 5’-
GCCTGTTGTCATGACGAAGTTAGC-3’. Amplification condi-tions were 5 min at 95◦C 
followed by 35 cycles of 30 s denaturation at 92ºC, 40 s annealing at the recommended 
temperature for each primer pair and 40 s extension at 72ºC followed by a final extension for 
5 min at 72ºC using the 2.5× Master Mix Taq polymerase from Eppendorf. The products of 
the PCR reaction were separated on a 1% agarose gel and the DNA bands were visualized by 
Ethidium Bromide staining. 
 
SR isolation, Western blotting and biochemical assays 
 
Total SR was prepared as previously described from mouse skeletal muscle [20]; vesicles 
enriched in terminal cisteranae, longitudinal SR and plasmalemma were prepared as 
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described by Saito et al. [21] and stored in liquid nitrogen until used. C2C12 myotubes were 
treated for 16 h with 20 μM rapamycin or left untreated; cells were then washed twice with 
PBS, harvested, and the heavy SR protein fraction was obtained by differential 
centrifugation. For Western blotting, proteins were separated by SDS/PAGE, blotted on to 
nitrocellulose and probed with commercial antibodies (Abs) against SR proteins [SERCA1, 
SERCA 2, calsequestrin, calreticulin (CR), sarcalumenin, RyR1, DHPRα1, DHPR β1, 
albumin, SRP- 35 (SR protein of 35 kDa) or anti-JP-45 Abs; 20]) followed by peroxidase-
conjugated secondary Abs. The immunopositive bands were visualized by 
chemiluminescence as previously described [22]. To accurately quantify DHPR and RyR 
content in the SR and the Ca2+ dependency of [3H]-ryanodine binding, radioligand-binding 
experiments using [3H]-PN200-110 (DHPR expression) and [3H]-ryanodine were performed 
as described [23]. The different free [Ca2+ ] (750 pM, 9.1 nM, 95 nM, 1.1 μM, 9 μM, 104 
μM, 1 mM) were obtained by the addition of different amounts of CaCl2 as described by 
Fabiato [24]. The amount of bound [3H] ligand was measured by liquid scintillation counting. 
 
In vitro muscle strength assessment 
 
To test force in vitro, EDL and soleus muscles were dissected and mounted into a muscle-
testing setup (Heidelberg Scientific Instruments). Muscles were stimulated with 15-V pulses 
for 0.5 ms and force was digitized at 4 kHz by using an AD instruments converter. EDL 
tetanus was recorded in response to a 400 ms train of pulses delivered at 10–120 Hz; soleus 
tetanus was recorded in response to an 1100 ms train of pulses delivered at 10–150 Hz. 
Specific force was normalized to the muscle CSA per wet weight (mg)/length (mm) per 1.06 
(density mg/mm3)as previously described [23]. 
 
Isolation of extensor digitorum longus and soleus muscle fibres 
 
Single muscle fibres were obtained from 6–8 week old mouse hindlimbs by enzymatic 
dissociated, as previously described [25]. Briefly, muscles were dissected and pinned via the 
tendons to a Sylgard-lined dissecting chamber. The outer connective tissue was removed and 
the muscles were incubated in Tyrode’s solution containing 0.22% type I collagenase 
(Sigma) at 37°C for 1h followed by rinsing in 10% fetal bovine serum (FBS) in DMEM 
(Dulbecco’s Modified Eagle’s medium). To release single fibres, muscles were triturated 
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gently in serum-free DMEM, then plated on glass coverslips pre-treated for 2 h with 1.5 μl of 
natural mouse laminin (Invitrogen) diluted with distilled water. Fibres were then incubated in 
DMEM, 10% FBS, 1% penicillin/streptomycin, 5% CO2 at 37ºC overnight. FDB fibres were 
isolated as previously described [23]. 
 
Calcium measurements 
 
The resting [Ca2+ ] was monitored in isolated fibres from RamKO mice and control 
littermates with the ratiometric fluorescent Ca2+ -indicator indo-1/AM (acetoxymethylesther); 
changes in the [Ca2+ ]i induced by electrical depolarization were monitored in EDL and 
soleus fibres loaded with mag–fluo–4/AM in Tyrode’s buffer. All experiments were carried 
out at room temperature (20°C–22°C) in the presence of 50 μM N-benzyl-p-
toluensulfonamide (BTS; Tocris) to minimize movement artefacts. Measurements were 
carried out with a Nikon ECLIPSE TE2000-U inverted fluorescent microscope equipped with 
a 20× PH1 DL magnification objective. The light signals from a spot of 1 mm diameter of the 
magnified image of flexor digitorum brevis (FDB) fibres, were converted into electrical 
signals by a photomultiplier connected to a Nikon Photometer P101 amplifier. Calcium 
transients were collected by custom made (RCS AUTOLAB) software and analysed by 
PowerLab Chart5 and Origin.6 programs. Changes in fluorescence were calculated as ∆F/F = 
(Fmax-Frest)/(Frest). 
   FDB fibres were isolated, kept for 4 h in a 37ºC, 5%CO2 cell incubator, placed on a 
laminin-coated coverslip and loaded for 20 min at room temperature with 10 μM fluo-4 AM 
Ca2+ indicator (fluo-4/AM, Molecular Probes). All experiments were performed at room 
temperature. ECREs were measured using a Nikon A1R laser scanning confocal microscope 
(Nikon Instruments Inc.) with a 60× oil immersion Plan Apo VC Nikon objective, numerical 
aperture 1.4. (Nikon Instruments Inc.). Five-second-duration linescan images (x,t) were 
acquired in resonant mode at 7680 lps with 512 pixels (0.05 μm/pixel) in the x- and 39936 
pixels (0.126 ms/pixel) in the t-direction using a pinhole size of 72.27 μm. Fifteen images 
were taken at different positions across each cell. The Ca2+ indicator was excited with a laser 
at 487 nm and the fluorescence emitted at 525 ± 25 nm was recorded. To minimize photo 
damage, the laser intensity was set at 3%–4% of the maximal power. The viability of fibres 
after osmotic shock was assessed by monitoring single calcium transient evoked by 
supramaximal field stimulation pulses. Fibres were first perfused with isotonic (∼290 mOsm) 
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normal Ringer (NR) (in mM, 140 NaCl; 2 MgCl2; 2.5 CaCl2; 10 HEPES; 5 KCl; pH adjusted 
to 7.4) using a Minipuls 2 peristaltic pump (Gilson Medical Electronics). To induce ECREs, 
cells were perfused with a hypertonic solution (∼420 mOsm) by increasing the [Ca2+ ] to 50 
mM (in mM, 140 NaCl; 2 MgCl2; 50 CaCl2; 10 HEPES; 5 KCl; pH adjusted to 7.4) [26,27]. 
Osmolarity of the solution was assessed with a Vogel 801 Osmometer (Vogel GmbH). All 
solution contained 10 μM BTS. 
 
ECRE analysis 
 
ECREs morphology [amplitude, ∆F/F0; full width at half-maximum amplitude (FWHM); full 
duration at half-maximum amplitude (FDHM)] were determined from linescan images using 
the open source image analyser software Fiji [28]. After images were binned by average 4× at 
the t-axis, they were processed using the automated spark detection plugin Sparkmaster [29]. 
Because of the heterogeneity of the ECREs duration, events were split in two groups: the 
short lasting events with <50 ms of FWHM and the long lasting events ECREs with >50 ms 
of FWHM duration [30]. Frequency was calculated for each group by counting the number of 
events occurring per image. The mass was determined by the following formula mass = 
1.206·∆F/F0·FWHM3 [31]. Statistical analysis was performed using the program OriginPro® 
version 8.6.0. ECRE derived from 25 and 26 fibres obtained from five wild-type (WT) and 
RamKO mice respectively. Data are expressed as mean ± S.E.M.; values were considered 
statistically significant if P < 0.05 using the Student’s t-test. 
 
Glycogen phosphorylase activity measurement 
 
GP activity was measured as described [32–34]. Reactions were initiated by adding 30–60 μg 
of SR to a 500μl of reaction buffer containing 50 mM imidazole pH 7.0, 20 mM K2HPO4, 
1.25 mM MgCl2, 5μM glucose 1,6-diphosphate, 0.5 mM DTT, 3 μg/ml phosphoglucomutase, 
0.25% BSA, 10 mg/ml AMP-free glycogen. For measurement of total activity (forms ‘a’ and 
‘b’ of GP) AMP was added to obtain a final concentration of 3 mmol/l. The reaction was 
carried out at 30°C for 30 min (total activity) or for 60 min (to determine the amount of form 
‘a’) and terminated by the addition of 60 μl of 0.5 M HCl. Aliquots of 50 or 100 μl (for total 
and form ‘a’ measurement respectively) of primary reaction mixture were added to 1 ml of a 
glucose- 6-phosphate dehydrogenase reaction buffer containing 50 mM Tris/HCl, pH 8.0, 1 
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mM EDTA, 250 μM NADP and 0.5 μg/ml glucose-6-phosphate dehydrogenase. This reaction 
was allowed to proceed for 10 min at room temperature and the absorbance of the samples at 
340 nm was determined spectrophotometrically to quantify the degree of conversion of 
NADP into NADPH (which is proportional to the content of glucose 6-phosphate formed in 
the first reaction). GP activity is expressed in micromoles per minute per milligram protein 
(unit/mg). 
 
Luciferase reporter assay 
 
The constructs containing DHPRα1.1 promoter region fragments (Luc7P–724, Luc/P756) 
were cloned in frame in pGL3-basic expression vector (Promega) [35]. C2C12 myoblasts (2 × 
104 cells per dish) were plated on gelatin-coated 35 mm cell culture dishes and allowed to 
grow in DMEM plus Glutamax, 4.5 g/l glucose, 20% FBS, 50 units/ml penicillin, 50 μg/ml 
streptomycin until 50% confluent. Two microgram of each construct and 200 ng of the 
control vector pRL–TK were used for transfection using the FuGENE6 transfection reagent 
(Roche). Twenty-four hours after transfection, cells were induced to differentiate by changing 
the medium to DMEM plus Glutamax, 4.5 g/l glucose, 5% horse serum and 
penicillin/streptomycin. After 4–6 days, when cells had visibly fused into mytoubes, 20 μM 
rapamycin (Sigma) was added as described [36,37]. Cells were then washed twice with PBS 
and lysed using Passive Lysis Buffer (Promega). Firefly luciferase and renilla activity were 
measured with Victor2 Luminometer (PerkinElmer). Firefly luciferase activity was 
normalized to renilla activity and expressed as mean (± S.E.M.) enzymatic activity units. 
 
 
Results 
 
Mechanical properties of isolated fibres and content of proteins involved in excitation–
contraction coupling in skeletal muscles of RamKO mice 
 
Ablation of raptor induces changes in the mechanical properties of fast and slow twitch 
muscles [12]; Figure 1 shows representative traces of twitch and tetanic force of EDL and 
soleus from control and RamKO mice [12]. Although tetanic-specific force in EDL and 
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soleus muscles do not vary between control and RamKO [12] mice, the twitch kinetics in 
RamKO soleus show a remarkable prolongation of the half relaxation time at lower peak 
force. The changes of the mechanical properties of the twitch in EDL and soleus muscles 
could be due (i) to fibre-type switching induced by ablation of raptor, (ii) to an effect on the 
contractile protein machinery, (iii) to alterations of the E–C coupling mechanism or (iv) to a 
combination of two or more of these mechanisms. 
 
Protein composition of skeletal muscle sarcoplasmic reticulum from RamKO mice 
 
Analysis of the main protein components of total SR membranes from RamKO mice and 
control littermates revealed no significant changes in the content of SERCA1, SERCA2, JP-
45, calsequestrin and CR. In addition, there was a small but significant decrease in 
sarcalumenin (Figure 2), a modulator of SERCA activity [38]. We also found a decrease in 
SRP-35, a newly identified membrane-bound retinol dehydrogenase of sarcotubular 
membranes [22]. 
 
RamKO ablation affects the excitation–contraction coupling macromolecular complex 
 
To study in greater detail the effect of raptor ablation, we determined the membrane density 
of the two core components of the E–C coupling machinery, namely the Cav1.1 (α1.1 of the 
DHPR) and RyR1 by performing quantitative Western blot analysis and equilibrium ligand 
binding on the crude microsomal preparation isolated from skeletal muscle of RamKO and 
control littermates. The most interesting results of the present study are that the content of 
Cav1.1 in RamKO mice was reduced by almost 50% compared with control littermates 
(Figure 3A). Equilibrium binding of the Cav1.1 ligand PN200-100 to crude SR membranes 
shows that the maximal binding capacity (Bmax) for PN200-100 binding was 0.68 ± 0.05 and 
1.25 ± 0.13 pmol/mg protein in RamKO and control littermates respectively with no 
significant changes of its dissociation constant (KD = 0.96 ± 0.16 compared with 1.35 ± 0.32 
nM, mean ± S.E.M., n=6 for RamKO and control littermates respectively). The reduced 
expression of Cav1.1 is, surprisingly, accompanied by a 3.5-fold increase in the content of the 
Cavβ1 subunit (Figures 3B and 3C). On the other hand, the decrease in the total amount of 
Cav1.1 was not due to a reduction in the relative amount in T-tubule membranes in the total 
sarcotubular membrane fraction, as the content of albumin, a marker for T-tubules [39] was 
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unchanged (Figures 3B, 3C and 4B). mTORC1 regulates protein expression by affecting 
translation via S6K1 and 4E–BP [5] and/or by controlling the transcription of several 
additional genes [40]. To determine if the decrease in Cav1.1 in the muscles of RamKO mice 
was due to alterations in transcription we performed semi-quantitative PCR experiments. As 
shown in Figure 4(A), there were no significant changes in Cav1.1 mRNA content in RamKO 
mice. We next evaluated the activity of the Cav1.1 promoter in C2C12 myotubes and human 
embryonic kidney (HEK)293 cells transfected with a luciferase reporter construct containing 
the 5’ flanking region of the Cav1.1 gene. Figure 4(C) shows that the Cav1.1 promoter is 
active in C2C12 myotubes but not in HEK293 cells. Since FKBP12 is a ubiquitously 
expressed protein, including in C2C12 myotubes [41], we next tested the effect of rapamycin, 
a drug which pharmacologically mimics the effect of knocking out raptor, on the activity of 
the Cav1.1 promoter. Incubation of C2C12 myotubes for 2 and 16 h with 20 μM rapamycin 
abolished the phosphorylation of the mTORC1 downstream target S6 ribosomal protein 
(Figure 4D), without influencing the activity of the Cav1.1 promoter (Figure 4C). 
Nevertheless, rapamycin treatment of C2C12 myotubes causes a decrease in the 
immunoreactive band corresponding to the Cav1.1 (Figure 4E) without effecting CR content, 
an extrinsic protein of the SR membrane. Our data clearly show that, even in the presence of 
a partial inhibition of the mTORC1 complex [42], the phenotype of rapamycin-treated C2C12 
cells recapitulates the effect of Cav1.1 expression observed in RamKO mature skeletal muscle 
fibres. In particular, it appears that functional ablation of mTORC1 affects the synthesis 
and/or the stability of Cav1.1. A great deal of data show that rapamycin dissociates FKBP12 
from the RyR complex, leading to leaky RyRs [43]. It is unlikely that the decrease in the 
Cav1.1 expression results from the acute appearance of leaky RyR in C2C12 cells, since 
chronic disregulation of intracellular calcium concentration in muscle fibres expressing leaky 
RyR1 mutation do not display a decrease in Cav1.1 current density [44]. The decrease in the 
total sarcotubular membrane density of Cav1.1 was apparently also not paralleled by a 
decrease in the SR RyR1 calcium release channels, as we found no change in the Bmax of 
equilibrium [3H]ryanodine binding to the total SR membrane fraction (0.99 ± 0.10 compared 
with 0.92 ± 0.07 pmol/mg protein for WT and RamKO respectively) (Figure 5) from RamKO 
and control littermates. 
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Glycogen phosphorylase is targeted to sarcoplasmic reticulum membrane in skeletal muscle 
from RamKO mice 
 
Skeletal muscles from RamKO and control littermates were homogenized and fractionated by 
differential centrifugation. Comparison with the protein profile of total homogenates shows a 
decrease in a band of 97 kDa in the total homogenate of skeletal muscle from RamKO mice 
compared with that from control littermates (Figure 6A,*). It was previously shown that 
skeletal-muscle-specific mTORC1 inactivation reduces the content of GP, a result consistent 
with glycogen accumulation in RamKO muscle fibres [11,12]. Nevertheless, SDS gel 
electrophoresis of isolated SR membrane fractions revealed that the band with an apparent 
molecular mass of 97 kDa was enriched in the total SR of RamKO mice (Figure 6A, **). MS 
identified the 97 kDa SR protein band as the GP. This finding was further confirmed by 
staining a Western blot of total SR membrane proteins with specific anti-GP Abs (Figure 6D). 
Quantification showed that ablation of raptor led to a 2.9-fold increase in GP associated with 
the total SR membrane fraction (Figure 6B). Sub-fractionation of SR membranes by sucrose 
density centrifugation revealed that GP was enriched in the light R1 fraction (Figure 6C; 
white arrowheads), which is made up of membranes derived from longitudinal SR, 
sarcolemma and T-tubules. GP activity is regulated in several ways including (i) substrate 
availability, (ii) interconversion (phosphorylation/dephosphorylation), and (iii) allosteric 
modification, with AMP being a key activator [45,46]. We assessed whether the cAMP-
stimulated (GP-a) or cAMP non-stimulated (GP-b) forms of the enzyme are enriched in the 
muscle from RamKO mice. As shown in Figure 6(E), there was a similar increase in GP-total 
and GP-b activity, suggesting that the cyclic AMP-non-stimulated form of GP is enriched in 
the SR membranes of RamKO mice [47]. Hirata et al. reported that GP is a negative regulator 
of RyR since it decreases mastoparan-induced calcium release [48] and thus may affect the 
twitch kinetics. To explore this possibility, we studied Ca2+ homoeostasis in enzymatically-
dissociated single EDL and soleus fibres. 
 
Calcium transients on isolated EDL and soleus fibres 
 
To assess the resting calcium concentration, we loaded EDL and soleus fibres with the 
ratiometric fluorescent Ca2+ indicator Indo-1. In both WT and RamKO mice, the resting [Ca2+ 
] in EDL fibres from control mice is slightly higher compared with that in soleus fibres. On 
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the other hand, EDL and soleus fibres from RamKO mice exhibited a small but significant 
decrease in the resting [Ca2+ ] compared with control littermates (Table 1). Mag–fluo–4, a 
low affinity calcium indicator, was used to monitor rapid Ca2+ transients (Figure 7) elicited 
by an action potential in single EDL and soleus fibres excited by supramaximal field 
stimulation [49]. The results we obtained are summarized in Table1. The ∆F/F peak Ca2+ 
transient amplitude in EDL from WT (0.46 ± 0.04, mean ± S.E.M. n=29 fibres) mice was 
18% and 22% higher compared with that of soleus muscles from WT (0.38 ± 0.02, mean ± 
S.E.M., n=22 fibres) and RamKO (0.36 ± 0.02, mean ± S.E.M. n=5 fibres) mice respectively. 
Surprisingly, the peak amplitude and the 10%–90% rise time of the calcium transients were 
not different between RamKO mice and control littermates both in EDL and in soleus. The 
10%–90% fall time of the calcium transients in soleus from RamKO mice is increased 
compared with that of WT (120.2 ± 15.7, n=25 compared with 66.2 ± 7.4, n=22 fibres 
respectively; values are mean ± S.E.M.; P <0.05 Mann Whitney test). The 10%–90% fall 
time of the calcium transients reflects the removal of calcium from the cytosol leading to 
muscle relaxation. Slow fibres are distinct from fast fibres since they typically display a lower 
relaxation rate compared with fast fibres [50]. In addition, peak calcium release induced by 
an action potential is lower in slow fibres compared with fast fibres [51]. The increase in 
10%–90% fall time and the decrease in ∆F/F peak Ca2+ transient are consistent with the 
observation that almost 100% of the fibres of the soleus from RamKO mice are of type 1 
[12]. EDL fibres from RamKO mice exhibited a small and non-significant increase in 10%–
90% fall time of the calcium transients. Similar results were also obtained with 
enzymatically-dissociated FDB fibres (result not shown). 
   The lack of a decrease in the peak amplitude calcium transients evoked by an action 
potential in RamKO EDL and soleus fibres is apparently inconsistent with the decrease in 
density of Cav1.1 in the T-tubular membrane. A number of possibilities may account for this 
discrepancy. For example, the 50% decrease in Cav1.1 in RamKO fibres ought to be 
accompanied by a larger fraction of voltage-sensor uncoupled RyR1. It has been proposed 
that (i) the interaction of Cav1.1 with RyR1 inhibits the appearance of ECRE in mammalian 
adult muscle fibres [26,50,52] and that (ii) the global calcium transients supporting E–C 
coupling in skeletal muscle fibres may result from the summation of ECRE [30]. Equilibrium 
binding on total microsomes shows that in RamKO there are five/six uncoupled RyRs per 
voltage-sensor coupled RyR, whereas in WT there is one/two uncoupled RyR per voltage-
sensor-coupled RyR. On the basis of the equilibrium ligand-binding data, we reasoned that 
the doubling of the voltage-sensor-uncoupled RyRs may affect ECRE. If this were so, the 
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release of calcium from voltage-coupled RyRs in RamKO fibres might propagate to adjacent 
voltage-sensor-uncoupled RyRs triggering a larger number of ECRE, which together 
contribute to the global amplitude of the peak calcium transients in muscle fibres from 
RamKO. In the next set of experiments, we set out to test this idea by measuring the ECRE 
properties in FDB fibres from WT and RamKO mice induced by hyperosmotic shock [26,27], 
a treatment that weakens the inhibitory activity of Cav1.1 on the RyR1 and thus unmasks the 
spontaneous activity of RyR1. 
 
Elementary calcium release events in WT and RamKO FDB fibres 
 
Intact single FDB fibres from WT and RamKO mice were first perfused with NR solution and 
then they were exposed to hyperosmotic Ringer solution containing 50 mM CaCl2 [26,27]. 
After exposure to hyperosmotic solution, the FDB fibres were rinsed with NR and their 
viability was confirmed by their ability to respond with a robust global calcium transient 
upon the delivery of an action potential by supramaximal field stimulation (Supplementary 
Figure S1). The perfusion of FDB fibres from WT and RamKO with NR solution did not 
cause the appearance of spontaneous ECRE (Figures 8A, 8C, 8D and 8F left panels). 
Exposure to hyperosmotic Ringer solution solution containing 50 mM CaCl2 [26,27], induced 
localized increase in fluo-4 fluorescence signals, which were mostly distributed under the 
inner leaflet of the sarcolemma (Figures 8B and 8E, Supplementary videos). Reperfusion of 
FDB fibres with NR abolished the appearance of local transient increases in fluo-4 
fluorescence (Figures 8C and 8F). Figures 8(H) and 8(I) show x,t line scan images of fibre 
exposed to hyperosmotic solution. As can be seen, hyperosmotic treatment causes a transient 
increase in the fluorescence and, on the basis of the criteria proposed by Kirsch et al. [30], we 
refer to the local increase in fluo–4 fluorescence as ECRE. ECRE analysis was performed 
with Sparkmaster plug-in and ECRE were divided into two groups: short-lasting (sparks-like) 
events having a FDHM lower than 50 ms and long-lasting (ember-like) events with FDHM 
higher than 50 ms [29]. Analysis of 1923 and 2547 short-lasting ECRE from WT and 
RamKO fibres revealed significant differences of the morphological parameters of ECRE 
(Table 2). Although the amplitude of short-lasting ECRE was not different between WT and 
RamKO FDB fibres, the latter fibres exhibited a 10% increase in both FWHM (0.89 ± 0.01 
compared with 0.98 ± 0.01 μm for WT and RamKO FDB fibres respectively; P < 0.05) and 
FDHM (13.31 ± 0.26 compared with 14.11 ± 0.24 ms for WT and RamKO FDB fibres 
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respectively; P<0.05). The estimated ECRE mass at peak time of the ∆F/F was 37% 
increased in RamKO FDB fibres (0.62 ± 0.02 compared with 0.85 ± 0.03 μm3 for WT and 
RamKO FDB fibres respectively; P < 0.05). The increase in estimated ECRE mass was 
paralleled by a 30% increase in the frequency of short lasting ECRE events in RamKO fibre 
(6.81 ± 0.36 compared with 8.83 ± 0.40 sparks/image for WT and RamKO FDB fibres 
respectively; P < 0.05). The appearance of ECRE in both WT and RamKO fibres dropped to 
zero upon pre-incubation of the fibres with RyR, indicating that the calcium source flux of 
ECRE are the RyR calcium release channels (Figures 8J and 8K). 
 
 
Discussion 
 
In the present study, we investigated the structural and functional properties of the membrane 
compartment involved in E–C coupling of skeletal muscle from WT and raptor KO mice. Our 
results show that muscle-specific ablation of raptor, and the consequent down-regulation of 
the mTORC1 complex, causes a 1.70-fold increase in the RyR1 to DHPRs ratio in total 
sarcotubular membranes. This event increases both the frequency and the width of ECRE 
induced by exposure of FDB fibres to hyperosmotic shock. In addition, in RamKO skeletal 
muscles, the cAMP non-stimulated form b of GP is mostly associated with the sarcotubular 
membrane fraction. We propose that mTORC1 signalling affects the structure and function of 
the membrane compartments involved in E–C and excitation–glycogen metabolism coupling. 
 
Cav1.1 content in RamKO mice 
 
The transmission of the signal from the T-tubular membrane to the SR is performed by a 
supramolecular complex in the contact region between the two membrane systems. The core 
components of such a complex are the α1-subunit (Cav1.1) of the L-type Ca2+ channel DHPR, 
the RyR and calsequestrin which serve as voltage sensor, SR Ca2+ release channel and 
calcium storage protein respectively [13]. The decrease in the membrane density of DHPR is 
not accompanied by a decrease in the membrane density of the RyR1 whereby the ryanodine 
to DHPRs ratio of RamKO mice is higher compared with that of WT mice. The lower 
membrane density of the DHPR is neither due to mis-localization of the protein to a different 
membrane compartment as the total amount of Cav1.1 was also reduced in the total muscle 
   Manuscript 1: mTOR and EC coupling 
 
 51 
homogenate, nor to decreased levels of specific transcript. A similar decrease in the 
membrane density of DHPR was previously reported by Avila and Dirksen [37] upon acute 
treatment of cultured myotubes with 20 μM rapamycin and confirmed in the present study in 
C2C12 cells treated in culture with rapamycin. However, it seems that the functional effect 
caused by the decreased membrane density of DHPR depends on the maturation stage of 
muscle cells, namely in myotubes [37] it causes a substantial decrease in the voltage-
dependent calcium release, whereas in mature RamKO FDB fibres (in the present work) 
calcium release evoked by action potential is not affected. The decrease in DHPR content 
may be caused by increased degradation via ubiquitination and indeed it has been shown that 
rapamycin treatment induces protein ubiquitination in rat myocardium and mTOR inhibition 
induces autophagy [53,54]. Interestingly, the ratio of DHPR to RyR1 in slow fibres is lower 
compared with that in fast fibres, leading to a higher content of uncoupled RyR1 in soleus 
compared with fast twitch muscles [55]. Thus, our equilibrium binding results are consistent 
with the fast to slow fibre transition in RamKO muscles [12], in particular more than 90% of 
soleus’s fibres from RamKO are of type 1. Importantly, however, although this reduction in 
voltage sensor does not seem to be directly responsible for changes in E–C coupling, it may 
trigger some of the structural variations seen in biopsied muscles, particularly the presence of 
smaller fibres containing core-like structures such as those described in the mouse RamKO 
muscles [12]. Indeed, immunofluorescence analysis of skeletal muscle biopsies from some 
patients with recessive RYR1 mutations show that mis-alignment of RyR1 and DHPR is a 
feature of some patients with core myopathies [56]. A decrease in the DHPR calcium 
channels has also been reported in myotubular/centronuclear myopathy [57,58]. Razidlo et al. 
[59] proposed that the lack of myotubularin inhibits Akt signalling to mTORC1 leading to 
down-regulation of the signalling pathways mediated by the mTORC1 complex. 
 
RyR/Cav1.1 ratio in skeletal muscle of RamKO mice 
 
High resolution EM has demonstrated that Cav1.1 are organized in groups made up of four 
units regularly oriented in the T-tubular membrane to form structures referred to as tetrads, 
which correspond to the position of every other RyR localized in the opposite SR terminal 
cisternae membrane [14]. Equilibrium binding with total sarcotubular membrane fractions 
shows a ryanodine to DHPR ratio of 0.79 and 1.35 for WT and RamKO skeletal muscle 
respectively. The RyR/DHPR ratio we found in WT is consistent with that found by others in 
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total rabbit skeletal muscle homogenates and total microsomal fraction [60–62]. Assuming 
that there are four PN200-110 binding sites per tetrad and one ryanodine-binding site per 
RyR, these results imply that in sarcotubular membranes from RamKO mice there is one 
tetrad-coupled RyR every five/six RyRs, whereas in WT sarcotubular membranes there is one 
tetrad-coupled RyR every 2–3 RyRs. The ryanodine to DHPR ratio of skeletal muscle from 
RamKO mice is more similar to that of cardiac [60] and or amphibian [61] skeletal muscles 
than to that of mature mammalian skeletal muscle. Thus, at this time, it is difficult to 
reconcile the functional behaviour of such a large fraction of uncoupled RyR in RamKO 
fibres with that of uncoupled RyR present in WT skeletal muscle having canonical ryanodine 
to DHPR ratios. Although a great deal of data do not support the notion that in mammalian 
skeletal muscle fibres, uncoupled RyR are activated by the calcium released from voltage-
sensor coupled RyRs via calcium-induced calcium release [63–65], we cannot exclude the 
possibility that the large ‘cardiac-like’ fraction of voltage-sensor uncoupled RyR in RamKO 
fibres might have distinct functional behaviour. 
 
Global calcium signals and elementary calcium release events in WT and RamKO fibres 
 
Measurements of global calcium in single EDL, soleus and FDB show no differences in the 
peak amplitude of depolarization-induced Ca2+ release between WT and RamKO. Such a 
result was unexpected because of the significant decrease in the membrane density of DHPR 
and is not consistent with the general idea that the DHPR drives the voltage-dependent 
activation of RyR1. Nevertheless, it may be possible that a large fraction of uncoupled RyRs 
are sensitive to regulation by physiological modulators and the activation of the uncoupled 
RyRs might compensate for the lower content of voltage sensors in RamKO muscles. This 
line of reasoning is supported by our finding of the modification of the morphology of ECRE 
induced by osmotic shock, a manoeuvre which weakens the control of the DHPR over the 
RyR1 and may thus unmask a distinct regulatory mechanism of uncoupled RyR1 in RamKO 
fibres. ECRE in RamKO fibres are spatially wider and this apparently does not correlate with 
the changes of the amplitude of ECRE between WT and RamKO fibres. A larger FWHM of 
ECRE in FDB fibres from raptor KO mice may be caused by a decrease in the removal of 
calcium at the source site by SERCA and/or by cytosolic calcium-binding proteins. A 
decrease in removal of calcium is probably not due to the changes in the membrane density 
of the Ca2+ pump, since staining of Western blots with either SERCA1 or SERCA2 Ab did 
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not reveal differences in their protein level in crude SR membrane preparations. The wider 
ECRE in RamKO fibres may result from the recruitment of the larger fraction of RyRs which 
are not directly coupled to DHPRs, as described in frog skeletal muscles [65], a tissue with a 
ryanodine to DHPRs ratio higher than that of mammalian skeletal muscle fibres [61]. If such 
a distinct functional behaviour is also operating in RamKO skeletal muscle fibres under 
physiological condition, it is possible that during an action potential voltage-operated RyR1 
channels open and the calcium released by the voltage-operated RyR1s propagates to 
neighbouring uncoupled RyR1 channels. The latter channels release calcium by a calcium-
induced calcium release mechanism and ultimately contribute to the calcium transient. 
 
Compartmentalization of glycogen phosphorylase to SR membrane 
 
In skeletal muscle, glycogen forms a dense network of granules which are mostly localized 
on the myoplasmic surface of terminal cisternae and along the membrane of the fenestrated 
collar [66]. Excitation of skeletal muscle is associated by a rapid (seconds) glycogen 
breakdown via activation of GP, the enzyme responsible for the release of glucose-1-
phosphate from glycogen particles, which ultimately supports muscle metabolism during 
exercise. It has been demonstrated that excitation–glycolysis coupling occurs without an 
increase in the myoplasmic concentration of cAMP and without the subsequent conversion of 
GP-b into GP-a by the cAMP-dependent activity of phosphorylase kinase [67]. GP-b can be 
allosterically activated by AMP; this cAMP-non-stimulated activity is thought to be 
predominant during the early phases of skeletal muscle contraction [68]. In resting 
conditions, the intracellular concentration of AMP is not sufficient to activate GP-b, thus GP-
b is thought to be inactive in resting muscles [69]. During strenuous muscle activity however, 
the intracellular AMP concentration increases, signalling a demand in energy requirement. 
AMP is the product of the activity myokinase, an enzyme which utilizes as a substrate the 
ADP generated by the activity of the SR calcium ATPase (CaATPase), Na+ /K+ -ATPase 
and myosin-ATPase. In resting conditions, the average myoplasmic concentration of AMP is 
0.2 μM and it increases 10-fold during intense muscle activity [70,71]. However, in regions 
of high ATP consumption, such as in domains where the SERCA enzyme pumps calcium 
back into the SR, a greater amount of ATP is required and this may be made available by the 
allosteric activation of GP-b by AMP. Interestingly, lower glycogen content and an increase 
in its degradation have been linked to a fast decay of calcium transients and force during 
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tetanic stimulation [72,73]. The cAMP-dependent active form of GP-a inhibits the activation 
of the RyR1 by caffeine [48]. Thus, the presence of GP-b associated with the SR membrane 
is consistent with the concept that the increase in fatigue resistance described in RamKO [11] 
mice correlates with sustained calcium release, thanks to the compartmentalization to the SR 
of an energy supplying system made up of glycogen and GP-b. 
   Overall these results indicate that the muscle phenotype of RamKO mice is complex and 
due to the interaction of multiple biochemical pathways governed by the mTORC1 signalling 
complex. The present study shows that an adequate mTORC1 activity is required to maintain 
the structure and the function of the membrane compartments involved in E–C coupling. 
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Figures, Legends and Tables 
 
 
 
 
Figure 1. Mechanical properties of isolated EDL and soleus muscles from RamKO and 
control littermates 
 
Isolated muscles from 8-week-old mice were electrically stimulated as described in the 
‘Materials and Methods’ section. Top panels show single twitches, bottom panels maximal 
tetanus force. Dotted line RamKO mice, continuous line control littermates. Note that the 
muscles from RamKO mice developed approximately 20% less force than controls. Slow 
twitch muscles also showed a significant decrease in the half relaxation time. Traces are 
representative of experiments carried out by Bentzinger et al. [12] on at least three/four 
different muscle preparations. 
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Figure 2. Biochemical characterization of SR proteins from RamKO mice 
 
Left panels show representative Western blots with specified Abs; right panels, mean band 
intensity (± S.D.) of 6–9 determinations from three different SR preparations. Values were 
normalized with respect to intensity values obtained from control littermates. White bars, 
controls; black bars, RamKO. **P < 0.002. 
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Figure 3. Cav1.1 is decreased in RamKO mice 
 
(A) Equilibrium binding of PN200-110 to skeletal muscle SR of control (filled circle) and 
RamKO (empty boxes) mice. Data points represent mean (± S.E.M.) of six determinations 
carried out in two different SR preparations. (B and C) Western blots of Cav1.1 and Cav β1 in 
SR of control (empty bars) and RamKO (filled bars) mice; the mean band intensity of 5–7 
determinations from three different SR preparations.  
 
   Manuscript 1: mTOR and EC coupling 
 
 58 
 
 
Figure 4. Cav1.1 decrease in RamKO mice is not due to a decrease in transcription of Cav1.1 
mRNA 
 
(A) Semi-quantitative RT–PCR of Cav1.1. The Figure represents results obtained in four 
different experiments with RNA extracted from two muscle preparations. (B) Western blot of 
total muscle homogenate with anti-Cav1.1 and anti-albumin, a marker for transverse tubule 
content. The bar histogram shows mean (± S.E.M.) band intensity of six determinations from 
four different muscle preparations; band intensity from the RamKO mice are normalized to 
that obtained in control littermates. (C) The Cav1.1 promoter is not affected by treatment with 
20 μM rapamycin as determined by luciferase activity. No activity was seen upon 
transfection of cells with either a control plasmid (white bars) or upon transfection of 
HEK293 with the luciferase reporter (black bars). C2C12 cells transfected with a control 
plasmid showed no luciferase activity, whereas transfection with the luciferase reporter 
resulted in strong activity which was not affected by 2 or 16 h incubation with rapamycin 
(black bars). (D) Rapamycin treatment of C2C12 cells was effective as it resulted in the 
decrease in phosphorylation of S6 after 2 and 16 h. (E) Rapamycin treatment of differentiated 
C2C12 causes a decrease in Cav1.1 as determined by Western blotting. Cells were treated with 
20 μM rapamycin for 16 h and 25 μg of microsomes were loaded on SDS/7.5% PAGE and 
blotted on to nitrocellulose. The blot was probed with anti-Cav1.1, stripped and re-probed 
with anti-CR Ab as a loading control; *band corresponding to the Cav1.1 protein. 
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Figure 5. RyR content and functional characteristics are not changed in RamKO mice 
 
Left panel: Representative Western blot of total SR and mean band intensities (± S.D.) of 
eight determinations from three different SR preparations. Top right: [3H]ryanodine binding 
to SR preparations from control (filled circles) and RamKO (open boxes) mice were 
performed as described in the ‘Materials and Methods’. Data points represent the mean (± 
S.E.M.) of 12 determinations from three different SR preparations. No significant change in 
the Bmax or apparent KD was found. Bottom right: Ca
2+ -dependent [3H]ryanodine binding to 
SR preparations from control (filled circles) and RamKO (open boxes) mice. Data points 
represent mean (± S.E.M.) of six determinations on two different SR preparations. 
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Figure 6. GP is accumulated in the SR of RamKO mice and represents mainly the 
enzymatically-inactive form 
 
(A) Ten μg of protein from total skeletal muscle homogenate, myoplasm or SR fraction was 
separated on a SDS/7.5% PAGE and stained with SimplyBlue Safe Stain. *Represents a band 
present in the total homogenate from WT muscle but not in RamKO muscle; **represents a 
band present in the SR fraction of RamKO mice but not in WT mice. (B) Densitometric 
analysis of GP band in total SR of control (white bars) and RamKO (black bar) mice. (C) SR 
was fractioned into light SR (R1), longitudinal SR (R2) and terminal cisternae (R4). Fifteen 
μg of protein from each fraction was loaded on a SDS/7.5% PAGE and stained with 
SimplyBlue Safe Stain or (D) blotted on to nitrocellulose and stained with anti-GP Abs. 
White arrows in C indicate GP, which is enriched in the light SR fraction R1. (E) Total (left 
bar histogram) and inactive form (right bar histogram) GP enzymatic activity in SR from 
control (white bars) and RamKO (black bars) mice. Values represent the mean (+ S.D.) of 11 
determinations from three different SR preparations. ***P < 0.05. 
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Figure 7. Changes in the myoplasmic [Ca2+ ] of individual, enzymatically dissociated EDL 
and soleus fibres 
 
Control and RamKO fibres were loaded with 10 μM mag–fluo–4AM in Tyrode’s solution for 
10–15 min at 20◦C. This solution was replaced and acquisitions were made during continuous 
perfusion with Tyrode’s buffer plus 50 μM BTS. Calcium transients were elicited by single 
pulses of 1 ms duration, through a platinum electrode inside a glass pipette placed near the 
fibre surface. The representative traces from EDL (A) and soleus (B) show no differences in 
the peaks and velocities of the Ca2+ transients; there is a significant increase in the half 
relaxation time in soleus fibres from RamKO mice. See Table 1 for a thorough analysis of the 
kinetic parameters. 
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Figure 8. Osmotic-shock triggered ECRE are more frequent in FDB fibres from RamKO than 
WT mice 
 
ECREs were triggered by exposure of FDB fibres to a hyperosmotic solution. (A–F) Left 
images show fluo–4 fluorescence and right images bright-field images of the same FDB fibre. 
Scales bars = 30 μm. (A and D) show (xy) images of the calcium fluorescence (AU) in WT 
and RamKO fibres in NR, (B and E) show images of the same fibres after hyperosmotic 
shock treatment and (C and F) show images of the fibres after 10 min re-perfusion with a 
normo-osmotic Ringer solution; as shown after removal of the hyperosmotic medium ECRE 
are no longer visible. (H and I) are pseudocoloured linescan images (xt) showing in detail the 
ECREs shape in WT and RamKO fibres when bathed with hypertonic solution (Hy). (J and 
K) show that ECREs are due to the opening of RyRs as they are abolished by a 30 min pre-
incubation with 10 μM. Scale bar (H–K): horizontal: 100 ms, vertical: 10 μm. 
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Table 1. Kinetic properties of calcium transients of isolated EDL and soleus fibres from 
control and RamKO mice 
 
Values are mean + S.E.M.; n, number of fibres from six WT and RamKO mice. 
 
Resting Ca2+ 
[nM]† 
Peak amplitude‡ 
(∆F/F) 
Time to peak 
(ms) 
Rise time 10%–
90% (ms) 
Fall time 10%–90% 
(ms) 
EDL control 141.0±0.35 (n=23) 0.46±0.04 (n=29) 2.9±0.1 (n=29) 1.7±0.05 (n=29) 34.1±4.3 (n=29) 
EDL RAmKO 115.5±4.8* (n=21) 0.43±0.02 (n=27) 3±0.1 (n=27) 1.8±0.06 (n=27) 39.4±5.4 (n=27) 
Soleus control 117±3.6 (n=26) 0.38±0.02 (n=22) 3.4±0.2 (n=22) 2.1±0.2 (n=22) 66.2±7.4 (n=22) 
Soleus RamKO 93.8±4.26* (n=8) 0.36±0.02 (n=25) 3.4±0.1 (n=25) 2.1±0.1 z(n=25) 120.3±15.7* (n=25) 
* P < 0.05 Mann Whitney U test. 
‡†Calcium measurements performed with the ratiometric indicator indo-1. 
‡Calcium measurements performed with mag–fluo–4. 
 
 
Table 2. Morphology of ECREs in skeletal muscle fibres  
 
Values are expressed as mean ± S.E.M. 
  
Amplitude 
(∆F/F0) 
FWHM 
(μm)  
FDHM 
(ms) 
Mass 
Freq* 
(Sparks/imag) 
N† 
<50 ms ECREs 
WT 0.38±0.00 0.89±0.01 13.31±0.26   0.62±0.02 6.81±0.36 1923 
RamKO 0.38±0.00   0.98±0.01‡ 14.11±0.24‡   0.85±0.03‡   8.83±0.40‡ 2547 
>50 ms ECREs 
WT 0.56±0.01 1.32±0.02 143.36±3.32   2.51±0.17 2.51±0.17 538 
RamKO  0.60±0.01‡   1.45±0.02‡ 138.49±2.80   3.56±0.18‡   3.56±0.18‡ 731 
*WT 168 images, RamKO 162 images. 
†Number of ECREs analysed in 25 fibres and 26 fibres from five WT and RamKO five mice respctively.  
‡ p < 0.005 Student t test. 
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Supplementary Material 
 
Tis work contains 1Supplementary Figure and 6 Supplementary videos. 
Supplementary Figure 
 
 
 
 
Figure S1. Global Ca2+ transients in mouse FDB fibers isolated from WT and RamKO 
littermates elicited before and after hyperosmotic stress-induced-ECREs.  
 
FDB fibers were loaded with Fluo4 and electrically stimulated to check their viability before, 
during and after application of the hypertonic solution. Panels A and D display representative 
traces of Ca2+ transient triggered by an electrical pulse (4ms, 30-40 V) in WT (panel A) and 
RamKO (panel B) fibers respectively. Cells lose the ability to contract after a 10 min 
exposure to the hyperosmotic solution (B, E). Panels C and F show that the Ca2+ transients 
recover after 10 min of washing with NR (290 mOsm). 
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Supplementary Videos 
 
The supplementary videos 1, 2 and 3 show simultaneously white field and the fluorescence 
calcium changes of a single WT FDB fiber electrically stimulated when perfused when 
exposed to isotonic, hyperosmotic and return to isosmotic medium respectively as indicated 
in the Supplementary Figure 2-9. Similarly the videos 4, 5 and 6 show FDB fibers from 
RamKO mice under the same protocol followed before (isosmotic, hyperosmotic and 
isosmotic restitution respectively). To get access to the videos refer to the links indicated 
bellow. 
Supplementary video 1 
File name: WT Single twitch Pre-HyperOsm.avi 
https://www.dropbox.com/s/0d5gvkas4h0rce6/WT%20Single%20twitch%20Pre-
HyperOsm.avi?dl=0 
Supplementary video 2 
File name: WT Single twitch HyperOsm.avi 
https://www.dropbox.com/s/mvhe8pq2r2m2hix/WT%20Single%20twitch%20HyperOsm.avi
?dl=0 
Supplementary video 3 
File name: WT Single twitch Post-HyperOsm.avi 
https://www.dropbox.com/s/unvaxpc7dnljmld/WT%20Single%20twitch%20Post-
HyperOsm.avi?dl=0 
Supplementary video 4 
File name: RamKO Single twitch Pre-HyperOsm.avi 
https://www.dropbox.com/s/8xas03dqyq9xt5a/RamKO%20Single%20twitch%20Pre-
HyperOsm.avi?dl=0 
Supplementary video 5 
File name: RamKO Single twitch HyperOsm.avi 
https://www.dropbox.com/s/6z9by7rytppslof/RamKO%20Single%20twitch%20HyperOsm.a
vi?dl=0 
Supplementary video 6 
File name: RamKO Single twitch Post-HyperOsm.avi 
https://www.dropbox.com/s/cmw3tchbs2mkycl/RamKO%20Single%20twitch%20Post-
HyperOsm.avi?dl=0 
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Clinical observations have indicated MHS patients carrying RyR1 have a slight but consistent 
bleeding disorder (Junghbluth 2015, personal communication). Interestingly, such finding 
was confirmed by Vuckevick (personal communication, 2014) while working with a MH 
mouse model knocked-in for the MH mutation RyR1Y522S (Chelu et al., 2006). Curiously, 
patients and the animal model do not show apparent alterations of platelet or coagulation 
function. 
Intrigued by this apparent discrepancy, we decided to assess the bleeding time in tail of the 
RyR1Y522S MH mouse model. Surprisingly the bleeding times were increased in the knock-in 
mice compared to their WT littermates. Furthermore, the prolonged bleeding was reversed by 
treatment with Dantrolele. This result prompted us to characterize at the molecular, 
biochemical and physiological levels vascular smooth muscle cells (VSMCs) from the tail 
artery. We showed the determined RyR1 transcripts expressed in VSMCs by Real Time 
Polimerase Chain Reaction (RT-PCR) and supported this by immunoblotting Western Blot 
assays. We then identified the subcellular localization of RyR1 by confocal 
immunofluorescence microscopy. Interestingly, we found that RyR1 distributes principally at 
the periphery of smooth muscle cells. We also studied Ca2+ homeostasis in VSMCs by 
fluorescence microscopy and found that cells from the MH knock-in exhibited significant 
more frequent discrete spontaneous calcium release events referred as ECREs (Elementary 
Calcium Release Events) compared to their WT littermates. Pharmacological assessments 
using different Ca2+ channels blockers confirmed that the source of ECREs was the RyR1. 
Interesting, in smooth muscle cells ECREs are important in controlling vasodilation by 
activating STOCs currents through the Ca2+ dependent potassium channels (BK channels) 
that hyperpolarizes the membrane potential and therefore reduce calcium entrance via the 
voltage dependent Ca2+ channel (Cav1.2) (Nelson et al., 1995). We evaluate the resting 
membrane potential of VSMCs with the potentiometric fluorescent dye BisOxonol and we 
found that cells isolated from the MH mice exhibit a resting membrane potential that is 
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hyperpolarized by 14 mV compared to that of cells from WT mice. Altogether our evidence 
strongly suggests that RyR1 mutations affect not only skeletal muscle function but also 
vascular homeostasis and we propose that alteration of RyR1 function may be responsible for 
those bleeding disorders lacking a defined cause, thereby opening a potential use of 
Dantrolene (or analogous drugs) as an antidote for this sort of bleeding abnormalities 
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Abstract 
 
Background: Bleeding abnormalities have been reported in some patients with RYR1-related 
Malignant Hyperthermia (MH) but the frequency and molecular basis for this observation are 
currently uncertain.   
Methods: RYR1–mutated patients and their healthy relatives were identified through the 
participating tertiary neuromuscular and MH centers; bleeding was assessed by means of a 
standardized questionnaire (MCMDM-1VWD). Bleeding times in wild type and mice 
knocked in for the Malignant Hyperthermia RYR1 mutation Y522S (MHS RYR1Y522S) were 
determined. Single tail arterial smooth muscle cells were isolated, loaded with Fluo-4 and 
observed by confocal microscopy for spontaneous Ca2+ release events. 
Results: 8/20 patients had abnormal bleeding scores compared to 0/11 controls (P=0.028); 
the mean bleeding score in patients was 2.3 and -0.5 in controls (P<0.004). MHS RYR1Y522S 
knock in mice exhibited 3 times longer bleeding times compared to their wild type 
littermates. The bleeding defect of MHS mice could be reversed by pre-treatment with the 
ryanodine receptor 1 antagonist dantrolene. Primary vascular SMCs from RYR1Y522S knock-
in mice exhibited a higher frequency of subplasmalemmal Ca2+ sparks leading to a more 
negative resting membrane potential. Ca2+ sparks were blocked by pre-treatment with 
ryanodine or dantrolene.  
Conclusions: RYR1 mutations cause prolonged bleeding by altering vascular SMC function 
and, importantly, dantrolene has potential therapeutic value in the treatment of bleeding 
disorders.  
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Overview, results and finding implications 
 
Bleeding disorders are clinically and genetically heterogeneous and may affect all aspects of 
hemostasis. Mild bleeding disorders are common in the general population but their precise 
incidence as well as their genetic background remain often unresolved (1,2). 
Mutations in RYR1, the gene encoding the skeletal muscle Ca2+ channel ryanodine 
receptor 1 (RyR1), have a calculated frequency of 1:3000. Dominant RYR1 mutations are 
commonly associated with Malignant Hyperthermia (MH), a severe pharmacogenetic 
reaction to halogenated anesthetics and muscle relaxants, exertional rhabdomyolysis/myalgia 
(ERM) (3) and the congenital myopathy Central Core Disease (CCD). Recessive RYR1 
mutations have been associated with the congenital myopathies Multi-minicore Disease 
(MmD), Centronuclear Myopathy (CNM) and Congenital Fiber Type Disproportion (CFTD) 
(4-6). Bleeding abnormalities have been reported in isolated patients with MH susceptibility 
(MHS) (7-9). Interestingly, homozygous mouse embryos knocked in for the MHS RYR1 
mutation Y522S display massive edema and subcutaneous blood effusions at birth, 
suggestive of a severe bleeding disorder with antenatal onset (10).  
To investigate bleeding in RYR1-associated myopathies, we invited RYR1-mutated 
individuals and their non-mutated relatives to complete a standardized questionnaire 
(MCMDM-1VWD) validated for the evaluation of bleeding disorders (Table 1). Patients had 
neuromuscular features of MH, ERM, a congenital myopathy (CCD/MmD) or a combination 
of these features, associated with mainly dominant heterozygous RYR1 missense mutations. 
The neuromuscular features of patients from families 1, 2, 4, 6, 7, 8 and of their relatives 
have been previously reported. (3,11,12(Snoeck et al., 2015). MCMDM-1VWD bleeding 
questionnaires were obtained from 23 RYR1-mutated patients (12 females, 11 males) and 11 
relatives without the familial RYR1 mutation (3 females, 8 males). Symptoms of abnormal 
bleeding were common in RYR1-mutated individuals, characterized by severe menorrhagia 
and postpartum hemorrhage in females and milder symptoms of epistaxis and easy bruising 
in males. One patient reported an additional history of recurrent and unexplained 
miscarriages. Interestingly, improvement of menorrhagia was reported in one female (Patient 
4.2) after prescription of sodium dantrolene, a specific RyR1 antagonist used clinically to 
reverse acute MH reactions (13-14), for her severe ERM. Baseline haematological studies 
including evaluation of clotting factors and platelet aggregation studies were normal in all 
patients with symptoms of increased bleeding, except in patients 2.6 and 2.7 in whom 
abnormal von Willebrand factor (vWF) levels were found, and patient 5.1 who had evidence 
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of abnormal platelet function; bleeding scores from these patients were excluded from further 
statistical analysis as an alternative haematological diagnosis could not be confidently ruled 
out. Eight out of twenty (40%) patients included in the statistical analysis had a pathological 
bleeding score (≥4) on the questionnaire compared to 0/11 (0%) of controls (P=0.028, Fisher 
exact testing with 2-tailed P value). The mean bleeding score for patients was 2.3 (range -2 to 
9), and -0.5 (range -1 to 3) in controls (P=0.004, Student’s t-test) (Figure 1A). 
In order to gain mechanistic insight linking RYR1 mutations to bleeding, we used the 
heterozygous RYR1Y522S MH mouse (10). Applying a standardized test to accurately 
determine bleeding times in mice (15), we demonstrate that bleeding times in RYR1Y522S 
mice are 2-3 longer than in their WT littermates (Figure 1B). Bleeding times in male mice 
were 136.59±19.41 sec. vs 57.59±6.56 sec (P< 0.0014 Student’s t test). Bleeding times in 
female mice were 93.0±10.4 sec vs 48.7±4.3 sec (P<0.003 Student’s t test; Supplementary 
Figure 1). Intraperitoneal dantrolene administration (10 mg/Kg) to WT mice 60 minutes prior 
to the bleeding test did not affect bleeding times (P=0.827 Student’s t test). However, pre-
treatment of RYR1Y522S MH mice with 10 mg/Kg dantrolene reduced bleeding to the same 
times as those seen in their WT littermates (57.15±6.90 sec; P< 0.002 Student’s t test). This 
effect was not observed in mice treated with vehicle alone.  
Bleeding times depend on the activation of circulating clotting factors, platelet 
number and function and on the contraction of injured blood vessels. In a previous study we 
found no difference in the number and function of circulating platelets between WT and 
RYR1Y522S MH (16). We also found no significant RyR1 expression in platelets, virtually 
excluding disturbed platelet function as a potential cause for the observed bleeding disorder. 
Since WT and knock-in littermates only differ in their RYR1, we hypothesized that these 
differences could be due to changes in the contraction/relaxation properties of the smooth 
muscle cells lining the blood vessels. Vascular SMCs (VSMC) have an elaborate Ca2+ 
homeostasis as they not only express InsP3R but also different RyR isoforms (17-21). While 
InsP3R act as channels releasing Ca
2+ from the endo(sarco)plasmic reticulum leading to 
smooth muscle cell contraction, the specific role of RyR is more complex, and experimental 
evidence indicates that they are also involved in SMC relaxation (21-23). In the next series of 
experiments we verified if primary arterial VSMC express RyR1 by performing qPCR 
experiments using primers specific for mouse RYR1 and normalized the expression levels in 
the different muscle tissues to desmin (DES), as this protein is present in skeletal and smooth 
muscle cells (24). Figure 2A shows that mouse aorta and tail artery express the RYR1 
transcript, though as expected, to a much lower extent than in skeletal muscle. Figure 2B 
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shows that the presence of the RYR1Y522S mutation in the heterozygous state does not affect 
the expression levels of RYR1. Figure 2C shows the results of RT-PCR on mRNA isolated 
from the tail artery confirming the expression of a mutated transcript in the heterozygous 
RYR1Y522S knock in mice.  
We next performed confocal immunohistochemical analysis on isolated primary 
VSMCs. Figure 2D shows that the cells are positive for the specific smooth muscle marker 
actin (Fig. 2D panel b). Analysis of the subcellular distribution of RyR1 using an antibody 
that does not cross react with RyR2 (Supplementary figure 2) shows that RyR1s are localized 
on the cell periphery close to the plasma membrane (Figure 2E, panel b). This distribution is 
compatible with that of the voltage sensing dihydropyridine receptor Cav1.2 which is 
expressed on the plasma membrane of VSMC (figure 2E panel c) (25-26). The subcellular 
distribution of RyR1in isolated primary VSMC is similar to that reported in pulmonary artery 
smooth muscle cells and in vas deferens (27-29); in the latter cells localized RyR1-mediated 
calcium release from subplasmalemmal stores causes activation of BK channels resulting in 
cellular hyperpolarization leading to vasodilation (29, 30).  
To investigate how RYR1 mutations affect Ca2+ homeostasis, we isolated primary 
VMCs from mouse tail arteries. We used this model since (i) bleeding times were assessed on 
this tissue and (ii) these cells are the major cells responsible for the control of the vasomotor 
activity in the tail (31). No changes in the resting [Ca2+] were observed between primary 
VSMC isolated from WT and RYR1Y522S mice (Fig.3 A and B), though the latter cells 
showed significantly smaller (P<0.05 Student’s t test) total rapidly releasable Ca2+ stores 
compared to those isolated from WT littermates (Fig.3C). In SMC local calcium release 
events termed “Ca2+ sparks” have been ascribed to the opening of single or clusters of RyR 
channels; though they have little or no direct effect on contraction, they indirectly lead to 
vasodilation through activation of BK channels (21,22). We studied spark activity in isolated 
primary VSMCs loaded with the calcium dye Fluo-4. A representative image of an isolated 
tail VSMC is displayed on the top panel of Figure 3 D and the same cell loaded with Fluo-4 
is shown in Figure 3D panel b. The bottom panels of Figure 3D show representative linescan 
images (x,t) of Ca2+ sparks observed in WT and RYR1Y522S knock in mice. The grey images 
have been pseudocoloured and normalized to F/F0. A trace showing the detailed time course 
of several sparks in WT and RYR1Y522S cells is shown beneath each linescan image. Detailed 
analysis of spark activity from 28 SMCs isolated from 6 WT mice (n=877 sparks) and 28 
SMCs from 6 RYR1Y522S knock in mice (n=1388 sparks), revealed a minor decrease in the 
amplitude (∆F/F0 in WT vs knock in mice was 0.83±0.01 vs 0.79±0.01, respectively. P<0.05 
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Student’s t test), Full Duration Half Maximum (FDHM in WT vs knock in mice was 
1.72±0.04 vs 1.56±0.03, respectively. P<0.05 Student’s t test) and Full Width Half Maximum 
(FWHM in WT vs knock in mice was 22.09±0.75 vs 19.52±0.64, respectively. P<0.05 
Student’s t test). Furthermore, the frequency of sparks was significantly increased in the 
VSMC from the RYR1Y522S mice (P< 0.00001 Student’s t test) (Supplementary Table 2.4 and 
Supplementary Videos 1 and 2).  
We next used several drugs including RyR1 blockers and the InsP3R antagonist 
Xestospongin C to determine the origin of these spontaneous Ca2+ release event. Sparks were 
totally extinguished in WT and RYR1Y522S primary VSMC by pre-incubation with 10 µM 
Ryanodine (Supplementary Video 3 and 4). Additionally, pre-incubation with 20 µM 
dantrolene significantly decreased spark frequency in both WT and RYR1Y522S cells from 
6.33±0.91 to 3.38±0.70 (P<0.03) and 9.56±0.61 to 5.36±0.87, respectively (P< 0.0001) 
(Supplementary Video 5 and 6 and Supplementary Table 2.4). This effect was not observed 
when cells were incubated with the InsP3 antagonist Xestospongin C (250 nM) 
(Supplementary video 7 and 8). Altogether the results obtained so far confirmed that: (i) 
primary VSMCs express RyR1; (ii) RYR1 mutations leading to MHS are not only expressed 
in skeletal muscles but also in arterial SMCs; (iii) the RYR1Y522S MH mutation increases the 
frequency of spark events. In skeletal muscle, RYR1 mutations associated with MHS cause an 
increased sensitivity to activating stimuli, resulting in prolonged and sustained muscle 
contractions (32-35). A similar mechanism does not operate in SMCs since RYR1 mutations 
cause a prolonged and not a shorter bleeding time, the latter would be expected if mutated 
RyR1 caused a gain of function in primary VSMCs. In skeletal muscle excitation-contraction 
coupling depends on the mechanical interaction between the voltage sensing dihydropyridine 
receptor and the RyR1 (36), whereas in SMCs the functional unit is made up of 
dihydropyridine receptors, ryanodine receptors and BKCa channels (21,22).  RyR dependent 
Ca2+ sparks activate BKCa channels causing plasma membrane hyperpolarization thereby 
decreasing Ca2+ influx via the dihydropyridine receptor and leading to smooth muscle 
relaxation (21,22) (see Figure 4b). Consistently, we found that the membrane potential of 
primary VSMCs from WT mice is -39.6±3.4 mV, a value in line with previous reports (22). 
On the other hand that of primary VSMCs isolated from RYR1Y522S mice was significantly 
more hyperpolarized (-53.7±3.2 mV) (Figure 4A).  
In conclusion, we demonstrate that RYR1 mutations cause a mild but distinct bleeding 
disorder in humans and a corresponding phenotype in a murine model of MH. Although in 
our study we evaluated a relatively small sample size of RYR1-mutated patients and controls, 
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the clinical data are consistent with the data obtained from the mouse model and the 
demonstration of complete reversibility of the observed bleeding phenotype through 
administration of dantrolene. Our findings are important for the surveillance and anticipatory 
management of patients with RYR1-related myopathies, particularly females as SMCs play an 
important role in uterine vasoregulation and myometrial contraction (37, 38). Moreover, 
considering that MH-related RYR1 mutations are frequent but often asymptomatic, they may 
account for common mild bleeding abnormalities in humans that are currently without 
genetic explanation and, more importantly, may be amenable to dantrolene treatment. Lastly, 
our findings may also lead to further investigations into the role of RYR1-mediated 
vasoregulation in other organ systems, including the CNS and the lungs.  
 
Methods 
Patients 
 
Patients were identified through the participating tertiary neuromuscular and malignant 
hyperthermia (MH) centers. Genetic testing and haematological studies including evaluation 
of clotting factors and platelet aggregation were performed as part of the routine diagnostic 
workup. Patients were invited to complete the MCMDM-1VWD (= Molecular and Clinical 
Markers for the Diagnosis and Management of Type 1 Von Willebrand’s Disease) bleeding 
questionnaire, a validated and widely used diagnostic tool in the evaluation of bleeding 
disorders (39). MCMDM1-VWD bleeding questionnaires were scored independently by two 
clinicians blinded to the genetic status (mutated vs non-mutated) of the proband. The study 
received UK Research Ethics Committee approval (15/WS/204, granted by the West of 
Scotland REC 5). Patients gave informed consent for anonymized publication of their clinical 
information. 
 
Animal Model 
 
Experiments were carried out on 7-12 week old heterozygous RYR1Y522S knock-in mice 
(MHS) and their wild type littermates. The mouse model was generated by Chelu et al. (10) 
and was a generous gift of Dr. Susan Hamilton, Baylor College of Medicine, Houston, Texas 
USA. Experimental procedures were approved by the Veterinary Cantonal Authorities 
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(Permit numbers 1728 and 1729).  
Bleeding time assay 
 
Bleeding time was determined according to Liu et al. (15). Intraperitoneal injections with 
dantrolene (10 mg/kg) or vehicle alone (saline solution) were administered 1 h prior to 
bleeding time determination. 
 
Isolation of single smooth muscle cells 
 
Primary vascular smooth muscle cells were isolated essentially as described (40) using an 
enzymatic cocktail containing 9.6 U/ml papain (Sigma # P4762), 1200U/ml collagenase 
(Worthington # LS004176), 2.58U/ml elastase (Worthington # LS002292), 0.6% bovine 
serum albumin (BSA) and 1 mg/ml soybean trypsin inhibitor (Worthington # LS003587).  
 
Calcium imaging and Spark analysis 
 
The resting calcium fluorescence was measured using the calcium indicator fura-2 AM 
(Invitrogen) (16) and the total amount of Ca2+ present in the rapidly releasable intracellular 
stores was determined as previously described (41). Calcium sparks were measured in cells 
loaded with 5 µM Fluo-4 using a Nikon A1R laser scanning confocal microscope (Nikon 
Instruments Inc. Melville, USA) with a 60 oil immersion Plan Apo VC Nikon objective 
(NA 1.4). Five sec duration linescan images (x,t) were acquired in resonant mode at super 
high temporal resolution (7680 lps) with 512 pixels (0.05 μm/pixel) in the x- and 39936 
pixels (0.126 ms/pixel) in the t-direction using a pinhole size of 72.27 µm. Four to five 
images were taken at different positions across each cell. Fluo-4 was excited with a laser at 
487 nm and the fluorescence emitted at 525+/-25 nm was recorded. Images were analysed 
using the open source image processor software Fiji (42). After binning 4X in the temporal 
axes, linescan images were run with the automated sparks processor plugin SparkMaster (43). 
 
Immunofluorescence  
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Cells were fixed with ice-cold methanol: acetone (1:1) for 30 min and processed as 
previously described (41). The primary antibodies used were: mouse anti-smooth muscle 
actin (Sigma #A5228), mouse anti-RyR1 (Thermo Scientific #MA3-925), rabbit anti-Cav1.2 
(Santa Cruz # sc-25686) and the secondary conjugates were anti-mouse Alexa Fluor 568 and 
chicken anti-rabbit Alexa Fluor 488 (Lubio science). Nuclei were counterstained with DAPI 
(25-30 µM) for 5 min prior to mounting. Cells were examined by confocal microscopy using 
a Nikon A1R laser scanning confocal microscope with a 60 oil immersion Plan Apo 
objective. 
 
 Real Time qPCR and RT PCR 
 
Total RNA was extracted and treated with deoxyribonuclease I (Invitrogen) as previously 
described (16). After reverse transcription using 1000-1500 ng of RNA, cDNA was amplified 
by quantitative real-time PCR with a 7500 Fast Real-Time PCR system (Applied Biosystems) 
using SYBR Green technology (fast SYBR green master mix, Applied Biosystems) and the 
following primers: RYR1 F: 5’-TCA CTC ACA ATG GAA AGC AG-3’; R: 5’-AGC AGA 
ATG ACG ATA ACG AA-3’; Desmin F: 5’-TGA GAC CAT CGC GGC TAA GA-3’ and R: 
5’-GTG TCG GTA TTC CAT CAT CTC C-3’. Gene expression was normalized to desmin 
(DES) content as this marker is specifically expressed in muscle cells (24, 44). RYR1 
expression levels in mouse aorta, tail artery and mesenteric artery were compared to RYR1 
expression levels in Extensor Digitorum Longus (EDL), that latter being the reference tissue 
set to 1. RYR1 expression in aorta was also investigated by semi-quantitative RT PCR as 
previously described (16). 
 
Membrane potential measurements 
 
Membrane potential measurements were performed using the potentiometric fluorescence 
dye Bis-Oxonol as described (45). Briefly, isolated arterial smooth muscle cells (SMC) were 
plated on laminin: gelatin (1:10 ratio) pre-coated coverslips and allowed to attach for 20 min 
in a modified Krebs-Ringer solution (in mM: NaCl: 140; CaCl2: 0.5; KCl: 5; MgSO4: 1; 
HEPES: 10; Na2HPO4: 1; Glucose: 5.5 and Albumin 1%). Cells were loaded with the 
potentiometric fluorescence dye Bis-Oxonol (Molecular Probes, B438) at room temperature 
for 30-40 min. To calibrate the membrane potential cells were incubated with the Na+ 
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ionophore gramacidin (10 µM) (Sigma, G 5002) and then exposed to different Na+ containing 
solutions (Supplementary Figure 3a). The concentration ratios of Na+ and Choline were 
varied in order to maintain [Na+] + [Choline] = 144 mM. Theoretical values for membrane 
potential (Supplementary Figure 3b) were calculated according to the formula: 
 
Em = 60 Log([Na+]o + [K
+]o)/( [Na
+]i + [K
+]i)           (Eq 1) 
 
and considering the internal concentration of Na+ and K+ as described by Nelson et al. (22). 
Fluorescence was recorded every 0.5 min with a Nikon A1 plus confocal microscope, using a 
60X oil objective. Samples were illuminated with a Sapphire Laser at 488 nm and the 
fluorescence emitted at 525/50 nm was recorder. Fluorescence images were processed using 
the open source software Fiji. 
 
Statistical analysis and graphical software  
 
Statistical analysis on the MCMDM1-VWD bleeding questionnaires was performed by 
converting raw bleeding scores to binary numbers for use in Fisher exact testing with 2-tailed 
p value (negative screening test ≤3, positive screening test ≥4). Mean scores were compared 
using Student’s t test. For all other experiments statistical analysis was performed using the 
Student's t test; means were considered statistically significant when the P value was <0.05. 
Data was processed, analysed and plotted using the software OriginPro 8.6.0 (OriginLab 
Corporation). Images were assembled using Adobe Photoshop CS (version 8.0). 
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Figures, legends and Table 
 
 
 
Figure 1. RYR1 mutations are associated with prolonged bleeding times.  
 
A. Scatterplot of MCMDM-1VWD bleeding scores for RYR1-mutated patients compared to 
related controls without the familial RYR1 mutation(s) (mean score 2.3 in cases compared to -
0.5 in controls, P<0.0001). B. RYR1Y522S knock in MHS mice show prolonged bleeding 
times that are reversed by dantrolene. Each symbol represents the bleeding time (in sec) of a 
singly wild type (light grey) and RYR1Y522S (dark grey) mouse. Mice were either untreated 
(left panel), pre-treated with 10 mg/Kg dantrolene prior to the experiment (central panel) or 
pre-treated with vehicle alone right panel. *P<0.05 Students t-test.  
  Manuscript II: RyR1 and bleeding abnormalities 
 
 88 
 
 
 
 
Figure 2. RyR1 is expressed in aorta and tail arteries and has a sub-plasma membrane 
localization.  
 
A. RYR1 expression in skeletal muscle (SKL), aorta, tail and mesenteric artery was 
normalized to DES content, which is present in skeletal and smooth muscle cells (24). The 
numbers below the bars indicate number of mice used in the experiment. B. The presence of 
the Y522S mutation does not affect the levels of RYR1 expression as determined by qPCR. 
The numbers below the bars indicate number of mice used in the experiment. C. Total RNA 
was extracted from purified aortas and the expression of RYR1 was evaluated by RT-PCR. 
Digestion of the amplified RYR1 cDNA from wild-type mice (wt) yields the uncut band of 
about 376 bp, whereas digestion of the cDNA from heterozygous RYR1Y522S (het) yields two 
bands of 276 bp and 100 bp plus the uncut 376 bp band from the wild-type allele D. Phase 
contrast of an isolated primary VSMC (a); confocal immunofluorescence on the same cell 
using a mouse antibody specific for smooth muscle actin followed by anti–mouse Alexa 
Fluor 569 (panel b) or DAPI to localize the nucleus (panel c). E. Phase contrast on an isolated 
primary VSMC (panel a); Confocal immunofluorescence of the same cell stained with mouse 
monoclonal anti-RyR1 mAb followed by anti-mouse Alexa Fluor-568 (red, b), rabbit anti-
Cav1.2 followed by anti-rabbit Alexa Fluor-488 (green, c), DAPI (panel d). Composite image 
showing co-localization of RyR1 and Cav1.2 (panel e). Images were acquired with a Nikon 
A1R confocal microscope using a 60 oil immersion Plan Apo objective. Scale bar = 10 µm. 
 
  
D 
A B C 
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Figure 3. Arterial SMC from the RYR1Y522S mouse exhibit smaller intracellular Ca
2+ stores 
and a higher frequency of spontaneous Ca2+ sparks.  
 
A. Fura-2 traces of resting fluorescence ratios (340/380 nm) of primary VSMC isolated from 
WT (light grey) and RYR1Y522S knock in (dark grey) mice. B Resting fluorescence ratios 
from primary VSMC isolated from WT (n=20) and RYR1Y522S knock in (n=20) mice. The 
values were not significantly different. C. Total amount of Ca2+ in the 
thapsigargin/ionomycin-sensitive stores was significantly lower in VSMC from RYR1Y522S 
mice (n=20 cells) compared to those from WT (n=20 cells) littermates. P< 0.05 Student’s t 
test. Experiments were performed as described in (41). D. Top images show a brightfield 
image (a) and fluo-4 fluorescent image (b) photomicrograph of isolated SMC. Bar indicates 
10 µm. Bottom pseudocolour and greyscale linescan images of spontaneous localized 
calcium release events (sparks) in SMC from a WT (top) and a RYR1Y522S (bottom) mouse. 
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The color scale indicates the fluorescence change expressed as the ratio of F/F0. The traces 
under the linescan images show the time course of the calcium sparks. Scale bars: vertical 10 
µm, horizontal 100 ms, pseudocolor F/F0. Note the higher frequency of sparks in the knock in 
compared to its WT littermate. 
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Figure 4. The resting membrane potential in SMC from the RYR1Y522S mouse is significantly 
different from that of WT cells. Schematic representation of RyR1 function in arterial smooth 
muscle cells. 
 
A. The resting membrane potential was measured using the potentiometric probe Bis-Oxonol 
in 6 WT (6 mice) and 8 MHS (6 mice) smooth muscle cells (See Methods and Supplementary 
Figure 1 for details). * Mean resting membrane potential was significantly different 
(Student’s t-test P<0.05). B. Schematic representation of the mechanism leading to prolonged 
bleeding time due to RYR1 mutations. In normal conditions (left panel), early vasospasm 
occurring immediately after injury, reduces bleeding (in coordination with platelets and 
coagulation factors not shown here). Mutation and the RYR1 (right panel) results in 
hyperpolarization of the SMC membrane potential, reducing the ability of vessels to contract 
and ultimately increasing the bleeding time. PM: Plasma Membrane, SR: Sarcoplasmic 
Reticulum, RyR1: Ryanodine Receptor Type 1, caBK: Calcium activated Potassium Channel. 
Blue balls: Potassium, Yellow balls: calcium sparks, WT: Wild Type, RyR1Y522S : MH knock-
in condition. 
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Table 1. Genetic details, neuromuscular features, MCMDM-1VWD bleeding questionnaire scores and bleeding phenotypes from patients with 
RYR1-related myopathies and their non-mutated relatives.  
F P/C S RYR1 mutation(s) I NM 
RYR1 
+/- BS Bleeding phenotype 
         
1 1.1 F 
p.R2241X, p.D708N; 
p.R2939K AR 
MmD/M
H + 5 Severe menorrhagia; Postpartum bleeding 
         
 
2.1 F p.G4638D AD 
CCD/MH
S + 6 Severe menorrhagia; Postpartum bleeding 
 
2.2 F p.G4638D AD 
CCD/MH
S + 9 Severe menorrhagia; Postpartum bleeding 
 
2.3 M - - - - -2 not applicable 
 
2.4 M - - - - 3 
Rectal bleeding (diverticulitis ?); Bleeding after dental 
extraction 
2 2.5 M - - - - 2 Rectal bleeding (colitis ?) 
 
2.6 M p.G4638D AD 
CCD/MH
S + 4 Epistaxis; Easy bruising* 
 
2.7 M p.G4638D AD 
CCD/MH
S + 1 Easy bruising* 
 
2.8 M - - - - 0 not applicable 
 
2.9 F - - - - -1 not applicable 
 
2.10 F - - - - -2 not applicable 
 
2.11 M - - - - -1 not applicable 
        
3 3.1 F 
p.S1342G, p.A1352G, 
p.T2787S AD ERM + 2 Menorrhagia; Epistaxis 
 
3.2 F 
p.S1342G, p.A1352G, 
p.T2787S AD ERM + 2 Menorrhagia; Oral cavity bleeding 
         
 
4.1 F p.G2434R AD 
ERM, 
MHS + 7 Severe menorrhagia; Epistaxis 
 
4.2 F p.G2434R AD 
ERM, 
MHS + 4 Severe menorrhagia# 
4 4.3 M - - - - 0 Epistaxis 
 
4.4 F - - - - -2 not applicable 
   Manuscript II: RyR1 and bleeding abnormalities  
 
 93 
 
4.5 M p.G2434R AD 
ERM, 
MHS + 3 Epistaxis; Bleeding after dental extraction 
        
5 5.1 F p.H3981Y AD ERM + 13 Severe menorrhagia;  Postpartum bleeding* 
   
   
   
 
6.1 F p.T4288_A4290dup AD ERM + 4 Menorrhagia; Postpartum bleeding 
6 6.2 F p.T4288_A4290dup AD ERM + 4 Easy bruising; Oral cavity bleeding; GI bleeding 
 
6.3 M p.T4288_A4290dup AD ERM + 1 Bleeding from minor wounds 
         
 
7.1 M p.V4849I AD ERM + -2 not applicable 
7 7.2 M p.V4849I AD ERM + -1 not applicable 
 
7.3 M p.I2321V; p.V4849I AD ERM + 0 not applicable 
 
7.4 M - - - - 0 not applicable 
         
 
8.1 M p.R614C AD MHS + 1 Oral cavity bleeding 
 
8.2 M p.R2676W AD MHS + -2 not applicable 
8 8.3 M p.R614C AD MHS + -1 not applicable 
 
8.4 M - - - - -2 not applicable 
 
8.5 F p.R2676W AD MHS + 2 Menorrhagia 
         9 9.1 F p.R2454H AD MHS + 4 Easy bruising; Postpartum bleeding; Muscle hematoma 
 
9.2 M p.R2454H AD MHS + -2 not applicable 
 
        
Abnormal MCMDM-1VWD bleeding scores (>4) are highlighted in red. Patient 1.1 was deceased and the MCMDM-1VWD bleeding 
questionnaire was completed retrospectively based on information derived from the patient medical notes. *Three patients (2.6, 2.7, 5.1) were 
excluded from further statistical analysis because of abnormal von Willebrand factor levels (2.6, 2.7) and evidence of abnormal platelet function 
(5.1), respectively. #Patient 4.2 reported improvement of bleeding symptoms following commencement of dantrolene treatment, prescribed for 
exertional myalgia. Two dominant heterozygous MHS-related RYR1 mutations were running independently in families 5, 7 and 8. 
Neuromuscular features from families 1, 2, 4, 6, 7 and 8 have been previously reported. F = Family; P/C = Patient/Control; I = Inheritance; NM 
= Neuromuscular phenotype; RYR1 +/- = RYR1 mutation carrier state; BS = MCMDM-1VWD. 
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Supplementary material 
 
This manuscript contains 3 Supplementary Figure, 1 Supplementary Table and 10 
Supplementary videos. 
 
Supplementary Figures 
 
 
Supplementary Figure 1. Female RYR1Y522S knock in MHS mice show prolonged bleeding 
times.  
 
Each symbol represents the bleeding time (in sec) of a singly wild type (light grey) and 
RYR1Y522S (dark grey) mouse. *P<0.005 Students t-test. 
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Supplementary Figure 2. Specificity of the anti-RyR1 antibodies used for IHC: western blots 
of skeletal and cardiac total sarcoplasmic reticulum membranes using isoform specific anti-
RyR antibodies.   
 
Thirty micrograms of sarcoplasmic reticulum proteins were separated on a 6% SDS PAG and 
blotted onto nitrocellulose. Blots were blocked with 1% blocking buffer (Roche) in TBS for 
60 min and probed with 1:5000 dilution monoclonal anti-RyR1 specific mAb34-C (left 
panel) or anti-RyR2 mAb C3-33 (right panel) for 60 min in TBST, rinsed 3 times with TBST, 
incubated with peroxidase-conjugate anti-mouse IgG (1:200,000 in TBST), rinsed 3 times 
and developed using the enhanced chemiluminescence kit from Thermo Scientific. As shown, 
the anti-RyR1 mAb does not cross react with cardiac RyR2. The blot on the right shows a 
positive control for cardiac RyR2. 
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A       B     
 
Supplementary Figure 3. Membrane potential measurements using the fluorescence 
potentiometric probe Bis-Oxonol.  
 
A Representative trace of the changes in fluorescence obtained in primary VSMC, expressed 
as Arbitrary Units (AU). The arrows indicate addition of Gramicidin or the indicated [Na+] in 
mM. Dark squares VSMC from WT mice, grey squares VSMC from RYR1Y522S mice. B 
Values derived from Equation 1 (Methods section) with the best linear fitting regression 
(R2=0.90; Y = 0.0065X + 2.6525) of the log of the fluorescence obtained at each [Na+]. 
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Supplementary Table 
 
Supplementary Table 2.4.  Effect of Dantrolene and Ryanodine on the frequency of 
spontaneous Ca2+ Sparks 
Spark Frequency 
(Sparks/image) 
 No treatment 
Dantrolene        
20 µM 
N  No treatment 
Ryanodine 10 
µM 
N 
1WT 6.33±0.91 3.38±0.70* 81  6.69±1.30 0.00±0.00 107 
2RYR1Y522S 9.56±0.61 5.36±0.87** 236  10.75±1.00 0.00±0.00 215 
 
Values are expressed as Mean ± SEM. * P< 0.03 **P<0.0001 Student’s t-test. N represent the 
number of sparks analyzed in 20 images taken from cells isolated from 5-10 different WT 
and RYR1Y522S mice respectively, before and after drug application. 
1Cells were isolated from 10 and 5 WT mice for the experiments ± 20 µM dantrolene and ± 
10 µM ryanodine, respectively. 
2Cells were isolated from 16 and 5 RYR1Y522S heterozygous mice for the experiments ± 20 
µM dantrolene and ± 10 µM ryanodine, respectively. 
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Supplementary Videos 
 
The Videos 1 and 2 show the white-field and calcium fluorescence signal of spontaneous 
ECREs activity of a WT and knock-in RYR1Y522S VSMC respectively. ECREs activity of 
knock-in RYR1Y522S VSMCs before and after incubation with the RyR blockers Ryanodine 
10 µM (Videos 3 and 4), Dantrolene 20 µM (Videos 5 and 6) and the InsP3 antagonist 
Xestospongin C 250 nM (Videos 7 and 8) can be visualized in the following videos 
respectively. Scale bar for videos = 10 µM. 
 
Supplementary video 1  
File name: WT Spontaneous ECREs.avi 
https://www.dropbox.com/s/j1lvec63bblsv9y/WT%20Spontaneous%20ECREs.avi?dl=0 
 
Supplementary video 2  
File name: RyR1Y522S Spontaneous ECREs.avi 
https://www.dropbox.com/s/rgvcsx0pdz13swb/RyR1Y522S%20Spontaneous%20ECREs.avi
?dl=0 
Supplementary video 3  
File name: RyR1Y522S Pre-Ryanodine treatment ECREs.avi 
https://www.dropbox.com/s/strrhxyg9vvb7a3/RyR1Y522S%20Pre-
Ryanodine%20treatment%20ECREs.avi?dl=0 
Supplementary video 4  
File name: RyR1Y522S Post-Ryanodine treatment ECREs.avi 
https://www.dropbox.com/s/hns7thv61qnruy4/RyR1Y522S%20Post-
Ryanodine%20treatment%20ECREs.avi?dl=0 
Supplementary video 5  
File name: RyR1Y522S Pre-Dantro treatment ECREs.avi 
https://www.dropbox.com/s/5pygnnwoiw03nzn/RyR1Y522S%20Pre-
Dantro%20treatment%20ECREs.avi?dl=0 
Supplementary video 6  
File name: RyR1Y522S Post-Dantro treatment ECREs.avi 
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https://www.dropbox.com/s/ufxpjn0gogsaoif/RyR1Y522S%20Post-
Dantro%20treatment%20ECREs.avi?dl=0 
Supplementary video 7 
File name: RyR1Y522S Pre-XeC treatment ECREs.avi 
https://www.dropbox.com/s/vkfpop47je3eo6s/RyR1Y522S%20Pre-
XeC%20treatment%20ECREs.avi?dl=0 
Supplementary video 8 
File name: RyR1Y522S Post-XeC treatment ECREs.avi 
https://www.dropbox.com/s/uy0irqh8ckrks48/RyR1Y522S%20Post-
XeC%20treatment%20ECREs.avi?dl=0 
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CONCLUSIONS AND PERSPECTIVES 
 
Discrete calcium releases events namely ECREs are complex and diverse among 
different excitable tissues. Since Cheng and colleagues described in 1993 for the first time the 
so called “calcium sparks” in cardiomyocites, much has advanced in our understanding the 
nature of this phenomenon and its participation in EC coupling in normal and pathological 
conditions. In this thesis we have studied ECREs and characterize in detail their role in 
calcium hemostasis in two different systems: skeletal muscles and arterial smooth muscles. 
 
Regarding skeletal muscle, study of the biochemistry and molecular composition of the SR 
membranes in the RamKO animals revealed an important change in the stoichiometry of the 
two most important players of EC coupling: RyR1 and Cav1.1. This finding not only 
demonstrates the importance of mTORC1 as a master regulator for the integrity of the protein 
composition of skeletal muscle as finely described by Bentzinger et al. (2008) and confirmed 
and extended by Risson et al. (2009), but also open a new perspective in understanding the 
EC coupling mechanism under particular conditions occurring when there is a reduced 
control of RyR1 by the voltage sensor DHPR. Interesting, this particular finding recalls the 
uncoupling of the RyR1-Cav1.1 proteins observed in aging mice by Renganathan et al (1997) 
by a similar decrease in the Cav1.1 expression, interpreted as an important cause of loss of 
strength.  
Although these observations provide an important contribution on our understanding the role 
of mTORC1 in muscle biology and particularly in EC coupling, a number of questions arise 
from this study that still require to be answered, for example how does mTORC1 control 
Cav1.1 expression? Can the increase in calcium spark frequency and mass observed in 
RamKO mice be reverted by restoration of functional Cav1.1? Is this reversion directly 
mTORC1 dependent or are there other unknown factors involved in governing Cav1.1 
expression?  
 
As far as my results on ECREs in smooth muscle cells are concerned, unpaired 
ECREs activity as seen in the MH mouse model knocked-in for the RYR1 Y522S mutation 
leads to a prolonged bleeding disorder. Interestingly, this bleeding abnormality is similarly 
observed in some patients who are MH susceptible. These findings place RyR1 in a new 
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physiological perspective and highlight how disturbances of calcium homeostasis could go 
beyond skeletal muscle myopathies and incur in other(s) physiological process such as 
primary hemostasis. 
Although we postulate a mechanistic model of a bleeding disorder supported by 
strong biochemical, molecular and functional evidence at the cellular level, direct studies on 
the reactivity of the intact blood vessels using different RyR1 agonist/antagonist would 
provide additional evidence of the pathological mechanism observed in the bleeding disorder 
we described. This is particular important in order to have a complete picture of this vascular 
disorder at a multiscale level. 
Another important point that should be mentioned is that although the patient’s 
bleeding scores correlate strongly with the bleeding abnormalities of the MH animal model, 
the small number of patients analyzed in this study might be another limitation. A larger 
number of patients with RYR1-associated myopathies may be required to further support our 
hypothesis. 
Several technical limitations of this study must also be pointed out for future 
considerations. Although the use of potentiometric fluorescent dyes was suitable to reveal the 
resting membrane potential of smooth muscles, the results were at times variable and it took 
many attempts before I was able to set up the appropriate experimental conditions. As an 
alternative approach, electrophysiological measurements as determined by patch clamp 
experiments would have been a potentially more accurate method. I would like to mention 
that we did attempt to patch isolated smooth muscle cells but we encountered many problems 
that could not be overcome. For example we could not adequately restrain the isolated cells 
and achieve a Giga seal with the glass pipette. This was probably due to the nature of the cell 
preparation (small size, membrane surface properties, etc). 
Finally, although skeletal muscle and smooth muscle cells differ significantly in their 
calcium homeostasis, in both systems calcium is probably the most important regulator of 
contraction and relaxation. We demonstrate that proteins controlling directly or indirectly 
calcium homeostasis are of critical importance for the maintenance of a normal physiological 
balance. Thus, the study of ECREs in other tissues that functionally express RyR1 deserves 
further attention particularly when investigating the underlying mechanisms of different 
pathologies of unknown origin. 
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APPENDIX 
Blood pressure assessment in RyR1Y522S mice 
 
In order to explore the effect of altered calcium homeostasis of VSMCs of the MH mouse 
model on vascular hemodynamics, we evaluated the blood pressure of the animals in resting 
conditions. Additionally, we investigated if the blood pressure in MH susceptible animals is 
affected by the MH trigger agent isoflurane. 
Blood pressure was monitored in conscious and anesthetized mice using a non- invasive 
method by a tail-cuff photoplethysmography sytstem (BP-2000 Blood Pressure Analysis 
System, Visitech Systems). Because the system could not accurately estimate the diastolic 
pressure, we considered systolic pressure only. 
The blood pressure of the animals was assessed one time per day for a period of 7 days prior 
to the real measurements, in a quiet environment and at the same time of day in order to 
allow the mice to adjust to the protocol. For the anesthetized group of animals, inhaled 
isoflurane was administered (1,5-3%, 900 cc/min O2) for a period no longer than 15 min so 
the animals were asleep but an MH crisis was avoided. 
Figure A1 shows the blood pressure of WT and MH (RyR1Y522S) susceptible animals in 
conscious, untreated animals (left side). We found no statistical difference between 9 WT and 
9 RyR1Y522S mice (Mean ± SEM: WT= 128.68±2.31; RyR1Y522S= 126.10±2.76). When the 
mice were lightly anesthetized, the blood pressure was consistently depressed in both WT 
and MH susceptible mice (Figure A1, right panel). Although a consistent depression of blood 
pressure was observed (Figure A1, right panel), statistical analysis revealed no differences 
between the MH susceptible animals and the control group (Mean ± SEM: WT= 96.11±3.87; 
RyR1Y522S= 93.85±4.87). 
 
   
 
 108 
 
Figure A1. Isoflurane reduces the blood pressure of both WT and RyR1Y522S animals to 
similar levels. The blood pressure of MH susceptible RyR1Y522S and WT mice was not 
different under normal conditions (conscious animals, left panel: Awake). Animals under 
anesthesia (right panel of the figure: Isoflurane) exhibited a lower blood pressure compared 
to wakeful animals but there was no difference between the WT and MH susceptible groups.  
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Detailed kinetics Analysis of ECREs activity in VSMCs  
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Table A1. Detailed Analysis of full kinetics parameters of ECREs activity quantified in VSMCs from WT and RyR1Y522S animals 
respectively. 
 
Morphology of ECREs in Arterial Smooth Muscle Cells 
 
Amplitude 
(DF/F0) 
FWHM 
(μm) 
FDHM 
(ms) 
Full Widht 
(μm) 
Full Dur 
(ms) 
TtP (ms) Tau (ms) 
Freq 
(Sparks/image) 
N† 
WT 0.83±0.01 1.72±0.04 22.09±0.75 4.38±0.10 69.93±2.05 20.72±0.64 128.56±33.66 6.96±0.49 877 
RyR1Y522S 0.79±0.01* 1.56±0.03* 19.52±0.64* 4.04±0.07* 59.32±1.32* 19.76±0.54 72.81±9.13 10.68±0.55* 1388 
* Statistic significance with T-Test (p<0.05). 
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Table A2. Detailed Analysis of full kinetics parameters of ECREs activity quantified in VSMCs from WT and RyR1Y522S animals respectively 
treated with Dantrolene. 
 
 Morphology of ECREs in Arterial Smooth Muscle Cells 
 
  
Amplitude 
(DF/F0) 
FWHM 
(μm) 
FDHM 
(ms) 
Full Widht 
(μm) 
Full Dur 
(ms) 
TtP (ms) Tau (ms) 
Freq 
(Sparks/image) 
N† 
Dantrolene       
20 µM 
WT 0.55±0.02 1.21±0.09 15.72±2.14 4.76±0.31 82.68±7.70 25.34±2.91 120.18±55.59 3.38±0.70 81 
RyR1Y522S 0.78±0.03* 1.31±0.05 19.75±1.18 4.52±0.13 87.18±4.12 23.95±1.22 59.33±3.98 5.36±0.87 236 
 
 
* Statistic significance with T-Test (p<0.05) compared with the control untreated group respectively. 
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Effect of Tetracain 150 µM on ECREs activity in VSMCs 
 
 
 
Video A1 
File name: RyR1Y522S Pre-TTC treatment ECREs.avi 
https://www.dropbox.com/s/cv6jvlbjgmcqxz2/RyR1Y522S%20Pre-
TTC%20treatment%20ECREs.avi?dl=0 
Video A2 
File name: RyR1Y522S Post-TTC treatment ECREs.avi 
https://www.dropbox.com/s/gs2yn87vdzwiq0k/RyR1Y522S%20Post-
TTC%20treatment%20ECREs.avi?dl=0 
 
 
 
   
 
 113 
REFERENCES 
 
Administration, U.S.F.a.D. 2015. Rapamune (sirolimus) Oral Solution, Tablets Prescribing 
Information. 
Agency, E.M. 2015. European public assessment report (EPAR) for Rapamune. 
Albert, V., and M.N. Hall. 2015. mTOR signaling in cellular and organismal energetics. Curr 
Opin Cell Biol. 33:55-66. 
Anderson, A.A., S. Treves, D. Biral, R. Betto, D. Sandona, M. Ronjat, and F. Zorzato. 2003. 
The novel skeletal muscle sarcoplasmic reticulum JP-45 protein. Molecular cloning, 
tissue distribution, developmental expression, and interaction with alpha 1.1 subunit 
of the voltage-gated calcium channel. J Biol Chem. 278:39987-39992. 
Apostol, S., D. Ursu, F. Lehmann-Horn, and W. Melzer. 2009. Local calcium signals induced 
by hyper-osmotic stress in mammalian skeletal muscle cells. J Muscle Res Cell Motil. 
30:97-109. 
Augustine, G.J., and H. Kasai. 2007. Bernard Katz, quantal transmitter release and the 
foundations of presynaptic physiology. J Physiol. 578:623-625. 
Bankhead, P., C.N. Scholfield, T.M. Curtis, and J.G. McGeown. 2011. Detecting Ca2+ 
sparks on stationary and varying baselines. Am J Physiol Cell Physiol. 301:C717-728. 
Baretic, D., and R.L. Williams. 2014. PIKKs--the solenoid nest where partners and kinases 
meet. Curr Opin Struct Biol. 29:134-142. 
Barone, V., D. Randazzo, V. Del Re, V. Sorrentino, and D. Rossi. 2015. Organization of 
junctional sarcoplasmic reticulum proteins in skeletal muscle fibers. J Muscle Res 
Cell Motil. 
Baselga, J., M. Campone, M. Piccart, H.A. Burris, 3rd, H.S. Rugo, T. Sahmoud, S. Noguchi, 
M. Gnant, K.I. Pritchard, F. Lebrun, J.T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, 
T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, and G.N. Hortobagyi. 
2012. Everolimus in postmenopausal hormone-receptor-positive advanced breast 
cancer. N Engl J Med. 366:520-529. 
Beard, N.A., M.G. Casarotto, L. Wei, M. Varsanyi, D.R. Laver, and A.F. Dulhunty. 2005. 
Regulation of ryanodine receptors by calsequestrin: effect of high luminal Ca2+ and 
phosphorylation. Biophys J. 88:3444-3454. 
   
 
 114 
Beard, N.A., D.R. Laver, and A.F. Dulhunty. 2004. Calsequestrin and the calcium release 
channel of skeletal and cardiac muscle. Prog Biophys Mol Biol. 85:33-69. 
Beard, N.A., L. Wei, and A.F. Dulhunty. 2009. Ca(2+) signaling in striated muscle: the 
elusive roles of triadin, junctin, and calsequestrin. Eur Biophys J. 39:27-36. 
Ben-Sahra, I., J.J. Howell, J.M. Asara, and B.D. Manning. 2013. Stimulation of de novo 
pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 
339:1323-1328. 
Benham, C.D., and T.B. Bolton. 1986. Spontaneous transient outward currents in single 
visceral and vascular smooth muscle cells of the rabbit. J Physiol. 381:385-406. 
Bentzinger, C.F., S. Lin, K. Romanino, P. Castets, M. Guridi, S. Summermatter, C. 
Handschin, L.A. Tintignac, M.N. Hall, and M.A. Ruegg. 2013. Differential response 
of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet 
Muscle. 3:6. 
Bentzinger, C.F., K. Romanino, D. Cloetta, S. Lin, J.B. Mascarenhas, F. Oliveri, J. Xia, E. 
Casanova, C.F. Costa, M. Brink, F. Zorzato, M.N. Hall, and M.A. Ruegg. 2008. 
Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes 
and results in muscle dystrophy. Cell Metab. 8:411-424. 
Berridge, M.J. 2006. Calcium microdomains: organization and function. Cell Calcium. 
40:405-412. 
Berridge, M.J., M.D. Bootman, and H.L. Roderick. 2003. Calcium signalling: dynamics, 
homeostasis and remodelling. Nat Rev Mol Cell Biol. 4:517-529. 
Beurg, M., C.A. Ahern, P. Vallejo, M.W. Conklin, P.A. Powers, R.G. Gregg, and R. 
Coronado. 1999a. Involvement of the carboxy-terminus region of the dihydropyridine 
receptor beta1a subunit in excitation-contraction coupling of skeletal muscle. Biophys 
J. 77:2953-2967. 
Beurg, M., M. Sukhareva, C.A. Ahern, M.W. Conklin, E. Perez-Reyes, P.A. Powers, R.G. 
Gregg, and R. Coronado. 1999b. Differential regulation of skeletal muscle L-type 
Ca2+ current and excitation-contraction coupling by the dihydropyridine receptor beta 
subunit. Biophys J. 76:1744-1756. 
Biral, D., P. Volpe, E. Damiani, and A. Margreth. 1992. Coexistence of two calsequestrin 
isoforms in rabbit slow-twitch skeletal muscle fibers. FEBS Lett. 299:175-178. 
Block, B.A., T. Imagawa, K.P. Campbell, and C. Franzini-Armstrong. 1988. Structural 
evidence for direct interaction between the molecular components of the transverse 
   
 
 115 
tubule/sarcoplasmic reticulum junction in skeletal muscle. J Cell Biol. 107:2587-
2600. 
Bodine, S.C., T.N. Stitt, M. Gonzalez, W.O. Kline, G.L. Stover, R. Bauerlein, E. Zlotchenko, 
A. Scrimgeour, J.C. Lawrence, D.J. Glass, and G.D. Yancopoulos. 2001a. Akt/mTOR 
pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle 
atrophy in vivo. Nat Cell Biol. 3:1014-1019. 
Bodine, S.C., T.N. Stitt, M. Gonzalez, W.O. Kline, G.L. Stover, R. Bauerlein, E. Zlotchenko, 
A. Scrimgeour, J.C. Lawrence, D.J. Glass, and G.D. Yancopoulos. 2001b. Akt/mTOR 
pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle 
atrophy in vivo. Nature Cell Biology. 3:1014-1019. 
Bolton, T.B. 1979. MECHANISMS OF ACTION OF TRANSMITTERS AND OTHER 
SUBSTANCES ON SMOOTH-MUSCLE. Physiological Reviews. 59:606-718. 
Bottinelli, R., and C. Reggiani. 2000. Human skeletal muscle fibres: molecular and functional 
diversity. Prog Biophys Mol Biol. 73:195-262. 
Brattstrom, C., J. Sawe, B. Jansson, A. Lonnebo, J. Nordin, J.J. Zimmerman, J.T. Burke, and 
C.G. Groth. 2000. Pharmacokinetics and safety of single oral doses of sirolimus 
(rapamycin) in healthy male volunteers. Ther Drug Monit. 22:537-544. 
Broos, K., H.B. Feys, S.F. De Meyer, K. Vanhoorelbeke, and H. Deckmyn. 2011. Platelets at 
work in primary hemostasis. Blood Rev. 25:155-167. 
Buraei, Z., and J. Yang. 2013. Structure and function of the beta subunit of voltage-gated 
Ca(2)(+) channels. Biochim Biophys Acta. 1828:1530-1540. 
Burk, S.E., J. Lytton, D.H. MacLennan, and G.E. Shull. 1989. cDNA cloning, functional 
expression, and mRNA tissue distribution of a third organellar Ca2+ pump. J Biol 
Chem. 264:18561-18568. 
Calderon, J.C., P. Bolanos, and C. Caputo. 2010. Myosin heavy chain isoform composition 
and Ca(2+) transients in fibres from enzymatically dissociated murine soleus and 
extensor digitorum longus muscles. J Physiol. 588:267-279. 
Calne, R.Y., D.S. Collier, S. Lim, S.G. Pollard, A. Samaan, D.J. White, and S. Thiru. 1989. 
Rapamycin for immunosuppression in organ allografting. Lancet. 2:227. 
Capacchione, J.F., N. Sambuughin, S. Bina, L.P. Mulligan, T.D. Lawson, and S.M. Muldoon. 
2010. Exertional rhabdomyolysis and malignant hyperthermia in a patient with 
ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and 
calsequestrin-1 gene polymorphisms. Anesthesiology. 112:239-244. 
   
 
 116 
Cardamone, M., D. Flanagan, D. Mowat, S.E. Kennedy, M. Chopra, and J.A. Lawson. 2014. 
Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal 
giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 164:1195-1200. 
Cartwright, E.J., D. Oceandy, C. Austin, and L. Neyses. 2011. Ca2+ signalling in 
cardiovascular disease: the role of the plasma membrane calcium pumps. Sci China 
Life Sci. 54:691-698. 
Cassens, R.G., and C.C. Cooper. 1971. Red and white muscle. Adv Food Res. 19:1-74. 
Catterall, W.A. 1991. Excitation-contraction coupling in vertebrate skeletal muscle: a tale of 
two calcium channels. Cell. 64:871-874. 
Catterall, W.A. 1995. Structure and function of voltage-gated ion channels. Annu Rev 
Biochem. 64:493-531. 
Chapin, J.C., and K.A. Hajjar. 2015. Fibrinolysis and the control of blood coagulation. Blood 
Rev. 29:17-24. 
Chelu, M.G., S.A. Goonasekera, W.J. Durham, W. Tang, J.D. Lueck, J. Riehl, I.N. Pessah, P. 
Zhang, M.B. Bhattacharjee, R.T. Dirksen, and S.L. Hamilton. 2006. Heat- and 
anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J. 
20:329-330. 
Chen, J., X.F. Zheng, E.J. Brown, and S.L. Schreiber. 1995. Identification of an 11-kDa 
FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-
associated protein and characterization of a critical serine residue. Proc Natl Acad Sci 
U S A. 92:4947-4951. 
Cheng, H., and W.J. Lederer. 2008. Calcium sparks. Physiol Rev. 88:1491-1545. 
Cheng, H., W.J. Lederer, and M.B. Cannell. 1993. Calcium sparks: elementary events 
underlying excitation-contraction coupling in heart muscle. Science. 262:740-744. 
Chetty, R., S. Batitang, and R. Nair. 2000. Large artery vasculopathy in HIV-positive 
patients: another vasculitic enigma. Hum Pathol. 31:374-379. 
Clapp, L.H., M.B. Vivaudou, J.V. Walsh, and J.J. Singer. 1987. ACETYLCHOLINE 
INCREASES VOLTAGE-ACTIVATED CA-2+ CURRENT IN FRESHLY 
DISSOCIATED SMOOTH-MUSCLE CELLS. Proceedings of the National Academy 
of Sciences of the United States of America. 84:2092-2096. 
Clarke, N.F., L.B. Waddell, S.T. Cooper, M. Perry, R.L. Smith, A.J. Kornberg, F. Muntoni, 
S. Lillis, V. Straub, K. Bushby, M. Guglieri, M.D. King, M.A. Farrell, I. Marty, J. 
Lunardi, N. Monnier, and K.N. North. 2010. Recessive mutations in RYR1 are a 
common cause of congenital fiber type disproportion. Hum Mutat. 31:E1544-1550. 
   
 
 117 
Collier, M.L., A.P. Thomas, and J.R. Berlin. 1999. Relationship between L-type Ca2+ 
current and unitary sarcoplasmic reticulum Ca2+ release events in rat ventricular 
myocytes. J Physiol. 516 ( Pt 1):117-128. 
Colman, R.W. 2006. Hemostasis and thrombosis : basic principles and clinical practice. 
Lippincott Williams & Wilkins, Philadelphia, PA. xxiv, 1827 p. pp. 
Cornu, M., V. Albert, and M.N. Hall. 2013. mTOR in aging, metabolism, and cancer. Curr 
Opin Genet Dev. 23:53-62. 
Costello, B., C. Chadwick, A. Saito, A. Chu, A. Maurer, and S. Fleischer. 1986. 
Characterization of the junctional face membrane from terminal cisternae of 
sarcoplasmic reticulum. J Cell Biol. 103:741-753. 
Csernoch, L., J. Zhou, M.D. Stern, G. Brum, and E. Rios. 2004. The elementary events of 
Ca2+ release elicited by membrane depolarization in mammalian muscle. J Physiol. 
557:43-58. 
Cunningham, J.T., J.T. Rodgers, D.H. Arlow, F. Vazquez, V.K. Mootha, and P. Puigserver. 
2007. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha 
transcriptional complex. Nature. 450:736-740. 
Curtis, B.M., and W.A. Catterall. 1984. Purification of the calcium antagonist receptor of the 
voltage-sensitive calcium channel from skeletal muscle transverse tubules. 
Biochemistry. 23:2113-2118. 
Czarnecki, R.B.M.C.P.J. 2008. Hemostasis and Hemorrhagic Disorders. Fermentation-Biotec 
GmbH. 
Damiani, E., R. Betto, S. Salvatori, P. Volpe, G. Salviati, and A. Margreth. 1981. 
Polymorphism of sarcoplasmic-reticulum adenosine triphosphatase of rabbit skeletal 
muscle. Biochem J. 197:245-248. 
Damiani, E., and A. Margreth. 1994. Characterization study of the ryanodine receptor and of 
calsequestrin isoforms of mammalian skeletal muscles in relation to fibre types. J 
Muscle Res Cell Motil. 15:86-101. 
Damiani, E., C. Spamer, C. Heilmann, S. Salvatori, and A. Margreth. 1988. Endoplasmic 
reticulum of rat liver contains two proteins closely related to skeletal sarcoplasmic 
reticulum Ca-ATPase and calsequestrin. J Biol Chem. 263:340-343. 
Damiani, E., P. Volpe, and A. Margreth. 1990. Coexpression of two isoforms of calsequestrin 
in rabbit slow-twitch muscle. J Muscle Res Cell Motil. 11:522-530. 
de Maat, S., P.G. de Groot, and C. Maas. 2014. Contact system activation on endothelial 
cells. Semin Thromb Hemost. 40:887-894. 
   
 
 118 
DeFoor, P.H., D. Levitsky, T. Biryukova, and S. Fleischer. 1980. Immunological 
dissimilarity of the calcium pump protein of skeletal and cardiac muscle sarcoplasmic 
reticulum. Arch Biochem Biophys. 200:196-205. 
Del Castillo, J., and B. Katz. 1954. Action, and spontaneous release, of acetylcholine at an 
inexcitable nerve-muscle junction. J Physiol. 126:27P. 
Delbono, O., K.S. O'Rourke, and W.H. Ettinger. 1995. Excitation-calcium release uncoupling 
in aged single human skeletal muscle fibers. J Membr Biol. 148:211-222. 
Delbono, O., J. Xia, S. Treves, Z.M. Wang, R. Jimenez-Moreno, A.M. Payne, M.L. Messi, A. 
Briguet, F. Schaerer, M. Nishi, H. Takeshima, and F. Zorzato. 2007. Loss of skeletal 
muscle strength by ablation of the sarcoplasmic reticulum protein JP45. Proc Natl 
Acad Sci U S A. 104:20108-20113. 
Demuro, A., and I. Parker. 2008. Multi-dimensional resolution of elementary Ca2+ signals by 
simultaneous multi-focal imaging. Cell Calcium. 43:367-374. 
Denborough, M. 1998. Malignant hyperthermia. Lancet. 352:1131-1136. 
Dibble, C.C., and B.D. Manning. 2013. Signal integration by mTORC1 coordinates nutrient 
input with biosynthetic output. Nat Cell Biol. 15:555-564. 
Dietze, B., J. Henke, H.M. Eichinger, F. Lehmann-Horn, and W. Melzer. 2000. Malignant 
hyperthermia mutation Arg615Cys in the porcine ryanodine receptor alters voltage 
dependence of Ca2+ release. J Physiol. 526 Pt 3:507-514. 
Dittus, C., M. Streiff, and J. Ansell. 2015. Bleeding and clotting in hereditary hemorrhagic 
telangiectasia. World J Clin Cases. 3:330-337. 
Dolphin, A.C. 2012. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and 
one step beyond. Nat Rev Neurosci. 13:542-555. 
Duvel, K., J.L. Yecies, S. Menon, P. Raman, A.I. Lipovsky, A.L. Souza, E. Triantafellow, Q. 
Ma, R. Gorski, S. Cleaver, M.G. Vander Heiden, J.P. MacKeigan, P.M. Finan, C.B. 
Clish, L.O. Murphy, and B.D. Manning. 2010. Activation of a metabolic gene 
regulatory network downstream of mTOR complex 1. Mol Cell. 39:171-183. 
Ebashi, S. 1972. Calcium ions and muscle contraction. Nature. 240:217-218. 
Ehninger, D., F. Neff, and K. Xie. 2014. Longevity, aging and rapamycin. Cell Mol Life Sci. 
71:4325-4346. 
European Malignant Hyperthermia, G. 2016. Mutations in RyR1. 
Fabiato, A. 1983. Calcium-induced release of calcium from the cardiac sarcoplasmic 
reticulum. Am J Physiol. 245:C1-14. 
   
 
 119 
Fatt, P., and B. Katz. 1951. An analysis of the end-plate potential recorded with an 
intracellular electrode. J Physiol. 115:320-370. 
Ferreiro, A., N. Monnier, N.B. Romero, J.P. Leroy, C. Bonnemann, C.A. Haenggeli, V. 
Straub, W.D. Voss, Y. Nivoche, H. Jungbluth, A. Lemainque, T. Voit, J. Lunardi, M. 
Fardeau, and P. Guicheney. 2002. A recessive form of central core disease, transiently 
presenting as multi-minicore disease, is associated with a homozygous mutation in the 
ryanodine receptor type 1 gene. Ann Neurol. 51:750-759. 
Fliegel, L., E. Newton, K. Burns, and M. Michalak. 1990. Molecular cloning of cDNA 
encoding a 55-kDa multifunctional thyroid hormone binding protein of skeletal 
muscle sarcoplasmic reticulum. J Biol Chem. 265:15496-15502. 
Floyd, R., and S. Wray. 2007. Calcium transporters and signalling in smooth muscles. Cell 
Calcium. 42:467-476. 
Fok, W.C., Y. Chen, A. Bokov, Y. Zhang, A.B. Salmon, V. Diaz, M. Javors, W.H. Wood, 
3rd, Y. Zhang, K.G. Becker, V.I. Perez, and A. Richardson. 2014. Mice fed 
rapamycin have an increase in lifespan associated with major changes in the liver 
transcriptome. PLoS One. 9:e83988. 
Fosset, M., E. Jaimovich, E. Delpont, and M. Lazdunski. 1983. [3H]nitrendipine receptors in 
skeletal muscle. J Biol Chem. 258:6086-6092. 
Franzini-Armstrong, C. 1980. Structure of sarcoplasmic reticulum. Fed Proc. 39:2403-2409. 
Franzini-Armstrong, C., L.J. Kenney, and E. Varriano-Marston. 1987. The structure of 
calsequestrin in triads of vertebrate skeletal muscle: a deep-etch study. J Cell Biol. 
105:49-56. 
Franzini-Armstrong, C., M. Pincon-Raymond, and F. Rieger. 1991. Muscle fibers from 
dysgenic mouse in vivo lack a surface component of peripheral couplings. Dev Biol. 
146:364-376. 
Fritz, N., J.L. Morel, L.H. Jeyakumar, S. Fleischer, P.D. Allen, J. Mironneau, and N. Macrez. 
2007. RyR1-specific requirement for depolarization-induced Ca2+ sparks in urinary 
bladder smooth muscle. J Cell Sci. 120:3784-3791. 
Fritzsche, T., M. Schnolzer, S. Fiedler, M. Weigand, M. Wiessler, and E. Frei. 2004. 
Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) 
from purified plasma membranes of human tumour cell lines as albumin-binding 
proteins. Biochem Pharmacol. 67:655-665. 
Gallant, E.M., and L.R. Lentz. 1992. Excitation-contraction coupling in pigs heterozygous for 
malignant hyperthermia. Am J Physiol. 262:C422-426. 
   
 
 120 
Gangloff, Y.G., M. Mueller, S.G. Dann, P. Svoboda, M. Sticker, J.F. Spetz, S.H. Um, E.J. 
Brown, S. Cereghini, G. Thomas, and S.C. Kozma. 2004. Disruption of the mouse 
mTOR gene leads to early postimplantation lethality and prohibits embryonic stem 
cell development. Mol Cell Biol. 24:9508-9516. 
Ganitkevich, V., and G. Isenberg. 1990. Isolated guinea pig coronary smooth muscle cells. 
Acetylcholine induces hyperpolarization due to sarcoplasmic reticulum calcium 
release activating potassium channels. Circ Res. 67:525-528. 
Giannini, G., A. Conti, S. Mammarella, M. Scrobogna, and V. Sorrentino. 1995. The 
ryanodine receptor/calcium channel genes are widely and differentially expressed in 
murine brain and peripheral tissues. J Cell Biol. 128:893-904. 
Gillies, R.L., A.R. Bjorksten, D. Du Sart, and B.M. Hockey. 2015. Analysis of the entire 
ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor 
(CACNA1S) coding regions for variants associated with malignant hyperthermia in 
Australian families. Anaesth Intensive Care. 43:157-166. 
Glossmann, H., D.R. Ferry, A. Goll, and M. Rombusch. 1984. Molecular pharmacology of 
the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel 
subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium 
channel label, [125I]iodipine. J Cardiovasc Pharmacol. 6 Suppl 4:S608-621. 
Gollasch, M., and M.T. Nelson. 1997. Voltage-dependent Ca2+ channels in arterial smooth 
muscle cells. Kidney Blood Press Res. 20:355-371. 
Gonsalves, S.G., D. Ng, J.J. Johnston, J.K. Teer, P.D. Stenson, D.N. Cooper, J.C. Mullikin, 
L.G. Biesecker, and N.C.S. Program. 2013. Using exome data to identify malignant 
hyperthermia susceptibility mutations. Anesthesiology. 119:1043-1053. 
Gonzalez-Serratos, H., D.W. Hilgemann, M. Rozycka, A. Gauthier, and H. Rasgado-Flores. 
1996. Na-Ca exchange studies in sarcolemmal skeletal muscle. Ann N Y Acad Sci. 
779:556-560. 
Grabner, M., R.T. Dirksen, N. Suda, and K.G. Beam. 1999. The II-III loop of the skeletal 
muscle dihydropyridine receptor is responsible for the Bi-directional coupling with 
the ryanodine receptor. J Biol Chem. 274:21913-21919. 
Gregg, R.G., A. Messing, C. Strube, M. Beurg, R. Moss, M. Behan, M. Sukhareva, S. 
Haynes, J.A. Powell, R. Coronado, and P.A. Powers. 1996. Absence of the beta 
subunit (cchb1) of the skeletal muscle dihydropyridine receptor alters expression of 
the alpha 1 subunit and eliminates excitation-contraction coupling. Proc Natl Acad 
Sci U S A. 93:13961-13966. 
   
 
 121 
Guertin, D.A., D.M. Stevens, C.C. Thoreen, A.A. Burds, N.Y. Kalaany, J. Moffat, M. Brown, 
K.J. Fitzgerald, and D.M. Sabatini. 2006. Ablation in mice of the mTORC 
components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling 
to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 11:859-871. 
Gunteski-Hamblin, A.M., J. Greeb, and G.E. Shull. 1988. A novel Ca2+ pump expressed in 
brain, kidney, and stomach is encoded by an alternative transcript of the slow-twitch 
muscle sarcoplasmic reticulum Ca-ATPase gene. Identification of cDNAs encoding 
Ca2+ and other cation-transporting ATPases using an oligonucleotide probe derived 
from the ATP-binding site. J Biol Chem. 263:15032-15040. 
Gusev, N.B. 2001. Some properties of caldesmon and calponin and the participation of these 
proteins in regulation of smooth muscle contraction and cytoskeleton formation. 
Biochemistry (Mosc). 66:1112-1121. 
Halevy, O., and O. Lerman. 1993. Retinoic acid induces adult muscle cell differentiation 
mediated by the retinoic acid receptor-alpha. J Cell Physiol. 154:566-572. 
Hall, M.N. 2008. mTOR-what does it do? Transplant Proc. 40:S5-8. 
Harrison, D.E., R. Strong, Z.D. Sharp, J.F. Nelson, C.M. Astle, K. Flurkey, N.L. Nadon, J.E. 
Wilkinson, K. Frenkel, C.S. Carter, M. Pahor, M.A. Javors, E. Fernandez, and R.A. 
Miller. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous 
mice. Nature. 460:392-395. 
Hasselbach, W. 1980. Quantitative aspects of the calcium concept of excitation contraction 
coupling--a critical evaluation. Basic Res Cardiol. 75:2-12. 
Hayashi, T. 1952. Contractile properties of compressed monolayers of actomyosin. J Gen 
Physiol. 36:139-152. 
He, Z., A.K. Dunker, C.R. Wesson, and W.R. Trumble. 1993. Ca(2+)-induced folding and 
aggregation of skeletal muscle sarcoplasmic reticulum calsequestrin. The involvement 
of the trifluoperazine-binding site. J Biol Chem. 268:24635-24641. 
Heitman, J., N.R. Movva, and M.N. Hall. 1991. Targets for cell cycle arrest by the 
immunosuppressant rapamycin in yeast. Science. 253:905-909. 
Hill, J. 2012. Muscle: fundamental biology and mechanisms of disease. Academic Press, S.l. 
1 online resource. pp. 
Hill, R.W., G.A. Wyse, and M. Anderson. 2012. Animal physiology. Sinauer, Sunderland, 
Mass. 800 p. pp. 
   
 
 122 
Hirano, K., M. Hirano, and H. Kanaide. 2004. Regulation of myosin phosphorylation and 
myofilament Ca2+ sensitivity in vascular smooth muscle. J Smooth Muscle Res. 
40:219-236. 
Hopkins, P.M., F.R. Ellis, and P.J. Halsall. 1991. Evidence for related myopathies in 
exertional heat stroke and malignant hyperthermia. Lancet. 338:1491-1492. 
Hopkins, P.M., H. Ruffert, M.M. Snoeck, T. Girard, K.P. Glahn, F.R. Ellis, C.R. Muller, A. 
Urwyler, and G. European Malignant Hyperthermia. 2015. European Malignant 
Hyperthermia Group guidelines for investigation of malignant hyperthermia 
susceptibility. Br J Anaesth. 115:531-539. 
Huxley, H.E. 1957. The double array of filaments in cross-striated muscle. J Biophys 
Biochem Cytol. 3:631-648. 
Huxley, H.E. 1969. The mechanism of muscular contraction. Science. 164:1356-1365. 
Hwang, J.H., F. Zorzato, N.F. Clarke, and S. Treves. 2012. Mapping domains and mutations 
on the skeletal muscle ryanodine receptor channel. Trends Mol Med. 18:644-657. 
Iadevaia, V., Y. Huo, Z. Zhang, L.J. Foster, and C.G. Proud. 2012. Roles of the mammalian 
target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. 
Biochem Soc Trans. 40:168-172. 
Ikemoto, N., M. Ronjat, L.G. Meszaros, and M. Koshita. 1989. Postulated role of 
calsequestrin in the regulation of calcium release from sarcoplasmic reticulum. 
Biochemistry. 28:6764-6771. 
Ikura, M. 1996. Calcium binding and conformational response in EF-hand proteins. Trends 
Biochem Sci. 21:14-17. 
Inesi, G. 1985. Mechanism of calcium transport. Annu Rev Physiol. 47:573-601. 
Inoki, K., J. Kim, and K.L. Guan. 2012. AMPK and mTOR in cellular energy homeostasis 
and drug targets. Annu Rev Pharmacol Toxicol. 52:381-400. 
Inoue, M., and J.H. Bridge. 2003. Ca2+ sparks in rabbit ventricular myocytes evoked by 
action potentials: involvement of clusters of L-type Ca2+ channels. Circ Res. 92:532-
538. 
Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M.A. Ruegg, A. Hall, and M.N. Hall. 2004. 
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive. Nat Cell Biol. 6:1122-1128. 
Jaggar, J.H., G.C. Wellman, T.J. Heppner, V.A. Porter, G.J. Perez, M. Gollasch, T. 
Kleppisch, M. Rubart, A.S. Stevenson, W.J. Lederer, H.J. Knot, A.D. Bonev, and 
M.T. Nelson. 1998. Ca2+ channels, ryanodine receptors and Ca(2+)-activated K+ 
   
 
 123 
channels: a functional unit for regulating arterial tone. Acta Physiol Scand. 164:577-
587. 
Jiang, Y.H., M.G. Klein, and M.F. Schneider. 1999. Numerical simulation of Ca2+ "sparks" 
in skeletal muscle. Biophys J. 77:2333-2357. 
Jiao, Q., H. Takeshima, Y. Ishikawa, and S. Minamisawa. 2012. Sarcalumenin plays a critical 
role in age-related cardiac dysfunction due to decreases in SERCA2a expression and 
activity. Cell Calcium. 51:31-39. 
Johnson, S.C., G.M. Martin, P.S. Rabinovitch, and M. Kaeberlein. 2013. Preserving youth: 
does rapamycin deliver? Sci Transl Med. 5:211fs240. 
Jorgensen, A.O., W. Arnold, D.R. Pepper, S.D. Kahl, F. Mandel, and K.P. Campbell. 1988. A 
monoclonal antibody to the Ca2+-ATPase of cardiac sarcoplasmic reticulum cross-
reacts with slow type I but not with fast type II canine skeletal muscle fibers: an 
immunocytochemical and immunochemical study. Cell Motil Cytoskeleton. 9:164-
174. 
Jorgensen, A.O., and L.R. Jones. 1986. Localization of phospholamban in slow but not fast 
canine skeletal muscle fibers. An immunocytochemical and biochemical study. J Biol 
Chem. 261:3775-3781. 
Jurkat-Rott, K., T. McCarthy, and F. Lehmann-Horn. 2000. Genetics and pathogenesis of 
malignant hyperthermia. Muscle Nerve. 23:4-17. 
Kahan, B.D., J. Podbielski, K.L. Napoli, S.M. Katz, H.U. Meier-Kriesche, and C.T. Van 
Buren. 1998. Immunosuppressive effects and safety of a sirolimus/cyclosporine 
combination regimen for renal transplantation. Transplantation. 66:1040-1046. 
Kang, S.A., M.E. Pacold, C.L. Cervantes, D. Lim, H.J. Lou, K. Ottina, N.S. Gray, B.E. Turk, 
M.B. Yaffe, and D.M. Sabatini. 2013. mTORC1 phosphorylation sites encode their 
sensitivity to starvation and rapamycin. Science. 341:1236566. 
Kawamoto, R.M., J.P. Brunschwig, K.C. Kim, and A.H. Caswell. 1986. Isolation, 
characterization, and localization of the spanning protein from skeletal muscle triads. 
J Cell Biol. 103:1405-1414. 
Khurana, T.S., and K.E. Davies. 2003. Pharmacological strategies for muscular dystrophy. 
Nat Rev Drug Discov. 2:379-390. 
Kirsch, W.G., D. Uttenweiler, and R.H. Fink. 2001. Spark- and ember-like elementary Ca2+ 
release events in skinned fibres of adult mammalian skeletal muscle. J Physiol. 
537:379-389. 
   
 
 124 
Knudson, C.M., and K.P. Campbell. 1989. Albumin is a major protein component of 
transverse tubule vesicles isolated from skeletal muscle. J Biol Chem. 264:10795-
10798. 
Kolb, M.E., M.L. Horne, and R. Martz. 1982. Dantrolene in human malignant hyperthermia. 
Anesthesiology. 56:254-262. 
Koltin, Y., L. Faucette, D.J. Bergsma, M.A. Levy, R. Cafferkey, P.L. Koser, R.K. Johnson, 
and G.P. Livi. 1991. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated 
by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol 
Cell Biol. 11:1718-1723. 
Krause, T., M.U. Gerbershagen, M. Fiege, R. Weisshorn, and F. Wappler. 2004. Dantrolene--
a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 
59:364-373. 
Kugler, G., R.G. Weiss, B.E. Flucher, and M. Grabner. 2004. Structural requirements of the 
dihydropyridine receptor alpha1S II-III loop for skeletal-type excitation-contraction 
coupling. J Biol Chem. 279:4721-4728. 
Lacampagne, A., M.G. Klein, C.W. Ward, and M.F. Schneider. 2000. Two mechanisms for 
termination of individual Ca2+ sparks in skeletal muscle. Proc Natl Acad Sci U S A. 
97:7823-7828. 
Lamming, D.W., and D.M. Sabatini. 2013. A Central role for mTOR in lipid homeostasis. 
Cell Metab. 18:465-469. 
Lanner, J.T. 2012. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol. 
740:217-234. 
Lanner, J.T., D.K. Georgiou, A.D. Joshi, and S.L. Hamilton. 2010. Ryanodine receptors: 
structure, expression, molecular details, and function in calcium release. Cold Spring 
Harb Perspect Biol. 2:a003996. 
Laplante, M., and D.M. Sabatini. 2009. An emerging role of mTOR in lipid biosynthesis. 
Curr Biol. 19:R1046-1052. 
Laplante, M., and D.M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell. 
149:274-293. 
Large, W.A. 2002. Receptor-operated Ca2(+)-permeable nonselective cation channels in 
vascular smooth muscle: a physiologic perspective. J Cardiovasc Electrophysiol. 
13:493-501. 
   
 
 125 
Launikonis, B.S., J.S. Zhou, L. Royer, T.R. Shannon, G. Brum, and E. Rios. 2006. Depletion 
"skraps" and dynamic buffering inside the cellular calcium store. Proceedings of the 
National Academy of Sciences of the United States of America. 103:2982-2987. 
Laver, D.R., G.K. Lenz, and G.D. Lamb. 2001. Regulation of the calcium release channel 
from rabbit skeletal muscle by the nucleotides ATP, AMP, IMP and adenosine. J 
Physiol. 537:763-778. 
Lawrence, J.C., Jr. 2001. mTOR-dependent control of skeletal muscle protein synthesis. Int J 
Sport Nutr Exerc Metab. 11 Suppl:S177-185. 
Le Rumeur, E. 2015. Dystrophin and the two related genetic diseases, Duchenne and Becker 
muscular dystrophies. Bosn J Basic Med Sci. 15:14-20. 
Leberer, E., B.G. Timms, K.P. Campbell, and D.H. MacLennan. 1990. Purification, calcium 
binding properties, and ultrastructural localization of the 53,000- and 160,000 
(sarcalumenin)-dalton glycoproteins of the sarcoplasmic reticulum. J Biol Chem. 
265:10118-10124. 
Ledbetter, M.W., J.K. Preiner, C.F. Louis, and J.R. Mickelson. 1994. Tissue distribution of 
ryanodine receptor isoforms and alleles determined by reverse transcription 
polymerase chain reaction. J Biol Chem. 269:31544-31551. 
Leger, B., R. Cartoni, M. Praz, S. Lamon, O. Deriaz, A. Crettenand, C. Gobelet, P. Rohmer, 
M. Konzelmann, F. Luthi, and A.P. Russell. 2006. Akt signalling through GSK-3beta, 
mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J 
Physiol. 576:923-933. 
Liden, M., and U. Eriksson. 2006. Understanding retinol metabolism: structure and function 
of retinol dehydrogenases. J Biol Chem. 281:13001-13004. 
Lorber, M.I., S. Mulgaonkar, K.M. Butt, E. Elkhammas, R. Mendez, P.R. Rajagopalan, B. 
Kahan, H. Sollinger, Y. Li, N. Cretin, H. Tedesco, and B.S. Group. 2005. Everolimus 
versus mycophenolate mofetil in the prevention of rejection in de novo renal 
transplant recipients: a 3-year randomized, multicenter, phase III study. 
Transplantation. 80:244-252. 
Loscalzo, J. 1995. Endothelial injury, vasoconstriction, and its prevention. Tex Heart Inst J. 
22:180-184. 
Lu, X., L. Xu, and G. Meissner. 1994. Activation of the skeletal muscle calcium release 
channel by a cytoplasmic loop of the dihydropyridine receptor. J Biol Chem. 
269:6511-6516. 
   
 
 126 
Lukyanenko, V., and S. Gyorke. 1999. Ca2+ sparks and Ca2+ waves in saponin-
permeabilized rat ventricular myocytes. J Physiol. 521 Pt 3:575-585. 
Lytton, J., A. Zarain-Herzberg, M. Periasamy, and D.H. MacLennan. 1989. Molecular 
cloning of the mammalian smooth muscle sarco(endo)plasmic reticulum Ca2+-
ATPase. J Biol Chem. 264:7059-7065. 
Ma, X.M., and J. Blenis. 2009. Molecular mechanisms of mTOR-mediated translational 
control. Nat Rev Mol Cell Biol. 10:307-318. 
Mackrill, J.J., R.A. Challiss, A. O'Connell D, F.A. Lai, and S.R. Nahorski. 1997. Differential 
expression and regulation of ryanodine receptor and myo-inositol 1,4,5-trisphosphate 
receptor Ca2+ release channels in mammalian tissues and cell lines. Biochem J. 327 ( 
Pt 1):251-258. 
MacLennan, D.H. 2000. Ca2+ signalling and muscle disease. Eur J Biochem. 267:5291-5297. 
MacLennan, D.H., C. Duff, F. Zorzato, J. Fujii, M. Phillips, R.G. Korneluk, W. Frodis, B.A. 
Britt, and R.G. Worton. 1990. Ryanodine receptor gene is a candidate for 
predisposition to malignant hyperthermia. Nature. 343:559-561. 
MacLennan, D.H., and E.G. Kranias. 2003. Phospholamban: a crucial regulator of cardiac 
contractility. Nat Rev Mol Cell Biol. 4:566-577. 
MacLennan, D.H., and P.T. Wong. 1971. Isolation of a calcium-sequestering protein from 
sarcoplasmic reticulum. Proc Natl Acad Sci U S A. 68:1231-1235. 
Malfait, F., and A. De Paepe. 2014. The Ehlers-Danlos syndrome. Adv Exp Med Biol. 
802:129-143. 
Manring, H., E. Abreu, L. Brotto, N. Weisleder, and M. Brotto. 2014. Novel excitation-
contraction coupling related genes reveal aspects of muscle weakness beyond 
atrophy-new hopes for treatment of musculoskeletal diseases. Front Physiol. 5:37. 
Margreth, A., E. Damiani, and E. Bortoloso. 1999. Sarcoplasmic reticulum in aged skeletal 
muscle. Acta Physiol Scand. 167:331-338. 
Marx, S.O., K. Ondrias, and A.R. Marks. 1998. Coupled gating between individual skeletal 
muscle Ca2+ release channels (ryanodine receptors). Science. 281:818-821. 
Mascioni, A., C. Karim, G. Barany, D.D. Thomas, and G. Veglia. 2002. Structure and 
orientation of sarcolipin in lipid environments. Biochemistry. 41:475-482. 
McCarron, J.G., M.L. Olson, C. Wilson, M.E. Sandison, and S. Chalmers. 2013. Examining 
the Role of Mitochondria in Ca2+ Signaling in Native Vascular Smooth Muscle. 
Microcirculation. 20:317-329. 
   
 
 127 
McCarthy, T.V., J.M. Healy, J.J. Heffron, M. Lehane, T. Deufel, F. Lehmann-Horn, M. 
Farrall, and K. Johnson. 1990. Localization of the malignant hyperthermia 
susceptibility locus to human chromosome 19q12-13.2. Nature. 343:562-564. 
Meissner, G. 1975. Isolation and characterization of two types of sarcoplasmic reticulum 
vesicles. Biochim Biophys Acta. 389:51-68. 
Meissner, G., E. Darling, and J. Eveleth. 1986. Kinetics of rapid Ca2+ release by 
sarcoplasmic reticulum. Effects of Ca2+, Mg2+, and adenine nucleotides. 
Biochemistry. 25:236-244. 
Meissner, G., E. Rios, A. Tripathy, and D.A. Pasek. 1997. Regulation of skeletal muscle 
Ca2+ release channel (ryanodine receptor) by Ca2+ and monovalent cations and 
anions. J Biol Chem. 272:1628-1638. 
Merlot, A.M., D.S. Kalinowski, and D.R. Richardson. 2014. Unraveling the mysteries of 
serum albumin-more than just a serum protein. Front Physiol. 5:299. 
Michalak, M., E.F. Corbett, N. Mesaeli, K. Nakamura, and M. Opas. 1999. Calreticulin: one 
protein, one gene, many functions. Biochem J. 344 Pt 2:281-292. 
Mosca, B., O. Delbono, M. Laura Messi, L. Bergamelli, Z.M. Wang, M. Vukcevic, R. Lopez, 
S. Treves, M. Nishi, H. Takeshima, C. Paolini, M. Martini, G. Rispoli, F. Protasi, and 
F. Zorzato. 2013. Enhanced dihydropyridine receptor calcium channel activity 
restores muscle strength in JP45/CASQ1 double knockout mice. Nat Commun. 
4:1541. 
Muller, G., and C.W. Heizmann. 1982. Albumin in chicken skeletal muscle. Eur J Biochem. 
123:577-582. 
Mumford, A.D., J. O'Donnell, J.D. Gillmore, R.A. Manning, P.N. Hawkins, and M. Laffan. 
2000. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-
amyloidosis. Br J Haematol. 110:454-460. 
Murakami, M., T. Ichisaka, M. Maeda, N. Oshiro, K. Hara, F. Edenhofer, H. Kiyama, K. 
Yonezawa, and S. Yamanaka. 2004. mTOR is essential for growth and proliferation 
in early mouse embryos and embryonic stem cells. Mol Cell Biol. 24:6710-6718. 
Muscat, G.E., L. Mynett-Johnson, D. Dowhan, M. Downes, and R. Griggs. 1994. Activation 
of myoD gene transcription by 3,5,3'-triiodo-L-thyronine: a direct role for the thyroid 
hormone and retinoid X receptors. Nucleic Acids Res. 22:583-591. 
Nakamura, K., A. Zuppini, S. Arnaudeau, J. Lynch, I. Ahsan, R. Krause, S. Papp, H. De 
Smedt, J.B. Parys, W. Muller-Esterl, D.P. Lew, K.H. Krause, N. Demaurex, M. Opas, 
   
 
 128 
and M. Michalak. 2001. Functional specialization of calreticulin domains. J Cell Biol. 
154:961-972. 
Nakayama, K., and Y. Tanaka. 1994. Stretch-induced contraction and Ca-2+ mobilization in 
vascular smooth muscle. Biological Signals. 2:241-252. 
Napoli, J.L. 1996. Biochemical pathways of retinoid transport, metabolism, and signal 
transduction. Clin Immunol Immunopathol. 80:S52-62. 
Nazer, M.A., and C. van Breemen. 1998. Functional linkage of Na(+)-Ca2+ exchange and 
sarcoplasmic reticulum Ca2+ release mediates Ca2+ cycling in vascular smooth 
muscle. Cell Calcium. 24:275-283. 
Nelson, D.A., and E.S. Benson. 1963. On the structural continuities of the transverse tubular 
system of rabbit and human myocardial cells. J Cell Biol. 16:297-313. 
Nelson, M.T., H. Cheng, M. Rubart, L.F. Santana, A.D. Bonev, H.J. Knot, and W.J. Lederer. 
1995. Relaxation of arterial smooth muscle by calcium sparks. Science. 270:633-637. 
Neuhuber, B., U. Gerster, F. Doring, H. Glossmann, T. Tanabe, and B.E. Flucher. 1998. 
Association of calcium channel alpha1S and beta1a subunits is required for the 
targeting of beta1a but not of alpha1S into skeletal muscle triads. Proc Natl Acad Sci 
U S A. 95:5015-5020. 
Neylon, C.B., S.M. Richards, M.A. Larsen, A. Agrotis, and A. Bobik. 1995. Multiple types of 
ryanodine receptor/Ca2+ release channels are expressed in vascular smooth muscle. 
Biochem Biophys Res Commun. 215:814-821. 
Niggli, E., and N. Shirokova. 2007. A guide to sparkology: the taxonomy of elementary 
cellular Ca2+ signaling events. Cell Calcium. 42:379-387. 
Novak, P., and T. Soukup. 2011. Calsequestrin distribution, structure and function, its role in 
normal and pathological situations and the effect of thyroid hormones. Physiol Res. 
60:439-452. 
Obermair, G.J., P. Tuluc, and B.E. Flucher. 2008. Auxiliary Ca(2+) channel subunits: lessons 
learned from muscle. Curr Opin Pharmacol. 8:311-318. 
Odermatt, A., S. Becker, V.K. Khanna, K. Kurzydlowski, E. Leisner, D. Pette, and D.H. 
MacLennan. 1998. Sarcolipin regulates the activity of SERCA1, the fast-twitch 
skeletal muscle sarcoplasmic reticulum Ca2+-ATPase. J Biol Chem. 273:12360-
12369. 
Ohanna, M., A.K. Sobering, T. Lapointe, L. Lorenzo, C. Praud, E. Petroulakis, N. Sonenberg, 
P.A. Kelly, A. Sotiropoulos, and M. Pende. 2005. Atrophy of S6K1(-/-) skeletal 
   
 
 129 
muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell 
Biol. 7:286-294. 
Olesen, C., M. Picard, A.M. Winther, C. Gyrup, J.P. Morth, C. Oxvig, J.V. Moller, and P. 
Nissen. 2007. The structural basis of calcium transport by the calcium pump. Nature. 
450:1036-1042. 
Owen, V.J., N.L. Taske, and G.D. Lamb. 1997. Reduced Mg2+ inhibition of Ca2+ release in 
muscle fibers of pigs susceptible to malignant hyperthermia. Am J Physiol. 272:C203-
211. 
Paul-Pletzer, K., T. Yamamoto, M.B. Bhat, J. Ma, N. Ikemoto, L.S. Jimenez, H. Morimoto, 
P.G. Williams, and J. Parness. 2002. Identification of a dantrolene-binding sequence 
on the skeletal muscle ryanodine receptor. J Biol Chem. 277:34918-34923. 
Perez, G.J., A.D. Bonev, J.B. Patlak, and M.T. Nelson. 1999. Functional coupling of 
ryanodine receptors to KCa channels in smooth muscle cells from rat cerebral arteries. 
J Gen Physiol. 113:229-238. 
Periasamy, M., and A. Kalyanasundaram. 2007. SERCA pump isoforms: their role in calcium 
transport and disease. Muscle Nerve. 35:430-442. 
Picht, E., A.V. Zima, L.A. Blatter, and D.M. Bers. 2007. SparkMaster: automated calcium 
spark analysis with ImageJ. Am J Physiol Cell Physiol. 293:C1073-1081. 
Podolsky, R.J. 1961. The myocardium-its biochemistry and biophysics. II. Biochemistry. 
Muscle physiology and contraction theories. Circulation. 24:399-409. 
Porter, K.R., and G.E. Palade. 1957. Studies on the endoplasmic reticulum. III. Its form and 
distribution in striated muscle cells. J Biophys Biochem Cytol. 3:269-300. 
Prins, D., and M. Michalak. 2011. Organellar calcium buffers. Cold Spring Harb Perspect 
Biol. 3. 
Proenza, C., J. O'Brien, J. Nakai, S. Mukherjee, P.D. Allen, and K.G. Beam. 2002. 
Identification of a region of RyR1 that participates in allosteric coupling with the 
alpha(1S) (Ca(V)1.1) II-III loop. J Biol Chem. 277:6530-6535. 
Pulido-Perez, A., J.A. Aviles-Izquierdo, and R. Suarez-Fernandez. 2012. [Cutaneous 
vasculitis]. Actas Dermosifiliogr. 103:179-191. 
Qin, J., G. Valle, A. Nani, H. Chen, J. Ramos-Franco, A. Nori, P. Volpe, and M. Fill. 2009. 
Ryanodine receptor luminal Ca2+ regulation: swapping calsequestrin and channel 
isoforms. Biophys J. 97:1961-1970. 
Quiroga, T., and D. Mezzano. 2012. Is my patient a bleeder? A diagnostic framework for 
mild bleeding disorders. Hematology Am Soc Hematol Educ Program. 2012:466-474. 
   
 
 130 
Reho, J.J., X. Zheng, and S.A. Fisher. 2014. Smooth muscle contractile diversity in the 
control of regional circulations. Am J Physiol Heart Circ Physiol. 306:H163-172. 
Rembold, C.M. 1992. Regulation of contraction and relaxation in arterial smooth muscle. 
Hypertension. 20:129-137. 
Renganathan, M., M.L. Messi, and O. Delbono. 1997. Dihydropyridine receptor-ryanodine 
receptor uncoupling in aged skeletal muscle. J Membr Biol. 157:247-253. 
Ribeiro, C.B., D.C. Christofoletti, V.A. Pezolato, R. de Cassia Marqueti Durigan, J. Prestes, 
R.A. Tibana, E.C. Pereira, I.V. de Sousa Neto, J.L. Durigan, and C.A. da Silva. 2015. 
Leucine minimizes denervation-induced skeletal muscle atrophy of rats through 
akt/mtor signaling pathways. Front Physiol. 6:73. 
Rios, E., and G. Brum. 1987. Involvement of dihydropyridine receptors in excitation-
contraction coupling in skeletal muscle. Nature. 325:717-720. 
Risson, V., L. Mazelin, M. Roceri, H. Sanchez, V. Moncollin, C. Corneloup, H. Richard-
Bulteau, A. Vignaud, D. Baas, A. Defour, D. Freyssenet, J.F. Tanti, Y. Le-Marchand-
Brustel, B. Ferrier, A. Conjard-Duplany, K. Romanino, S. Bauche, D. Hantai, M. 
Mueller, S.C. Kozma, G. Thomas, M.A. Ruegg, A. Ferry, M. Pende, X. Bigard, N. 
Koulmann, L. Schaeffer, and Y.G. Gangloff. 2009. Muscle inactivation of mTOR 
causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 
187:859-874. 
Robitaille, A.M., S. Christen, M. Shimobayashi, M. Cornu, L.L. Fava, S. Moes, C. 
Prescianotto-Baschong, U. Sauer, P. Jenoe, and M.N. Hall. 2013. Quantitative 
phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 
339:1320-1323. 
Rommel, C., S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, 
and D.J. Glass. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by 
PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 3:1009-1013. 
Rosenberg, H., M. Davis, D. James, N. Pollock, and K. Stowell. 2007. Malignant 
hyperthermia. Orphanet J Rare Dis. 2:21. 
Rosenberg, H., N. Pollock, A. Schiemann, T. Bulger, and K. Stowell. 2015. Malignant 
hyperthermia: a review. Orphanet J Rare Dis. 10:93. 
Rosenberg, H., N. Sambuughin, S. Riazi, and R. Dirksen. 2003. GeneReviews® [Internet]. P. 
RA, A. MP, A. HH, and e. al., editors. Seattle (WA): University of Washington, 
Seattle. 
   
 
 131 
Rossi, A.E., and R.T. Dirksen. 2006. Sarcoplasmic reticulum: the dynamic calcium governor 
of muscle. Muscle Nerve. 33:715-731. 
Sabatini, D.M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S.H. Snyder. 1994. RAFT1: 
a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is 
homologous to yeast TORs. Cell. 78:35-43. 
Saito, A., S. Seiler, A. Chu, and S. Fleischer. 1984. Preparation and morphology of 
sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. J Cell Biol. 
99:875-885. 
Sandow, A. 1952. Excitation-contraction coupling in muscular response. Yale J Biol Med. 
25:176-201. 
Sandri, M. 2008. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 
23:160-170. 
Sarbassov, D.D., S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, H. Erdjument-Bromage, P. 
Tempst, and D.M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton. Curr Biol. 14:1296-1302. 
Sarbassov, D.D., S.M. Ali, S. Sengupta, J.H. Sheen, P.P. Hsu, A.F. Bagley, A.L. Markhard, 
and D.M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly 
and Akt/PKB. Mol Cell. 22:159-168. 
Sasaguri, T., M. Hirata, and H. Kuriyama. 1985. Dependence on Ca2+ of the activities of 
phosphatidylinositol 4,5-bisphosphate phosphodiesterase and inositol 1,4,5-
trisphosphate phosphatase in smooth muscles of the porcine coronary artery. Biochem 
J. 231:497-503. 
Satoh, H., L.A. Blatter, and D.M. Bers. 1997. Effects of [Ca2+]i, SR Ca2+ load, and rest on 
Ca2+ spark frequency in ventricular myocytes. Am J Physiol. 272:H657-668. 
Schiaffino, S., and C. Reggiani. 2011. FIBER TYPES IN MAMMALIAN SKELETAL 
MUSCLES. Physiological Reviews. 91:1447-1531. 
Schoneich, C., R.I. Viner, D.A. Ferrington, and D.J. Bigelow. 1999. Age-related chemical 
modification of the skeletal muscle sarcoplasmic reticulum Ca-ATPase of the rat. 
Mech Ageing Dev. 107:221-231. 
Schredelseker, J., V. Di Biase, G.J. Obermair, E.T. Felder, B.E. Flucher, C. Franzini-
Armstrong, and M. Grabner. 2005. The beta 1a subunit is essential for the assembly 
of dihydropyridine-receptor arrays in skeletal muscle. Proc Natl Acad Sci U S A. 
102:17219-17224. 
   
 
 132 
Schuler, W., R. Sedrani, S. Cottens, B. Haberlin, M. Schulz, H.J. Schuurman, G. Zenke, H.G. 
Zerwes, and M.H. Schreier. 1997. SDZ RAD, a new rapamycin derivative: 
pharmacological properties in vitro and in vivo. Transplantation. 64:36-42. 
Scott, B.T., H.K. Simmerman, J.H. Collins, B. Nadal-Ginard, and L.R. Jones. 1988. 
Complete amino acid sequence of canine cardiac calsequestrin deduced by cDNA 
cloning. J Biol Chem. 263:8958-8964. 
Sheridan, D.C., H. Takekura, C. Franzini-Armstrong, K.G. Beam, P.D. Allen, and C.F. Perez. 
2006. Bidirectional signaling between calcium channels of skeletal muscle requires 
multiple direct and indirect interactions. Proc Natl Acad Sci U S A. 103:19760-19765. 
Shimura, M., S. Minamisawa, H. Takeshima, Q. Jiao, Y. Bai, S. Umemura, and Y. Ishikawa. 
2008. Sarcalumenin alleviates stress-induced cardiac dysfunction by improving Ca2+ 
handling of the sarcoplasmic reticulum. Cardiovasc Res. 77:362-370. 
Shirokova, N., J. Garcia, and E. Rios. 1998. Local calcium release in mammalian skeletal 
muscle. J Physiol. 512 ( Pt 2):377-384. 
Slavik, K.J., J.P. Wang, B. Aghdasi, J.Z. Zhang, F. Mandel, N. Malouf, and S.L. Hamilton. 
1997. A carboxy-terminal peptide of the alpha 1-subunit of the dihydropyridine 
receptor inhibits Ca(2+)-release channels. Am J Physiol. 272:C1475-1481. 
Snoeck, M., B.G. van Engelen, B. Kusters, M. Lammens, R. Meijer, J.P. Molenaar, J. 
Raaphorst, C.C. Verschuuren-Bemelmans, C.S. Straathof, L.T. Sie, I.F. de Coo, W.L. 
van der Pol, M. de Visser, H. Scheffer, S. Treves, H. Jungbluth, N.C. Voermans, and 
E.J. Kamsteeg. 2015. RYR1-related myopathies: a wide spectrum of phenotypes 
throughout life. European journal of neurology : the official journal of the European 
Federation of Neurological Societies. 22:1094-1112. 
Somlyo, A.V., M. Bond, A.P. Somlyo, and A. Scarpa. 1985. INOSITOL TRISPHOSPHATE-
INDUCED CALCIUM RELEASE AND CONTRACTION IN VASCULAR 
SMOOTH-MUSCLE. Proceedings of the National Academy of Sciences of the United 
States of America. 82:5231-5235. 
Stern, M.D. 1992. Theory of excitation-contraction coupling in cardiac muscle. Biophys J. 
63:497-517. 
Suematsu, E., M. Hirata, T. Hashimoto, and H. Kuriyama. 1984. Inositol 1,4,5-trisphosphate 
releases Ca2+ from intracellular store sites in skinned single cells of porcine coronary 
artery. Biochem Biophys Res Commun. 120:481-485. 
Takuwa, Y. 1996. Regulation of vascular smooth muscle contraction. The roles of Ca2+, 
protein kinase C and myosin light chain phosphatase. Jpn Heart J. 37:793-813. 
   
 
 133 
Tanabe, T., K.G. Beam, B.A. Adams, T. Niidome, and S. Numa. 1990. Regions of the 
skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. 
Nature. 346:567-569. 
Theodosiou, M., V. Laudet, and M. Schubert. 2010. From carrot to clinic: an overview of the 
retinoic acid signaling pathway. Cell Mol Life Sci. 67:1423-1445. 
Thoreen, C.C., L. Chantranupong, H.R. Keys, T. Wang, N.S. Gray, and D.M. Sabatini. 2012. 
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 
485:109-113. 
Timchenko, L. 2013. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int 
J Biochem Cell Biol. 45:2280-2287. 
Tosetto, A., G. Castaman, and F. Rodeghiero. 2013. Bleeders, bleeding rates, and bleeding 
score. J Thromb Haemost. 11 Suppl 1:142-150. 
Toyoshima, C., M. Nakasako, H. Nomura, and H. Ogawa. 2000. Crystal structure of the 
calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature. 405:647-655. 
Treves, S., A.A. Anderson, S. Ducreux, A. Divet, C. Bleunven, C. Grasso, S. Paesante, and F. 
Zorzato. 2005. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis 
and neuromuscular disorders. Neuromuscul Disord. 15:577-587. 
Treves, S., M. De Mattei, M. Landfredi, A. Villa, N.M. Green, D.H. MacLennan, J. 
Meldolesi, and T. Pozzan. 1990. Calreticulin is a candidate for a calsequestrin-like 
function in Ca2(+)-storage compartments (calciosomes) of liver and brain. Biochem J. 
271:473-480. 
Treves, S., H. Jungbluth, F. Muntoni, and F. Zorzato. 2008. Congenital muscle disorders with 
cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol. 
8:319-326. 
Treves, S., R. Thurnheer, B. Mosca, M. Vukcevic, L. Bergamelli, R. Voltan, V. Oberhauser, 
M. Ronjat, L. Csernoch, P. Szentesi, and F. Zorzato. 2012. SRP-35, a newly identified 
protein of the skeletal muscle sarcoplasmic reticulum, is a retinol dehydrogenase. 
Biochem J. 441:731-741. 
Treves, S., M. Vukcevic, M. Maj, R. Thurnheer, B. Mosca, and F. Zorzato. 2009. Minor 
sarcoplasmic reticulum membrane components that modulate excitation-contraction 
coupling in striated muscles. J Physiol. 587:3071-3079. 
Triggle, D.J. 2006. L-type calcium channels. Curr Pharm Des. 12:443-457. 
Trombetta, E.S. 2003. The contribution of N-glycans and their processing in the endoplasmic 
reticulum to glycoprotein biosynthesis. Glycobiology. 13:77R-91R. 
   
 
 134 
Vazquez-Martin, A., S. Cufi, C. Oliveras-Ferraros, and J.A. Menendez. 2011. Raptor, a 
positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the 
rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer 
regions (NORs). Cell Cycle. 10:3140-3152. 
Versteeg, H.H., J.W. Heemskerk, M. Levi, and P.H. Reitsma. 2013. New fundamentals in 
hemostasis. Physiol Rev. 93:327-358. 
Vezina, C., A. Kudelski, and S.N. Sehgal. 1975. Rapamycin (AY-22,989), a new antifungal 
antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active 
principle. J Antibiot (Tokyo). 28:721-726. 
Vivaudou, M.B., L.H. Clapp, J.V. Walsh, and J.J. Singer. 1988. REGULATION OF ONE 
TYPE OF CA-2+ CURRENT IN SMOOTH-MUSCLE CELLS BY 
DIACYLGLYCEROL AND ACETYLCHOLINE. Faseb Journal. 2:2497-2504. 
Volpe, P., B.H. Alderson-Lang, L. Madeddu, E. Damiani, J.H. Collins, and A. Margreth. 
1990. Calsequestrin, a component of the inositol 1,4,5-trisphosphate-sensitive Ca2+ 
store of chicken cerebellum. Neuron. 5:713-721. 
Volpe, P., A. Martini, S. Furlan, and J. Meldolesi. 1994. Calsequestrin is a component of 
smooth muscles: the skeletal- and cardiac-muscle isoforms are both present, although 
in highly variable amounts and ratios. Biochem J. 301 ( Pt 2):465-469. 
Wagenknecht, T., C.E. Hsieh, B.K. Rath, S. Fleischer, and M. Marko. 2002. Electron 
tomography of frozen-hydrated isolated triad junctions. Biophys J. 83:2491-2501. 
Wang, S., W.R. Trumble, H. Liao, C.R. Wesson, A.K. Dunker, and C.H. Kang. 1998. Crystal 
structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. Nat 
Struct Biol. 5:476-483. 
Wang, X., N. Weisleder, C. Collet, J. Zhou, Y. Chu, Y. Hirata, X. Zhao, Z. Pan, M. Brotto, 
H. Cheng, and J. Ma. 2005. Uncontrolled calcium sparks act as a dystrophic signal for 
mammalian skeletal muscle. Nat Cell Biol. 7:525-530. 
Ward, C.W., and W.J. Lederer. 2005. Ghost sparks. Nat Cell Biol. 7:457-459. 
Weber, A., and S. Winicur. 1961. The role of calcium in the superprecipitation of 
actomyosin. J Biol Chem. 236:3198-3202. 
Weisleder, N., M. Brotto, S. Komazaki, Z. Pan, X. Zhao, T. Nosek, J. Parness, H. Takeshima, 
and J. Ma. 2006. Muscle aging is associated with compromised Ca2+ spark signaling 
and segregated intracellular Ca2+ release. J Cell Biol. 174:639-645. 
Weisleder, N., and J.J. Ma. 2006. Ca2+ sparks as a plastic signal for skeletal muscle health, 
aging, and dystrophy. Acta Pharmacol Sin. 27:791-798. 
   
 
 135 
Weisleder, N., J. Zhou, and J. Ma. 2012. Detection of calcium sparks in intact and 
permeabilized skeletal muscle fibers. Methods Mol Biol. 798:395-410. 
Wilmshurst, J.M., S. Lillis, H. Zhou, K. Pillay, H. Henderson, W. Kress, C.R. Muller, A. 
Ndondo, V. Cloke, T. Cullup, E. Bertini, C. Boennemann, V. Straub, R. Quinlivan, 
J.J. Dowling, S. Al-Sarraj, S. Treves, S. Abbs, A.Y. Manzur, C.A. Sewry, F. Muntoni, 
and H. Jungbluth. 2010. RYR1 mutations are a common cause of congenital 
myopathies with central nuclei. Ann Neurol. 68:717-726. 
Wray, S., and T. Burdyga. 2010. Sarcoplasmic reticulum function in smooth muscle. Physiol 
Rev. 90:113-178. 
Wu, D., A. Katz, C.H. Lee, and M.I. Simon. 1992. Activation of phospholipase C by alpha 1-
adrenergic receptors is mediated by the alpha subunits of Gq family. J Biol Chem. 
267:25798-25802. 
Wu, S., M.C. Ibarra, M.C. Malicdan, K. Murayama, Y. Ichihara, H. Kikuchi, I. Nonaka, S. 
Noguchi, Y.K. Hayashi, and I. Nishino. 2006. Central core disease is due to RYR1 
mutations in more than 90% of patients. Brain. 129:1470-1480. 
Yao, Y., J. Choi, and I. Parker. 1995. Quantal puffs of intracellular Ca2+ evoked by inositol 
trisphosphate in Xenopus oocytes. J Physiol. 482 ( Pt 3):533-553. 
Yao, Y., and I. Parker. 1994. Ca2+ influx modulation of temporal and spatial patterns of 
inositol trisphosphate-mediated Ca2+ liberation in Xenopus oocytes. J Physiol. 
476:17-28. 
Yasuda, T., O. Delbono, Z.M. Wang, M.L. Messi, T. Girard, A. Urwyler, S. Treves, and F. 
Zorzato. 2013. JP-45/JSRP1 variants affect skeletal muscle excitation-contraction 
coupling by decreasing the sensitivity of the dihydropyridine receptor. Hum Mutat. 
34:184-190. 
Yoshida, M., S. Minamisawa, M. Shimura, S. Komazaki, H. Kume, M. Zhang, K. 
Matsumura, M. Nishi, M. Saito, Y. Saeki, Y. Ishikawa, T. Yanagisawa, and H. 
Takeshima. 2005. Impaired Ca2+ store functions in skeletal and cardiac muscle cells 
from sarcalumenin-deficient mice. J Biol Chem. 280:3500-3506. 
Yu, X., S. Carroll, J.L. Rigaud, and G. Inesi. 1993. H+ countertransport and electrogenicity 
of the sarcoplasmic reticulum Ca2+ pump in reconstituted proteoliposomes. Biophys 
J. 64:1232-1242. 
Zalk, R., O.B. Clarke, A. des Georges, R.A. Grassucci, S. Reiken, F. Mancia, W.A. 
Hendrickson, J. Frank, and A.R. Marks. 2015. Structure of a mammalian ryanodine 
receptor. Nature. 517:44-49. 
   
 
 136 
Zalk, R., S.E. Lehnart, and A.R. Marks. 2007. Modulation of the ryanodine receptor and 
intracellular calcium. Annu Rev Biochem. 76:367-385. 
Zhang, L., J. Kelley, G. Schmeisser, Y.M. Kobayashi, and L.R. Jones. 1997. Complex 
formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins 
of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem. 272:23389-
23397. 
Zhao, F., P. Li, S.R. Chen, C.F. Louis, and B.R. Fruen. 2001. Dantrolene inhibition of 
ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform 
selectivity. J Biol Chem. 276:13810-13816. 
Zhao, Y., P.M. Vanhoutte, and S.W. Leung. 2015. Vascular nitric oxide: Beyond eNOS. J 
Pharmacol Sci. 
Zhou, J., B.S. Launikonis, E. Rios, and G. Brum. 2004. Regulation of Ca2+ sparks by Ca2+ 
and Mg2+ in mammalian and amphibian muscle. An RyR isoform-specific role in 
excitation-contraction coupling? J Gen Physiol. 124:409-428. 
Zhu, Z.M., M. Tepel, M. Neusser, and W. Zidek. 1994. ROLE OF NA+-CA2+ EXCHANGE 
IN AGONIST-INDUCED CHANGES IN CYTOSOLIC CA2+ IN VASCULAR 
SMOOTH-MUSCLE CELLS. American Journal of Physiology. 266:C794-C799. 
Zinzalla, V., D. Stracka, W. Oppliger, and M.N. Hall. 2011. Activation of mTORC2 by 
association with the ribosome. Cell. 144:757-768. 
Zorzato, F., A.A. Anderson, K. Ohlendieck, G. Froemming, R. Guerrini, and S. Treves. 2000. 
Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum 
junctional-face membrane. Biochem J. 351 Pt 2:537-543. 
Zorzato, F., A. Margreth, and P. Volpe. 1986. Direct photoaffinity labeling of junctional 
sarcoplasmic reticulum with [14C]doxorubicin. J Biol Chem. 261:13252-13257. 
Zubrzycka-Gaarn, E., G. MacDonald, L. Phillips, A.O. Jorgensen, and D.H. MacLennan. 
1984. Monoclonal antibodies to the Ca2+ + Mg2+-dependent ATPase of sarcoplasmic 
reticulum identify polymorphic forms of the enzyme and indicate the presence in the 
enzyme of a classical high-affinity Ca2+ binding site. J Bioenerg Biomembr. 16:441-
464. 
Zucchi, R., and S. Ronca-Testoni. 1997. The sarcoplasmic reticulum Ca2+ channel/ryanodine 
receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol 
Rev. 49:1-51. 
   
 
 137 
CURRICULUM VITAE 
 
Education 
University of Carabobo, Venezuela — B. Sc. in Biology, 2011 
Basel University, Switzerland — PhD, Cell Biology, currently finishing the 4th year, waiting for the 
final examination.  
Positions Held  
PHD RESEARCHER, DEPARTMENT OF BIOMEDICINE AND ANAESTHESIA - BASEL UNIVERSITY HOSPITAL; BASEL, 
SWITZERLAND  — 2012–PRESENT 
My current research project focuses on understanding the pathophysiologic mechanisms of 
neuromuscular diseases including malignant hyperthermia, multi minicore disease, central core 
disease and other ryanodine receptor-associated myopathies affecting the skeletal muscle calcium 
homeostasis. 
TEACHING ASSISTANT IN THE COURSE PHYSICAL-CHEMISTRY FOR BIOLOGISTS, DEPARTMENT OF BIOLOGY; 
VALENCIA, VENEZUELA  — 2007-2009 
I was in charge of preparing teaching material such as lectures and exercise as well as correcting 
exams and training students for the course themes. 
Conference Presentation 
“34th Annual Scientific Meeting European Malignant Hyperthermia Group” Lille, France. June 
11-13, 2015. Oral presentation. 
“Gordon Research Conference: Muscle: Excitation-Contraction Coupling (GRC)” Sunday River in 
Newry, US. May 31- June 05, 2015. Poster presentation.  
“Gordon Research Seminar: Muscle: Excitation-Contraction Coupling (GRS)” Sunday River in Newry, 
US. May 30-31, 2015. Poster presentation. 
“6th Basel Symposium on Skeletal Muscle” Basel, Switzerland. May 15th, 2015. Attendance. 
“10th Swiss Meeting on Muscle Research” Magglingen, Switzerland. November 9-10, 2014. Poster 
presentation. 
“3rd   Symposium der Jungen Physiologen”, Bonn, Germany. September 25-26, 2014. Oral 
presentation. 
“5th Basel Symposium on Skeletal Muscle” Basel, Switzerland. May 24th, 2013. Attendance. 
“Biophysical Society 57th Annual Meeting”, Philadelphia, US. February 2-6, 2013. Poster 
presentation 
“XI Colombian Congress of Phytochemistry”, Antioquia University, Colombia. October 5-7, 2011. 
Poster presentation. 
Ruben Lopez Tlf: 0041786938595     E-mail: rjlopez2@gmail.com       
Kleinhueningerstrasse 139  
Basel 4057  
Switzerland23. 09.1988  - Venezuela
   
 
 138 
 
